1life Healthcare (ONEM) 10-K17 Mar 212020 FY Annual reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - USD ($) $ in Billions	12 Months Ended
Document and Entity Information - USD ($) $ in Billions	Dec. 31, 2020	Feb. 26, 2021	Jun. 30, 2020
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Registrant Name	1Life Healthcare Inc
Entity Central Index Key	0001404123
Document Annual Report	true
Current Fiscal Year End Date	--12-31
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity File Number	001-39203
Entity Tax Identification Number	76-0707204
Entity Incorporation, State or Country Code	DE
Entity Filer Category	Non-accelerated Filer
Entity Address, Address Line One	One Embarcadero Center
Entity Address, Address Line Two	Suite 1900
Entity Address, City or Town	San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94111
City Area Code	415
Local Phone Number	814-0927
Document Transition Report	false
Entity Public Float			$ 2.5
Entity Common Stock Shares Outstanding		136,840,853
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	ONEM
Security Exchange Name	NASDAQ
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Portions of the Registrant’s definitive Proxy Statement relating to the 2021 Annual Meeting of Stockholders (the “Proxy Statement”) are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. The Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the Registrant’s fiscal year ended December 31, 2020.

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 112,975	$ 27,390
Short-term marketable securities	570,023	119,146
Accounts receivable, net	67,895	33,601
Inventories	7,113	3,192
Prepaid expenses and other current assets	16,693	16,708
Total current assets	774,699	200,037
Restricted cash	1,911	1,922
Property and equipment, net	126,037	90,716
Right-of-use assets	138,840	108,046
Intangible assets, net		23
Goodwill	21,301	21,301
Deferred income taxes	2,656
Other assets	5,546	8,249
Total assets	1,070,990	430,294
Current liabilities:
Accounts payable	12,654	13,853
Accrued expenses	46,527	24,863
Deferred revenue, current	35,966	27,024
Operating lease liabilities, current	17,418	12,575
Notes payable, current		3,282
Other current liabilities	4,861	1,884
Total current liabilities	117,426	83,481
Operating lease liabilities, non-current	153,614	120,497
Convertible senior notes	241,233
Redeemable convertible preferred stock warrant liability		7,220
Deferred revenue, non-current	7,624
Other non-current liabilities	2,618	639
Total liabilities	522,515	211,837
Commitments and contingencies (Note 19)
Redeemable convertible preferred stock		402,488
Equity (deficit):
Common stock, $0.001 par value, 1,000,000,000 and 150,000,000 shares authorized as of December 31, 2020 and December 31, 2019, respectively; 134,472,427 and 18,951,416 shares issued and outstanding as of December 31, 2020 and December 31, 2019, respectively	134	19
Additional paid-in capital	918,118	93,945
Accumulated deficit	(369,785)	(281,068)
Accumulated other comprehensive income	8	38
Total stockholders' equity (deficit) attributable to 1Life Healthcare, Inc. stockholders	548,475	(187,066)
Noncontrolling interest		3,035
Total equity (deficit)	548,475	(184,031)
Total liabilities, redeemable convertible preferred stock and equity (deficit)	$ 1,070,990	$ 430,294

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Redeemable convertible preferred stock, par value	$ 0.001	$ 0.001
Redeemable convertible preferred stock, shares authorized	0	89,338,425
Redeemable convertible preferred stock, shares issued	0	86,251,669
Redeemable convertible preferred stock, shares outstanding	0	86,251,669
Redeemable convertible preferred stock, aggregate liquidation preference	$ 0	$ 405,585
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	150,000,000
Common stock, shares, issued	134,472,427	18,951,416
Common stock, shares, outstanding	134,472,427	18,951,416

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Net revenue	$ 380,223	$ 276,258	$ 212,678
Operating expenses:
Cost of care, exclusive of depreciation and amortization shown separately below	234,959	167,618	136,180
Sales and marketing	36,967	39,520	25,789
General and administrative	157,282	108,965	85,808
Depreciation and amortization	22,374	14,268	9,947
Total operating expenses	451,582	330,371	257,724
Loss from operations	(71,359)	(54,113)	(45,046)
Other income (expense), net:
Interest income	1,809	4,498	2,251
Interest expense	(13,434)	(474)	(804)
Change in fair value of redeemable convertible preferred stock warrant liability	(6,560)	(3,519)	(1,877)
Total other income (expense), net	(18,185)	505	(430)
Loss before income taxes	(89,544)	(53,608)	(45,476)
Provision for (benefit from) income taxes	(123)	87	25
Net loss	(89,421)	(53,695)	(45,501)
Less: Net loss attributable to noncontrolling interest	(704)	(1,141)	(1,086)
Net loss attributable to 1Life Healthcare, Inc. stockholders	$ (88,717)	$ (52,554)	$ (44,415)
Net loss per share attributable to 1Life Healthcare, Inc. stockholders — basic and diluted	$ (0.75)	$ (2.84)	$ (2.65)
Weighted average common shares outstanding — basic and diluted	118,379,300	18,476,127	16,735,541

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (89,421)	$ (53,695)	$ (45,501)
Other comprehensive loss:
Net unrealized gain (loss) on short-term marketable securities	(30)	52	(5)
Comprehensive loss	(89,451)	(53,643)	(45,506)
Less: Comprehensive loss attributable to noncontrolling interest	(704)	(1,141)	(1,086)
Comprehensive loss attributable to 1Life Healthcare, Inc. stockholders	$ (88,747)	$ (52,502)	$ (44,420)

CONSOLIDATED STATEMENTS OF REDE

CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Cumulative Effect Period of Adoption Adjustment [Member]	IPO	Redeemable Convertible Preferred Stock	Redeemable Convertible Preferred StockIPO	Common Stock	Common StockIPO	Additional Paid-In Capital	Additional Paid-In CapitalIPO	Accumulated Deficit	Accumulated DeficitCumulative Effect Period of Adoption Adjustment [Member]	Accumulated Other Comprehensive Income (Loss)	Total Stockholders' Equity (Deficit) Attributable to 1Life Healthcare, Inc. Stockholders	Total Stockholders' Equity (Deficit) Attributable to 1Life Healthcare, Inc. StockholdersCumulative Effect Period of Adoption Adjustment [Member]	Total Stockholders' Equity (Deficit) Attributable to 1Life Healthcare, Inc. StockholdersIPO	Noncontrolling Interest
Beginning balances at Dec. 31, 2017	$ (119,784)					$ 16		$ 58,981		$ (184,034)		$ (9)	$ (125,046)			$ 5,262
Beginning balances, Shares at Dec. 31, 2017				68,326,054
Beginning balances at Dec. 31, 2017				$ 184,832
Beginning balances, Shares at Dec. 31, 2017						15,771,086
Issuance of Series I redeemable convertible preferred stock net of issuance costs of $3,336				$ 216,664
Issuance of Series I redeemable convertible preferred stock net of issuance costs of $3,336, Shares				17,699,115
Repurchase and retirement of common stock	(7,533)							(7,533)					(7,533)
Repurchase and retirement of common stock, Shares						(488,711)
Exercise of redeemable convertible preferred stock warrant				$ 992
Exercise of redeemable convertible preferred stock warrant, Shares				226,500
Exercise of common stock warrant	177							177					177
Exercise of common stock warrant, Shares						150,000
Exercise of stock options	$ 10,464					$ 2		10,462					10,464
Exercise of stock options, Shares	3,767,795					2,703,082
Stock-based compensation expense	$ 13,942							13,942					13,942
Net unrealized gain (loss) on short-term marketable securities	(5)											(5)	(5)
Net loss	(45,501)									(44,415)			(44,415)			(1,086)
Ending balances at Dec. 31, 2018	(148,240)	$ (65)				$ 18		76,029		(228,449)	$ (65)	(14)	(152,416)	$ (65)		4,176
Ending balances, Shares at Dec. 31, 2018				86,251,669
Ending balances at Dec. 31, 2018				$ 402,488
Ending balances, Shares at Dec. 31, 2018						18,135,457
Accounting Standards Update [Extensible List]		us-gaap:AccountingStandardsUpdate201409Member									us-gaap:AccountingStandardsUpdate201409Member			us-gaap:AccountingStandardsUpdate201409Member
Exercise of stock options	$ 3,040					$ 1		3,039					3,040
Exercise of stock options, Shares	815,959					815,959
Stock-based compensation expense	$ 14,877							14,877					14,877
Net unrealized gain (loss) on short-term marketable securities	52											52	52
Net loss	(53,695)									(52,554)			(52,554)			(1,141)
Ending balances at Dec. 31, 2019	$ (184,031)					$ 19		93,945		(281,068)		38	(187,066)			3,035
Ending balances, Shares at Dec. 31, 2019	86,251,669			86,251,669
Ending balances at Dec. 31, 2019	$ 402,488			$ 402,488
Ending balances, Shares at Dec. 31, 2019						18,951,416
Exercise of redeemable convertible preferred stock warrant				$ 76
Exercise of redeemable convertible preferred stock warrant, Shares				5,573
Conversion of redeemable convertible preferred stock into common stock upon closing of initial public offering			$ 402,564		$ (402,564)		$ 86		$ 402,478						$ 402,564
Conversion of redeemable convertible preferred stock into common stock upon closing of initial public offering, Shares					(86,257,242)		86,257,242
Issuance of common stock upon closing of initial public offering, net of issuance costs and underwriting fees of $23,631			$ 258,119				$ 20		$ 258,099						$ 258,119
Issuance of common stock upon closing of initial public offering, net of issuance costs and underwriting fees of $23,631, Shares							20,125,000
Fair value adjustment to redeemable convertible preferred stock warrants upon conversion into common stock warrants	13,740							13,740					13,740
Reimbursed secondary offering issuance costs	784							784					784
Exercise of common stock warrant	73							73					73
Exercise of common stock warrant, Shares						11,010
Cashless exercise of common stock warrants, Shares						590,265
Exercise of stock options	$ 35,686					$ 9		35,677					35,686
Exercise of stock options, Shares	8,122,909					8,122,909
Issuance of common stock under the employee stock purchase plan	$ 4,834							4,834					4,834
Issuance of common stock under the employee stock purchase plan, Shares						349,562
Issuance of common stock for settlement of RSUs	(833)							(833)					(833)
Issuance of common stock for settlement of RSUs, Shares						40,166
Shares issued related to net share settlement	833							833					833
Shares issued related to net share settlement, Shares						24,857
Stock-based compensation expense	35,095							35,095					35,095
Net unrealized gain (loss) on short-term marketable securities	(30)											(30)	(30)
Equity component of convertible senior notes, net of issuance costs of $2,243	73,393							73,393					73,393
VIE deconsolidation	(2,331)															(2,331)
Net loss	(89,421)									(88,717)			(88,717)			$ (704)
Ending balances at Dec. 31, 2020	$ 548,475					$ 134		$ 918,118		$ (369,785)		$ 8	$ 548,475
Ending balances, Shares at Dec. 31, 2020	0		0
Ending balances, Shares at Dec. 31, 2020						134,472,427

CONSOLIDATED STATEMENTS OF RE_2

CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND EQUITY (DEFICIT) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2018
3.0% Convertible Senior Notes due 2025
Stock issuance costs	$ 2,242
IPO
Stock issuance costs	$ 23,631
Redeemable Convertible Preferred Stock
Issuance of Series I redeemable convertible preferred stock issuance costs		$ 3,336

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net loss	$ (89,421)	$ (53,695)	$ (45,501)
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for bad debts	105		3,237
Depreciation and amortization	22,374	14,268	9,947
Amortization of debt discount and issuance costs	7,767	84	148
Accretion of discounts and amortization of premiums on short-term investments, net	(933)	(3,359)	(1,631)
Change in fair value of redeemable convertible preferred stock warrant liability	6,560	3,519	1,877
Reduction of operating lease right-of-use assets	13,653	10,235
Stock-based compensation	35,095	14,877	13,942
Deferred income taxes	(2,656)
Other non-cash items	(8)	69	110
Changes in operating assets and liabilities:
Accounts receivable, net	(35,167)	(14,484)	(7,202)
Inventories	(3,921)	659	224
Prepaid expenses and other current assets	6,488	(1,027)	87
Other assets	(943)	(4,567)	26
Accounts payable	298	3,929	1,915
Accrued expenses	26,849	3,476	5,079
Deferred revenue	16,566	2,119	584
Operating lease liabilities	(12,169)	(8,087)
Other liabilities	5,085	310	(1,252)
Net cash used in operating activities	(4,378)	(31,674)	(18,410)
Cash flows from investing activities:
Purchases of property and equipment, net	(63,707)	(54,411)	(10,767)
Purchases of short-term marketable securities	(963,272)	(246,116)	(218,592)
Proceeds from sales and maturities of short-term marketable securities	513,315	324,250	52,600
VIE deconsolidation	(810)
Net cash (used in) provided by investing activities	(514,474)	23,723	(176,759)
Cash flows from financing activities:
Proceeds from issuance of convertible senior notes	316,250
Payment of convertible senior notes issuance costs	(9,374)
Proceeds from initial public offering	281,750
Payment of underwriting discount and commissions, and offering costs	(20,538)
Proceeds from the exercise of stock options	35,686	3,040	10,464
Proceeds from employee stock purchase plan	4,835
Taxes paid related to net share settlement of equity awards	(833)
Proceeds from the exercise of redeemable convertible preferred and common stock warrants	110		307
Repayment of notes payable	(3,300)	(4,400)	(3,300)
Payment of principal portion of finance lease liability	(58)	(16)
Repurchase and retirement of common stock			(7,533)
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs			216,664
Net cash provided by (used in) financing activities	604,528	(1,376)	216,602
Net increase (decrease) in cash, cash equivalents and restricted cash	85,676	(9,327)	21,433
Cash, cash equivalents and restricted cash at beginning of period	29,329	38,656	17,223
Cash, cash equivalent and restricted cash at end of period	115,005	29,329	38,656
Supplemental disclosure of cash flow information:
Cash paid for interest	5,251	414	666
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses	$ 4,571	9,093	1,644
Unpaid deferred offering costs		$ 1,318
Settlement of redeemable convertible preferred stock warrant liability in connection with Series B warrant exercise			$ 862

Nature of the Business and Basi

Nature of the Business and Basis of Presentation	12 Months Ended
Nature of the Business and Basis of Presentation	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of the Business and Basis of Presentation	1. Nature of the Business and Basis of Presentation 1Life Healthcare, Inc. (“1Life”) was incorporated in Delaware on July 25, 2002. 1Life’s headquarters are located in San Francisco, California. 1Life has developed a modernized healthcare membership model based on direct consumer enrollment as well as employer sponsorship. 1Life is also an administrative and managerial services company that provides services pursuant to contracts with physician-owned professional corporations (“PCs”) or “One Medical Entities” that provide medical services in-office and virtually. 1Life and the One Medical Entities are collectively referred to herein as the “Company” and operate under the brand name One Medical. Initial Public Offering On February 4, 2020, the Company closed its initial public offering (“IPO”) and sold 20,125,000 shares of common stock, including the underwriters’ option to purchase additional shares at the IPO price. The public offering price of the shares sold in the IPO was $14.00 per share. In aggregate, the shares issued in the offering generated $258,119 in net proceeds, which amount is net of $18,314 in underwriters’ discount and commissions, and $5,317 in offering costs. Upon the closing of the IPO, all shares of redeemable convertible preferred stock then outstanding were automatically converted into 86,257,242 shares of common stock and all redeemable preferred stock warrants were converted into warrants to purchase 667,668 shares of common stock. In addition, 1,589,798 options held by a named executive officer that were subject to immediate vesting upon the execution of the IPO underwriting agreement vested and accordingly, $3,506 of stock-based compensation expense was recognized. Certain Risks and Uncertainties The Company has incurred losses from operations since inception. Management expects that operating losses and negative cash flows from operations will continue in the foreseeable future; however, it currently believes that the Company’s current cash, cash equivalents and short-term marketable securities are sufficient to fund its operating expenses and capital expenditure requirements for the next twelve months. In March 2020, the World Health Organization declared a pandemic due to the global COVID-19 outbreak. Due to the ongoing COVID-19 pandemic, the global economy and financial markets have been and continue to be affected, and there is a significant amount of uncertainty about the length and severity of the consequences caused by the pandemic. The Company has considered information available to it as of the date of issuance of these financial statements and is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or an adjustment to the carrying value of its assets or liabilities. The accounting estimates and other matters assessed include, but were not limited to, allowance for doubtful accounts, inventory reserves, adverse inventory purchase commitments, goodwill and other long-lived assets, and revenue recognition. These estimates may change as new events occur and additional information becomes available. Actual results could differ materially from these estimates. Basis of Presentation The Company has prepared the consolidated financial statements in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and include the accounts of 1Life and variable interest entities (“VIE”) in which 1Life has an interest and is the primary beneficiary (see Note 3, “Variable Interest Entities”). All significant intercompany balances and transactions have been eliminated in consolidation. The noncontrolling interest attributable to the Company’s variable interest entities are presented as a separate component of equity in the consolidated balance sheets. Certain reclassifications have been made to prior periods to conform with the current presentation. During the three months ended March 31, 2020, the company identified a balance sheet misclassification which was not material to the previously issued financial statements. However, the Company has corrected the December 31, 2019 comparative amounts to increase accounts receivable, net and deferred revenue by $3,146 as presented in t he condensed consolidated balance sheet.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Use of Estimates The preparation of consolidated financial statements and related disclosures in conformity with U.S. GAAP and regulations of the SEC requires management to make estimates and assumptions that affect the amount reported in the consolidated financial statements and accompanying notes. Estimates include, but are not limited to, revenue recognition, determination of useful lives for property and equipment, intangible assets including goodwill, capitalized internal-use software, allowance for doubtful accounts, valuation of redeemable convertible preferred stock warrant liabilities, self-insurance reserves, valuation of common stock, stock options valuations, convertible senior notes fair value, contingent liabilities and income taxes. Actual results could differ materially from those estimates. Deferred Offering Costs The Company capitalizes certain legal, accounting and other third-party fees that are directly related to the Company’s in-process equity financings until such financings are consummated, including the Company’s initial public offering in January 2020. After the consummation of the equity financing, these costs are recorded as a reduction of the gross proceeds. Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are immediately written off to operating expenses. There were no deferred offering costs capitalized as of December 31, 2020. As of December 31, 2019, there were $3,627 of deferred offering costs included in other assets on the consolidated balance sheet. Cash, Cash Equivalents and Restricted Cash The Company considers all short-term, highly liquid investments purchased with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash deposits are all in financial institutions in the United States. Cash and cash equivalents consisted of cash on deposit, investments in money market funds and commercial paper. Restricted cash represents cash held under letters of credit for various leases. The expected duration of restrictions on the Company’s restricted cash generally ranges from 1 to 9 years. The reconciliation of cash, cash equivalents and restricted cash reported within the applicable balance sheet line items that sum to the total of the same such amount shown in the consolidated statements of cash flows is as follows: December 31, 2020 2019 2018 Cash and cash equivalents $ 112,975 $ 27,390 $ 36,692 Restricted cash, current (included in prepaid expenses and other current assets) 119 17 25 Restricted cash, non-current 1,911 1,922 1,939 $ 115,005 $ 29,329 $ 38,656 Marketable Securities The Company’s investments in marketable securities are classified as available-for-sale and are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in total equity (deficit). The Company determines the appropriate classification of these investments at the time of purchase and reevaluates such designation at each balance sheet date. The Company classifies the available-for-sale investments as current assets under the caption short-term marketable securities on the consolidated balance sheets as these investments generally consist of highly marketable securities that are identified to be available to meet near-term cash requirements. Realized gains and losses and declines in value determined to be other than temporary are based on the specific identification method and are included as a component of other income (expense), net in the consolidated statements of operations. The Company periodically evaluates its investments in marketable securities for other-than-temporary impairment. When assessing short-term marketable security investments for other-than-temporary declines in value, the Company considers such factors as, among other things, how significant the decline in value is as a percentage of the original cost, how long the market value of the investment has been less than its original cost, the Company’s ability and intent to retain the short-term marketable security investment for a period of time sufficient to allow for any anticipated recovery in fair value and market conditions in general. If any adjustment to fair value reflects a decline in the value of the marketable security that the Company considers to be “other than temporary,” the Company reduces the marketable securities through a charge to the consolidated statement of operations. No such adjustments were necessary during the periods presented. Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The three levels of inputs that may be used to measure fair value are defined below: • Level 1 — Quoted prices in active markets for identical assets or liabilities. • Level 2 — Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 — Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The Company determines the fair value of its marketable securities based on quoted prices in active markets (Level 1 inputs) for identical assets and on quoted prices for similar assets (Level 2 inputs), which are classified as available-for-sale. The carrying amounts of the Company’s term notes approximate the fair value based on consideration of current borrowing rates available to the Company (Level 2 inputs.) The Company’s redeemable convertible preferred stock warrant liability is carried at fair value, determined using Level 3 inputs in the fair value hierarchy (See Note 4 “Fair Value Measurements”). Upon the closing of the Company’s IPO in the first quarter of 2020, the warrants to purchase shares of redeemable convertible preferred stock became exercisable and were automatically converted to warrants to purchase shares of common stock. As a result, following the closing of the Company’s IPO, t Variable Interest Entities The Company evaluates its ownership, contractual and other interests in entities to determine if it has any variable interest in a variable interest entity (“VIE”). These evaluations are complex, involve judgment, and the use of estimates and assumptions based on available historical information, among other factors. If the Company determines that an entity in which it holds a contractual or ownership interest is a VIE and that the Company is the primary beneficiary, the Company consolidates such entity in its consolidated financial statements. The primary beneficiary of a VIE is the party that meets both of the following criteria: (i) has the power to make decisions that most significantly affect the economic performance of the VIE; and (ii) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively. Segment Information The Company operates and manages its business as one reportable and operating segment. The Company’s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of evaluating financial performance and allocating resources. All of the Company’s long-lived assets and customers are located in the United States. Concentration of Credit Risk and Significant Customers Financial instruments that potentially subject the company to concentration of credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. The Company’s cash balances with individual banking institutions might be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds and commercial paper. The Company’s marketable securities are invested in U.S. Treasury obligations and commercial paper. The Company is not exposed to any significant concentrations of credit risk from these financial instruments. The Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities. The Company grants unsecured credit to patients, most of whom reside in the service area of the One Medical facilities and are largely insured under third-party payer agreements. The Company’s concentration of credit risk is limited by the diversity, geography and number of patients and payers. The table below December 31, 2020 2019 Customer A * 10 % Customer E 12 % * Customer F 24 % 11 % Customer G * 12 % Customer H 16 % * * Represents percentages below 10% of the Company’s accounts receivable in the period. The table below Year Ended December 31, 2020 2019 2018 Customer A 13 % 14 % 15 % Customer B * * 12 % Customer C * * 10 % Customer E 10 % 10 % 10 % Customer F 12 % 12 % * * Represents percentages below 10% of the Company’s net revenue in the period. Accounts Receivable, net Accounts receivable is comprised of amounts due from third-party payers, patients, and health system and other partners for healthcare services and amounts due from enterprise clients, schools and universities who purchase access to memberships for their employees, students and faculty. The Company reports accounts receivable net of estimated contractual adjustments and any allowance for doubtful accounts. Collection of accounts receivable is the Company’s primary source of cash and is critical to its operating performance. The Company’s primary collection risks relate to co-payments and other amounts owed by patients. The Company reviews its overall reserve adequacy by monitoring historical cash collections as a percentage of net revenue as well as other collection indicators such as the age of the balance and the payment history of the customer. The Company writes off accounts against the allowance for doubtful accounts when they are deemed to be uncollectible. Increases and decreases in the allowance for doubtful accounts from patient service revenue are included in net revenue in the consolidated statements of operations. Changes in the allowance for doubtful accounts were as follows: Balance at Beginning of Period Additions Write-offs and Deductions Balance at End of Period Allowance for doubtful accounts Year ended December 31, 2018 $ 405 $ 3,237 $ (3,179 ) $ 463 Year ended December 31, 2019 $ 463 $ 2,931 $ (2,226 ) $ 1,168 Year ended December 31, 2020 $ 1,168 $ 5,773 $ (3,694 ) $ 3,247 Inventories Inventories consist of medical supplies such as vaccines and are stated at the lower of cost or net realizable value with cost being determined on a weighted average basis. Net realizable value is determined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of disposal and transportation. The cost of inventory includes product cost, shipping costs and taxes. Write-offs of potentially slow moving or damaged inventory are recorded based on management’s analysis of inventory levels, forecasted future sales volume and pricing and through specific identification of obsolete or damaged products. The Company assesses inventory quarterly for slow moving products and potential impairment. The Company records a reserve for obsolete inventory or inventory that may expire prior to use. The reserve for obsolete inventory was $1,386 as of December 31, 2020 and there was no reserve for obsolete inventory for the year ended December 31, 2019 . Property and Equipment, net Property and equipment are stated at cost, net of accumulated depreciation. Depreciation and amortization are computed using the straight-line method over the estimated useful lives. The general range of useful lives of other property and equipment is as follows: Estimated Useful Life Furniture and fixtures 5 to 7 years Computer equipment 3 to 5 years Computer software 1.5 to 5 years Laboratory equipment 5 to 7 years Leasehold improvements Lesser of lease term or 10 years When assets are sold or retired, the cost and related accumulated depreciation are removed from the accounts, with any resulting gain or loss recorded in general and administrative expenses in the consolidated statements of operations. Costs of repairs and maintenance are expensed as incurred. Software Developed for Internal Use The Company capitalizes costs related to internal-use software during the application development stage including consulting costs and compensation expenses related to employees who devote time to the development projects. The Company records software development costs in property and equipment, net. Costs incurred in the preliminary stages of development activities and post implementation activities are expensed in the period incurred and included in general and administrative expense in the consolidated statements of operations. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Capitalized costs associated with internal-use software are amortized on a straight-line basis over their estimated useful life, which is 1.5 to 5 years, and are included in depreciation and amortization in the consolidated statements of operations. Goodwill and Long-Lived Assets The Company recognizes the excess of the purchase price, plus the fair value of any noncontrolling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. The Company performs a qualitative assessment on goodwill at least annually or more frequently if events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable. If it is determined in the qualitative assessment that the fair value of a reporting unit is more likely than not below its carrying amount, then the Company will perform a quantitative impairment test. The quantitative goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. Any excess in the carrying value of a reporting unit’s goodwill over its fair value is recognized as an impairment loss, limited to the total amount of goodwill allocated to that reporting unit. For purposes of goodwill impairment testing, the Company has one reporting unit. The Company’s long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset or asset group may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset or asset group to the future undiscounted cash flows expected to be generated by the asset or asset group. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. During the years ended December 31, 2020 and 2019, the Company has not recorded any impairment charges related to goodwill or long-lived assets. Leases The Company adopted Accounting Standards Codification, Topic 842, Leases (“ASC 842”), using the modified retrospective approach through a cumulative-effect adjustment and utilizing the effective date of January 1, 2019 as its date of initial application. As of January 1, 2019, the impact of the adoption to the Company’s consolidated balance sheet includes the recognition of operating lease liabilities, current, of $9,643, operating lease liabilities, non-current, of $63,047 based on the present value of the remaining lease payments for existing operating leases with corresponding right-of-use assets of approximately $60,770. The difference between the amount of right-of-use assets and lease liabilities recognized upon the adoption of ASC 842 is related to adjustments to existing prepaid rent, deferred rent, and lease incentives. The Company determines if a contract meets with definition of a lease at inception of a contract. Lease liabilities represent the obligation to make lease payments and right-of-use (“ROU”) assets represent the right to use the underlying asset during the lease term. Leases with a term greater than one year are recognized on the consolidated balance sheet as The Company has elected not to recognize on the balance sheet leases with terms of one year or less. Operating lease ROU assets are adjusted for (i) payments made at or before the commencement date, (ii) initial direct costs incurred, and (iii) tenant incentives under the lease. When a lease contains an escalation clause or a concession, such as a rent holiday or tenant improvement allowance, the Company includes these items in the determination of the ROU asset and the lease liabilities. The effects of these escalation clauses or concessions have been reflected in lease expenses on a straight-line basis over the expected lease term and any variable lease payments subsequent to establishing the lease liability are expensed as incurred. Certain lease agreements include rental payments that are adjusted periodically for inflation or other variables. In addition to rent, the leases may require the Company to pay additional amounts for taxes, insurance, maintenance and other expenses, which are generally referred to as non-lease components. Such adjustments to rental payments and variable non-lease components are treated as variable lease payments and recognized in the period as incurred. Variable lease components and variable non-lease components are not measured as part of the right-of-use assets and lease liability. Only when lease components and their associated non-lease components are fixed are they recognized as part of the right-of-use assets and lease liability. The Company has made an accounting policy election to not separate lease and non-lease components to all asset classes. Rather, each lease component and the related non-lease components will be accounted for together as a single component. A portfolio approach is applied where appropriate to certain lease contracts with similar characteristics. The Company’s lease agreements do not contain any significant residual value guarantees or material restrictive covenants imposed by the leases. Operating leases are included in right of use assets, operating lease liabilities, current and operating lease liabilities, non-current on the Company’s consolidated balance sheets. Finance leases are included in property and equipment, net, other current liabilities, and other long-term liabilities on the Company’s consolidated balance sheets. Finance leases are not material. Redeemable Convertible Preferred Stock Warrant Liability The Company classifies the redeemable convertible preferred stock warrants as a liability on the consolidated balance sheets because the warrants are freestanding financial instruments that may require the Company to transfer assets upon exercise. The liability associated with each of these warrants was initially recorded at fair value upon the issuance date of each warrant and is subsequently re-measured to fair value at each reporting date. Changes in the fair value of the warrant liability are recognized as a component of other income (expense), net in the consolidated statements of operations. Upon the closing of the Company’s IPO in the first quarter of 2020, the warrants to purchase shares of redeemable convertible preferred stock became exercisable and were automatically converted to warrants to purchase Noncontrolling Interest The Company recognizes noncontrolling interest related to variable interest entities in which the Company is the primary beneficiary, as equity (deficit) in the consolidated balance sheets separate from 1Life’s equity (deficit). The earnings attributable to noncontrolling interest are recorded in the consolidated statements of operations as net loss attributable to noncontrolling interest. Any change in ownership of a subsidiary while the controlling financial interest is retained is accounted for as an equity transaction between the controlling and noncontrolling interests. In addition, when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary will be initially measured at fair value and the difference between the carrying value and fair value of the retained interest will be recorded as a gain or loss. Please see Note 3, “Variable Interest Entities” to our consolidated financial statements. Income Taxes Income taxes are computed using the asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s consolidated financial statements. In estimating future tax consequences, the Company considers all expected future events other than enactment of changes in tax laws or rates. A valuation allowance is recorded, if necessary, to reduce net deferred tax assets to their realizable values if management does not believe it is more likely than not that the net deferred tax assets will be realized. As of December 31, 2020, the Company had recorded a partial valuation allowance against its net deferred tax assets in loss generating entities; as of December 31, 2019, the Company had recorded a full valuation allowance against all its deferred tax assets. The Company follows the provisions of the authoritative guidance from the Financial Accounting Standards Board (“FASB”), on accounting for uncertainty in income taxes. These provisions provide a comprehensive model for the recognition, measurement and disclosure in financial statements of uncertain income tax positions that a company has taken or expects to take on a tax return. Under these provisions, a company can recognize the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit can be recognized. Assessing an uncertain tax position begins with the initial determination of the sustainability of the position and is measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed. Additionally, the Company must accrue interest and related penalties, if applicable, on all tax exposures for which reserves have been established consistent with jurisdictional tax laws. The Company’s policy is to recognize interest and penalties related to uncertain tax positions in the provision for income taxes. As of December 31, 2020 and 2019, the Company had no accrued interest or penalties related to uncertain tax positions. Net Loss per Share Attributable to 1Life Healthcare, Inc. Stockholders The Company applies the two-class method to compute basic and diluted net loss per share attributable to 1Life Healthcare, Inc. stockholders when shares meet the definition of participating securities. The two-class method determines net loss per share for each class of common and redeemable convertible preferred stock according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and redeemable convertible preferred stock based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed. During periods of loss, there is no allocation required under the two-class method since the redeemable convertible preferred stock does not have a contractual obligation to share in the Company’s losses. Basic net loss per share attributable to 1Life Healthcare, Inc. stockholders is computed by dividing net loss attributable to 1Life Healthcare, Inc. stockholders by the weighted-average number of common shares outstanding during the period without consideration of potentially dilutive common stock. Diluted net loss per share attributable to 1Life Healthcare, Inc. stockholders reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company unless inclusion of such shares would be anti-dilutive. For periods in which the Company reports net losses, diluted net loss per common share attributable to 1Life Healthcare, Inc. stockholders is the same as basic net loss per common share attributable to 1Life Healthcare, Inc. stockholders, because potentially dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. Revenue Recognition The Company adopted Accounting Standards Codification Topic 606, Revenue from Contracts with Customers, effective January 1, 2019, using the modified retrospective transition method. Net revenue for the years ended December 31, 2020 and 2019 is presented under Topic 606. Net revenue for the year ended December 31, 2018 is presented under Topic 605. The Company generates net revenue through net patient service revenue, partnership revenue and membership revenue. Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. The Company determines revenue recognition through the following steps: (i) Identify the contract(s) with a customer; (ii) Identify the performance obligations in the contract; (iii) Determine the transaction price; (iv) Allocate the transaction price to the performance obligations in the contract; and (v) Recognize revenue as the entity satisfies a performance obligation. Net Patient Service Revenue Net patient service revenue is generated from providing primary care services pursuant to contracts with patients. The Company recognizes revenue as services are rendered, which are delivered over a period of time but typically within one day, when the Company provides services to the patient. The Company receives payments for services from third-party payers as well as from patients who have health insurance where they may bear some cost of the service in the form of co-pays, coinsurance or deductibles. In addition, patients who do not have health insurance are required to pay for their services in full. Providing medical services to patients represents the Company’s performance obligation under the contracts, and accordingly, the transaction price is allocated entirely to the one performance obligation. Net patient service revenue is reported net of provisions for contractual allowances from third-party payers and patients. The Company has certain agreements with third-party payers that provide for reimbursement at amounts different from the Company’s standard billing rates. The differences between the estimated reimbursement rates and the standard billing rates are accounted for as contractual adjustments, which are deducted from gross revenue to arrive at net patient service revenue. The Company estimates implicit price concessions related to payer and patient receivable balances as part of estimating the original transaction price which is based on historical experience, current market conditions, the amount of any receivables in dispute, current receivables aging and other collection indicators. Partnership Revenue Partnership revenue is generated from (i) contracts with employers to provide professional clinical services to employee members at the Company’s on-site clinics, (ii) capitation payments from IPAs to provide professional clinical services to covered participants, (iii) contracts with employers, schools, and universities to provide COVID-19 on-site testing services, and (iv) contracts with health systems as health network partners beginning in 2019. The Company’s main performance obligation under the various partnership arrangements is to stand ready to provide professional clinical services and the associated management and administrative services. As the services are provided concurrently over the contract term and have the same pattern of transfer, the Company has concluded that this represents one performance obligation comprising of a series of distinct services over the contract term. The Company also receives an incentive from certain health network partners to open new clinics, which is considered a distinct performance obligation from the stand-ready obligation to provide clinical and administrative services. Revenue is recognized when the performance obligation is satisfied upon the opening of the new location. While the Company can receive either fixed or variable fees from its enterprise clients (i.e., stated fee per employee per month) for on-site medical services, it generally receives variable fees from IPAs and health networks on a stated fee per member per month basis, based on the number of members (or participants) serviced. The Company also receives variable fees from enterprise clients, schools and, universities on a stated fee per each COVID-19 on-site testing per month basis, based on the number of tests delivered. The Company recognizes revenue as it satisfies its performance obligation. For fixed-fee agreements with its enterprise clients, the Company uses a time-based measure to recognize revenue ratably over the contract term. For variable-fee agreements with health networks, the Company allocates the per member per month variable consideration to the month that the fee is earned, correlated with the amount of services it is providing, which is consistent with the allocation objective of the series guidance. For variable-fee arrangements with employers, schools, and universities to provide COVID-19 on-site testing services, revenue is recognized as services are rendered. The Company generally invoices for the on-site testing services as the work is incurred and monthly in arrears. From time to time, the Company may provide discounts and rebates to the customer. The Company estimates the variable consideration subject to the constraint and recognizes such variable consideration over the contract term. Membership Revenue Membership revenue is generated from annual membership fees paid by consumer members and from enterprise clients who purchase access to memberships for their employees and dependents. The terms of service on the Company’s website serve as the contract between the Company and consumer members. The Company enters into written contracts with enterprise clients. The transaction price for contracts with enterprise clients is determined on a per employee per month basis, based on the number of employees eligible for membership established at the beginning of the contract term, which is generally one year. The transaction price for the contract is stated in the contract or determinable and is generally collected in advance of the contract term. The Company may provide numerous services under the agreements; however, these services are generally not considered individually distinct as they are not separately identifiable in the context of the agreement. As a result, the Company’s single performance obligation in the transaction constitutes a series for the provision of membership and services as and when requested over the membership term. The transaction price relates specifically to the Company’s efforts to transfer the services for a distinct increment of the series. Accordingly, the transaction price is allocated entirely to the one performance obligation. Membership revenue is recognized ratably over the contract period with the individual member or enterprise client. Unrecognized but collected amounts are recorded to deferred revenue and amortized over the remainder of the applicable membership period. Contracts with Multiple Performance Obligations Certain contracts with customers contain multiple performance obligations that are distinct

Variable Interest Entities

Variable Interest Entities	12 Months Ended
Variable Interest Entities	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Variable Interest Entities	3. 1Life’s agreements with the PCs generally consist of both Administrative Services Agreements (“ASAs”), which provide for various administrative and management services to be provided by 1Life to the PC, and Succession Agreements, which provide for transition of ownership of the PCs under certain conditions. The ASAs typically provide that the term of the arrangements is ten years with automatic renewal for successive one-year terms, subject to termination by 1Life or the PC in certain specified circumstances. The outstanding voting equity instruments of the PCs are owned by nominee shareholders appointed by 1Life (or the PC in one instance) under the terms of the Succession Agreements or other shareholders who are also subject to the terms of the Succession Agreements. 1Life has the right to receive income as an ongoing administrative fee in an amount that represents fair value of services rendered and has provided all financial support through loans to the PCs. 1Life has exclusive responsibility for the provision of all nonmedical services including facilities, technology and intellectual property required for the day-to-day operation and management of each of the PCs, and makes recommendations to the PC in establishing the guidelines for the employment and compensation of the physicians and other employees of the PCs. In addition, the agreements provide that 1Life has the right to designate a person(s) to purchase the stock of the PCs for a nominal amount in the event of a succession event. Based upon the provisions of these agreements, 1Life determined that the PCs are variable interest entities due to its equity holder having insufficient capital at risk, and 1Life has a variable interest in the PCs. The contractual arrangement to provide management services allows 1Life to direct the economic activities that most significantly affect the PC. Accordingly, 1Life is the primary beneficiary of the PCs and consolidates the PCs under the VIE model. Furthermore, as a direct result of nominal initial equity contributions by the physicians, the financial support 1Life provides to the PCs (e.g. loans) and the provisions of the nominee shareholder succession arrangements described above, the interests held by noncontrolling interest holders lack economic substance and do not provide them with the ability to participate in the residual profits or losses generated by the PCs. Therefore, all income and expenses recognized by the PCs are allocated to 1Life stockholders. The aggregate carrying value of the current assets and liabilities included in the consolidated balance sheets for the PCs after elimination of intercompany transactions and balances were $48,182 and $31,462, respectively, as of December 31, 2020 and $28,227 and $13,927, respectively, as of December 31, 2019. The PCs did not have noncurrent assets or liabilities. In September 2014, 1Life entered into a joint venture agreement with a healthcare system to jointly operate physician owned primary care offices in a new market. Pursuant to the formation of this joint venture, the healthcare system contributed $10,000 for a 56.9% interest and 1Life contributed management expertise for a 43.1% interest. One of the PCs had the responsibility for the provision of medical services and 1Life had responsibility for the day-to-day operation and management of the offices, including the establishment of guidelines for the employment and compensation of the physicians. Based upon this and other provisions of the operating agreement that indicated that 1Life directed the economic activities that most significantly affected the economic performance of the joint venture, 1Life determined that the joint venture was a variable interest entity and that 1Life was the primary beneficiary. The Company recorded the $10,000 cash received in noncontrolling interest in the consolidated balance sheet. The income and expenses of the joint venture were recorded in the consolidated statements of operations and statements of comprehensive loss as net loss attributable to noncontrolling interest. Effective April 1, 2020, 1Life terminated the joint venture agreement with the healthcare system and transferred its ownership interest in the joint venture to the healthcare system. As a result, the joint venture became a wholly owned subsidiary of the healthcare system. The joint venture was deconsolidated in the consolidated financial statements as of April 1, 2020 and the Company derecognized all assets and liabilities of the joint venture. The Company did not record a gain or loss in association with the deconsolidation as the Company did not retain any noncontrolling interest in the joint venture and no consideration was transferred as a result of the ownership interest transfer to the healthcare system. At the point of deconsolidation, 100% of the net assets were attributable to the noncontrolling interest. The following table shows the balances immediately preceding the deconsolidation of the joint venture that occurred on April 1, 2020: Partially Owned April 1, 2020 Assets Current assets: Cash and cash equivalents $ 810 Accounts receivable, net 768 Prepaid expenses and other current assets 18 Total current assets 1,596 Other assets 19 Property and equipment, net 1,504 Right-of-use assets 1,509 Total assets $ 4,628 Liabilities Current liabilities: Accounts payable and accrued expenses $ 9 Operating lease liabilities, current 273 Other current liabilities 143 Total current liabilities 425 Operating lease liabilities, non-current 1,872 Total liabilities $ 2,297 The table below present the assets and liabilities (excluding intercompany balances that are eliminated in consolidation) for the joint venture as of December 31, 2019: Partially Owned December 31, 2019 Assets Current assets: Cash and cash equivalents $ 1,411 Accounts receivable, net 817 Prepaid expenses and other current assets 24 Total current assets 2,252 Other assets 19 Property and equipment, net 1,521 Right-of-use assets 1,553 Total assets $ 5,345 Liabilities Current liabilities: Accounts payable and accrued expenses $ 60 Operating lease liabilities, current 265 Other current liabilities 57 Total current liabilities 382 Operating lease liabilities, non-current 1,946 Total liabilities $ 2,328 The consolidated balance sheet as of December 31, 2019 and the consolidated statement of operations for the year ended December 31, 2020 include the operations of the joint venture through the date of deconsolidation. The consolidated balance sheet as of December 31, 2020 does not include the operations of the joint venture.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis: Fair Value Measurements as of December 31, 2020 Using: Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market fund $ 50,761 $ - $ - $ 50,761 Commercial paper - 19,999 - 19,999 Short-term investments: U.S. Treasury obligations 416,158 - - 416,158 U.S. government agency securities 20,000 - - 20,000 Commercial paper - 133,865 - 133,865 $ 486,919 $ 153,864 $ - $ 640,783 Fair Value Measurements as of December 31, 2019 Using: Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market fund $ 13,580 $ - $ - $ 13,580 Commercial paper - 4,997 - $ 4,997 Short-term investments: U.S. Treasury obligations 48,968 - - $ 48,968 Commercial paper - 70,178 - 70,178 $ 62,548 $ 75,175 $ - $ 137,723 Liabilities: Redeemable convertible preferred stock warrant liability $ - $ - $ 7,220 $ 7,220 $ - $ - $ 7,220 $ 7,220 During the years ended December 31, 2020 and 2019, there were no transfers between Level 1, Level 2 and Level 3. Valuation of Redeemable Convertible Preferred Stock Warrant Liability The redeemable convertible preferred stock warrant liability in the table above relates to redeemable convertible preferred stock warrants issued in connection with certain note payable transactions (See Note 12, “Debt”). The fair value of the redeemable convertible preferred stock warrant liability was determined based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The Company used the Black-Scholes option-pricing model, which incorporates assumptions and estimates, to value the redeemable convertible preferred stock warrants. Additionally, because the redeemable convertible preferred stock has certain conversion features, the fair value of the related redeemable convertible preferred stock warrants is re-measured to fair value on a periodic basis and any changes to the redeemable convertible preferred stock warrant liability are recorded in the consolidated statements of operations in the related period. The Company determined the fair value per share of the underlying redeemable convertible preferred stock by taking into consideration the most recent sales of its redeemable convertible preferred stock, results obtained from third-party valuations and additional factors that are deemed relevant. The Company historically has been a private company and lacks company-specific historical and implied volatility information of its stock. Therefore, it estimates its expected stock volatility based on the historical volatility of publicly traded peer companies for a term equal to the remaining contractual term of the redeemable convertible preferred stock warrant. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining contractual term of the redeemable convertible preferred stock warrant. The Company estimated a 0% expected dividend yield based on the fact that the Company has never paid or declared dividends and does not intend to do so in the foreseeable future. The assumptions that the Company used to determine the fair value of the redeemable convertible preferred stock warrants were as follows: Year Ended December 31, 2020 2019 2018 Expected stock price volatility 46.5% - 55.0% 39.9% - 55.4% 40.4% - 44.6% Risk-free interest rate 1.5% - 1.6% 1.6% - 1.7% 2.7 % Remaining contractual term 0.1 - 5 years 0.2 - 5 years 1 - 6 years Expected dividend yield 0.0 % 0.0 % 0.0 % Estimated fair value $16.93 - $22.52 $7.10 - $12.53 $2.67 - $6.90 The following table provides a roll forward of the aggregate fair values of the Company’s redeemable convertible preferred stock warrant liability, for which fair value is determined using Level 3 inputs: Convertible Redeemable Preferred Stock Warrant Liability Balance as of December 31, 2017 $ 2,686 Warrant exercise (862 ) Change in fair value 1,877 Balance as of December 31, 2018 3,701 Change in fair value 3,519 Balance as of December 31, 2019 7,220 Warrant exercise (40 ) Change in fair value 6,560 Conversion of preferred stock warrants into common stock warrants (13,740 ) Balance as of December 31, 2020 $ - Upon the closing of the Company’s IPO in the first quarter of 2020, the warrants to purchase shares of redeemable convertible preferred stock became exercisable and were automatically converted to warrants to purchase shares of common stock. As a result, following the closing of the Company’s IPO, the warrants are no longer subject to fair value accounting. Valuation of Convertible Senior Notes The Company has $316,250 aggregate principal amount outstanding of 3.0% convertible senior notes due in 2025 (the “2025 Notes”). Refer to Note 12, “Debt” for further details on the 2025 Notes. As of December 31, 2020, the fair value of the 2025 Notes was $397,472. The fair value was determined based on the closing trading price of the 2025 Notes as of the last day of trading for the period. The fair value of the 2025 Notes is primarily affected by the trading price of the Company's common stock and market interest rates. The fair value of the 2025 Notes is considered a Level 2 measurement as they are not actively traded.

Revenue Recognition

Revenue Recognition	12 Months Ended
Revenue Recognition	Dec. 31, 2020
Revenue From Contract With Customer [Abstract]
Revenue Recognition	5. The reported results for the years ended December 31, 2020 and 2019 reflect the application under the guidance of Topic 606, while the reported results for the year ending December 31, 2018 reflect the application of Topic 605 guidance. The following table summarizes the Company’s net revenue by primary source: Year Ended December 31, 2020 2019 2018 Net revenue: Net patient service revenue $ 149,695 $ 145,389 $ 144,080 Partnership revenue 159,482 78,734 25,408 Total net patient service and partnership revenue 309,177 224,123 169,488 Membership revenue 68,466 52,135 43,190 Grant income 2,580 - - Net revenue $ 380,223 $ 276,258 $ 212,678 Net patient service revenue is primarily generated from commercial third-party payers with which the One Medical entities have established contractual billing arrangements. The following table summarizes net patient service revenue by source: Year Ended December 31, 2020 2019 2018 Net patient service revenue: Commercial and government third-party payers 136,388 121,502 119,657 Patients, including self-pay, insurance co-pays and deductibles 13,307 23,887 24,423 Net patient service revenue 149,695 145,389 144,080 The CARES Act was enacted on March 27, 2020 to provide economic relief to those impacted by the COVID-19 pandemic. The CARES Act includes various tax and lending provisions, among others. Under the CARES Act, the Company received an income grant of $2,580 from the Provider Relief Fund administered by the Health and Human Services (“HHS”) during the year ended December 31, 2020. Management has concluded that the Company met conditions of the grant funds and has recognized it as Grant income for the year ended December 31, 2020. The Company cannot predict the extent to which it will receive any such additional funds in future periods. During the year ended December 31, 2020, the Company recognized revenue of $26,026, which was included in the beginning deferred revenue balance as of January 1, 2020. During the year ended December 31, 2019, the Company recognized revenue of $21,004, which was included in the beginning deferred revenue balance as of January 1, 2019. During the year ended December 31, 2020, the Company updated its assessment of variable consideration for its existing contracts which resulted in a reduction to net revenue in the amount of $7,390. As of December 31, 2020, a total of $6,774 is included within deferred revenue related to variable consideration, of which $5,865 is classified as non-current as it will not be recognized within the next twelve months. During the year ended December 31, 2019, the Company updated its assessment of variable consideration for its existing contracts which did not have a material impact. The estimate of variable consideration is based on the Company’s assessment of historical, current, and forecasted performance. As summarized in the table below, the Company recorded contract assets and deferred revenue as a result of timing differences between the Company’s performance and the customer’s payment. December 31, 2020 2019 Balances from contracts with customers: Accounts receivable $ 67,895 $ 33,601 Contract asset (included in prepaid expenses and other current assets) 513 600 Deferred revenue 43,590 27,024 The Company does not disclose the value of remaining performance obligations for (i) contracts with an original contract term of one year or less, (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice when that amount corresponds directly with the value of services performed, and (iii) variable consideration allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied distinct service that forms part of a single performance obligation. For those contracts that do not meet the above criteria, the Company’s remaining performance obligation as of December 31, 2020, is expected to be recognized as follows: Less than Greater or equal to than 12 months 12 months Total As of December 31, 2020 $ 5,107 $ 10,562 $ 15,669

Cash Equivalents and Short-Term

Cash Equivalents and Short-Term Marketable Securities	12 Months Ended
Cash Equivalents and Short-Term Marketable Securities	Dec. 31, 2020
Cash Cash Equivalents And Short Term Investments [Abstract]
Cash Equivalents and Short-Term Marketable Securities	6. Cash Equivalents and Short-Term Marketable Securities At December 31, 2020 and 2019, the Company’s cash equivalents and short-term marketable securities were as follows: December 31, 2020 Gross Amortized unrealized cost gains (losses) Fair value Cash equivalents: Money market fund $ 50,761 $ - $ 50,761 Commercial paper 19,999 19,999 Total cash equivalents 70,760 - 70,760 Short-term marketable securities: U.S. Treasury obligations 416,150 8 416,158 U.S. government agency securities 20,000 - 20,000 Commercial paper 133,865 - 133,865 Total short-term marketable securities 570,015 8 570,023 Total cash equivalents and short-term marketable securities $ 640,775 $ 8 $ 640,783 December 31, 2019 Gross Amortized unrealized cost gains (losses) Fair value Cash equivalents: Money market fund $ 13,580 $ - $ 13,580 Commercial paper 4,997 - 4,997 Total cash equivalents 18,577 - 18,577 Short-term marketable securities: U.S. Treasury obligations 48,930 38 48,968 Commercial paper 70,178 - 70,178 Total short-term marketable securities 119,108 38 119,146 Total cash equivalents and short-term marketable securities $ 137,685 $ 38 $ 137,723

Property and Equipment, net

Property and Equipment, net	12 Months Ended
Property and Equipment, net	Dec. 31, 2020
Property Plant And Equipment [Abstract]
Property and Equipment, net	7. Property and equipment consisted of the following: December 31, 2020 2019 Leasehold improvements 118,434 $ 83,018 Computer software, including internal-use software 25,708 16,508 Computer equipment 21,502 16,653 Furniture and fixtures 11,805 7,359 Laboratory equipment 6,541 3,428 Construction in progress 8,550 12,288 192,540 139,254 Less: Accumulated depreciation and amortization (66,503 ) (48,538 ) $ 126,037 $ 90,716 The Company capitalized $10,069, $6,914 and $3,466 in internal-use software development costs, and recognized depreciation expense related to these assets of $4,907, $3,152 and $2,137 during the years ended December 31, 2020, 2019 and 2018, respectively. As of December 31, 2020 and 2019, the net book value of internal-use software was $14,106 and $8,944, respectively. The Company had disposals in the ordinary course of business of $2,777, $6,466 and $2,735 during the years ended December 31, 2020, 2019 and 2018, respectively. The net loss on disposal was immaterial during the years ended December 31, 2020, 2019 and 2018, respectively. Total depreciation and amortization expense related to property and equipment for the years ended December 31, 2020, 2019 and 2018 was $22,301, $13,970 and $9,586, respectively. All long-lived assets are maintained in the United States. The Company had immaterial financing leased assets held within computer equipment and computer software as of December 31, 2020 and 2019.

Leases

Leases	12 Months Ended
Leases	Dec. 31, 2020
Leases [Abstract]
Leases	8. Leases Leases (under ASC 840) Rent expense for the year ended December 31, 2018, was $13,810. Of this amount, $10,698 was recorded in practice expenses and $3,112 was recorded in general and administrative expenses for the year ended December 31, 2018. Leases (under ASC 842) At inception of a contract, the Company determines if a contact meets the definition of a lease. A lease is a contract, or part of a contract, that conveys the right to control the use of identified property, plant, or equipment (an identified asset) for a period of time in exchange for consideration. The Company assesses throughout the period of use whether the Company has both of the following: i) the right to obtain substantially all of the economic benefits from use of the identified asset, and ii) the right to direct the use of the identified asset. This determination is reassessed if the terms of the contract are changed. Leases are classified as operating or finance leases based on the terms of the lease agreement and certain characteristics of the identified asset. Right-of-use assets and operating lease liabilities are recognized at lease commencement date based on the present value of the minimum future lease payments. The carrying value of the Company’s right-of-use assets are substantially concentrated in real estate as the Company primarily leases office space. The Company’s policy is not to record leases with an original lease term of one year or less on the consolidated balance sheets. The Company recognizes lease expense for these short-term leases on a straight-line basis over the lease term. Certain lease agreements include rental payments that are adjusted periodically for inflation or other variables. In addition to rent, the leases may require the Company to pay additional amounts for taxes, insurance, maintenance and other expenses, which are generally referred to as non-lease components. Such adjustments to rental payments and variable non-lease components are treated as variable lease payments and recognized in the period as incurred. Variable lease components and variable non-lease components are not measured as part of the right-of-use assets and lease liability. Only when lease components and their associated non-lease components are fixed are they recognized as part of the right-of-use assets and lease liability. Most leases contain clauses for renewal at the Company’s option with renewal terms that generally extend the lease term from 1 to 7 years. Certain lease agreements contain options to terminate the lease before maturity. The Company does not have any lease contracts with the option to purchase as of December 31, 2020. Payments to be made in option periods are recognized as part of the right-of-use lease assets and lease liabilities when the Company is reasonably certain that the option to extend the lease will be exercised or the option to terminate the lease will not be exercised, or is not at the Company’s option. The Company determines whether the reasonably certain threshold is met by considering contract-, asset-, market-, and entity-based factors. A portfolio approach is applied where appropriate to certain lease contracts with similar characteristics. The Company’s lease agreements do not contain any significant residual value guarantees or material restrictive covenants imposed by the leases. Certain of the Company’s furniture and fixtures and lab equipment are held under finance leases. Lease-related assets are included in property and equipment, net in the consolidated balance sheets and are immaterial as of December 31, 2020 and 2019. The components of operating lease costs were as follows: Year Ended December 31, 2020 2019 Operating lease costs $ 25,250 $ 19,165 Variable lease costs 4,166 2,612 Total lease costs $ 29,416 $ 21,777 Other information related to leases was as follows: Supplemental Cash Flow Information Year Ended December 31, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 24,735 $ 17,260 Non-cash leases activity: Right-of-use lease assets obtained in exchange for new operating lease liabilities $ 45,957 $ 57,621 Lease Term and Discount Rate As of December 31, 2020 2019 Weighted-average remaining lease term (in years) 8.36 7.26 Weighted-average discount rate 7.60 % 7.50 % At the lease commencement date, the discount rate implicit in the lease is used to discount the lease liability if readily determinable. If not readily determinable or leases do not contain an implicit rate, the Company’s incremental borrowing rate is used as the discount rate. Management determines the appropriate incremental borrowing rates for each of its leases based on the remaining lease term at lease commencement. Future minimum lease payments under non-cancellable operating leases as of December 31, 2020 were as follows (excluding the effect of lease incentives to be received that are recorded in prepaid expenses and other current assets of $5,563 which serve to reduce total lease payments): Year Ended December 31, As of December 31, 2020 2021 $ 29,866 2022 28,572 2023 27,763 2024 27,070 2025 25,071 Thereafter 97,247 Total lease payments 235,589 Less: interest (64,557 ) Total lease liabilities $ 171,032 The amounts in the table above do not reflect payments for leases that have not yet commenced in the amount of $40,809.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
Goodwill and Intangible Assets	Dec. 31, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	9. The Company’s goodwill was generated from business acquisitions of various PCs and a business acquisition in 2016. There have been no changes to the goodwill carrying value during the years ended December 31, 2020 and 2019. Intangible assets became fully amortized and were removed from the consolidated balance sheet as of December 31, 2020. The following summarizes the Company’s intangible assets and accumulated amortization as of December 31, 2019: December 31, 2019 Original Accumulated Net Book Cost Amortization Value Independent physician association agreements $ 6,460 $ (6,460 ) $ - Non compete agreements 1,175 (1,152 ) 23 Customer relationships 200 (200 ) - Trade names 100 (100 ) - $ 7,935 $ (7,912 ) $ 23 The Company recorded amortization expense of $23, $281 and $361 for the years ended December 31, 2020, 2019 and 2018, respectively. The intangible assets attributable to the PCs were amortized over five years. The intangible assets attributable to the medical practices were being amortized over the four-year term of the noncompete arrangements. The intangible assets attributable to a business acquisition in 2016 were being amortized over two to four years.

Accrued Expenses

Accrued Expenses	12 Months Ended
Accrued Expenses	Dec. 31, 2020
Payables And Accruals [Abstract]
Accrued Expenses	10. Accrued Expenses Accrued expenses consisted of the following: December 31, 2020 2019 Accrued employee compensation and benefits $ 28,414 $ 13,929 Inventories received not yet invoiced 3,749 563 Construction in progress 811 3,844 Self-insurance programs 1,936 1,753 Legal and professional fees 1,486 1,032 Medical office and lab supplies 3,581 289 Other accrued expenses 6,550 3,453 Total $ 46,527 $ 24,863

Self-Insurance Reserves

Self-Insurance Reserves	12 Months Ended
Self-Insurance Reserves	Dec. 31, 2020
Insurance Loss Reserves [Abstract]
Self-Insurance Reserves	11. Self-Insurance Reserves The following table provides a rollforward of the insurance reserves related to the Company’s self-insurance program: December 31, 2020 2019 Beginning balance $ 1,753 $ 819 Losses paid (16,394 ) (10,867 ) Reserves for current period 16,577 11,801 Ending balance $ 1,936 $ 1,753

Debt

Debt	12 Months Ended
Debt	Dec. 31, 2020
Debt Disclosure [Abstract]
Debt	12. Debt Term Notes In January 2013, the Company entered into a loan and security agreement with an institutional lender and with subsequent amendments for borrowings of $11,000 at an interest rate at the greater of prime plus 1.81% or 5.56%, (“the “LSA”). In connection with the LSA agreement, the Company issued to the lenders 494,833 warrants. Borrowings under the LSA were secured by substantially all of the Company’s properties, rights and assets, excluding intellectual property. On September 1, 2020, the term notes under the LSA matured and the remaining outstanding principal was repaid, plus accrued and unpaid interest. For the years ended December 31, 2020, 2019 and 2018, the Company recorded aggregate interest expense of $86, $469 and $801, respectively. The non-cash interest expense related to the accretion of debt discounts for common and redeemable convertible preferred stock warrants included in the aggregate interest expense for the years ended December 31, 2020, 2019 and 2018 was immaterial. The Company’s annual effective interest rate was approximately 6.0%, 7.2% and 6.7% for the years ended December 31, 2020, 2019 and 2018, respectively. During the years ended December 31, 2020, 2019 and 2018, the Company made aggregate principal payments of $3,300, $4,400 and $3,300, respectively. Convertible Senior Notes In May 2020, the Company issued and sold $275,000 aggregate principal amount of 3.0% convertible senior notes due 2025 in a private offering exempt from the registration requirements of the Securities Act of 1933, and in June 2020, the Company issued an additional $41,250 aggregate principal amount of such notes pursuant to the exercise in full of the over-allotment option by the initial purchasers of the 2025 Notes. The 2025 Notes are unsecured obligations and bear interest at a fixed rate of 3.0% per annum, payable semi-annually in arrears on June 15 and December 15 of each year, commencing on December 15, 2020. The 2025 Notes will mature on June 15, 2025, unless earlier converted, redeemed or repurchased. The total net proceeds from the debt offering, after deducting the initial purchasers’ commissions and other issuance costs, were $306,868. Each $1 principal amount of the 2025 Notes will initially be convertible into 22.5052 shares of the Company’s common stock, which is equivalent to an initial conversion price of $44.43 per share, subject to adjustment upon the occurrence of specified events but not for any accrued and unpaid interest. Holders may convert the 2025 Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2025 only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on September 30, 2020 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined below) per $1 principal amount of the 2025 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day; (3) if the Company calls such 2025 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. It is the Company’s current intent to settle conversions through combination settlement comprising of cash and equity On or after March 15, 2025 until the close of business on the business day immediately preceding the maturity date, holders may convert all or any portion of their 2025 Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock, at the Company’s election and in accordance with the terms of the indenture governing the 2025 Notes. If the Company satisfies its conversion obligation solely in cash or through payment and delivery, as the case may be, of a combination of cash and shares of the Company’s common stock, the amount of cash and shares of common stock, if any, due upon conversion will be based on a daily conversion value calculated on a proportionate basis for each trading day in a 40 trading day observation period. In addition, following certain corporate events that occur prior to the maturity date or if the Company delivers a notice of redemption, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its 2025 Notes in connection with such a corporate event or notice of redemption, as the case may be. If the Company undergoes a fundamental change prior to the maturity date, holders of the 2025 Notes may require the Company to repurchase for cash all or any portion of their notes at a repurchase price equal to 100% of the In addition, if specific corporate events occur prior to the applicable maturity date, the Company will increase the conversion rate for a holder who elects to convert their 2025 Notes The Company may not redeem the 2025 Notes prior to June 20, 2023. The Company may redeem for cash all or any portion of the 2025 Notes, at the Company’s option, on or after June 20, 2023 and prior to March 15, 2025, if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the 2025 Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the notes. In accounting for the issuance of the 2025 Notes, the Company separated the 2025 Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar debt instrument that does not have an associated convertible feature. As of the issuance date of the 2025 Notes, the liability component was initially measured at $240,637. The carrying amount of the equity component representing the conversion option was $75,635 and was determined by deducting the fair value of the liability component from the par value of the 2025 Notes. The equity component was recorded in additional paid-in capital and is not remeasured as long as it continues to meet the conditions for equity classification. The excess of the principal amount of the liability component over its carrying amount (debt discount) is amortized to interest expense over the contractual term of the 2025 Notes at an effective interest rate of 9.68%. In accounting for the debt issuance costs of $9,374 related to the 2025 Notes, the Company allocated the total amount incurred to the liability and equity components of the 2025 Notes based on their relative values. Issuance costs attributable to the liability component were $7,132 and will be amortized to interest expense using the effective interest method over the contractual terms of the 2025 Notes. Issuance costs attributable to the equity component of $2,242 were netted with the equity component in additional paid-in capital. The net carrying amount of the liability component of the 2025 Notes was as follows: December 31, 2020 Principal $ 316,250 Unamortized debt discount (68,441 ) Unamortized issuance costs (6,576 ) Net carrying amount $ 241,233 The net carrying amount of the equity component of the 2025 Notes was as follows: December 31, 2020 Debt discount related to value of conversion option $ 75,635 Issuance costs (2,242 ) Net carrying amount $ 73,393 The following table sets forth the interest expense recognized related to the 2025 Notes: Year Ended December 31, 2020 Contractual interest expense $ 5,587 Amortization of debt discount 7,194 Amortization of issuance costs 556 Total interest expense related to the 2025 Notes $ 13,337

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock Warrants	12 Months Ended
Redeemable Convertible Preferred Stock Warrants	Dec. 31, 2020
Warrants And Rights Note Disclosure [Abstract]
Redeemable Convertible Preferred Stock Warrants	13. Redeemable Convertible Preferred Stock Warrants Warrants to purchase 5,573 shares of Series G redeemable convertible preferred stock were converted to preferred stock prior to the closing of the Company’s IPO. Upon the closing of the IPO, all redeemable preferred stock warrants were converted into warrants to purchase 667,668 shares of common stock. As of December 31, 2019, outstanding redeemable convertible preferred stock warrants to purchase shares of redeemable convertible preferred stock consisted of the following: Number of Exercise Date Exercisable Shares Issuable Price Exercisable for Classification Expiration February 26, 2010 100,000 $ 0.92 Series C Liability February 26, 2020 June 28, 2011 250,000 $ 1.05 Series D Liability June 28, 2021 January 30, 2013 99,280 $ 1.61 Series E Liability January 30, 2023 October 3, 2015 11,010 $ 6.59 Series G Liability October 3, 2020 October 5, 2015 10,837 $ 6.59 Series G Liability October 5, 2020 October 7, 2015 4,918 $ 6.59 Series G Liability October 7, 2020 October 8, 2015 5,573 $ 6.59 Series G Liability October 8, 2020 October 12, 2015 5,619 $ 6.59 Series G Liability October 12, 2020 October 14, 2015 113,879 $ 6.59 Series G Liability October 14, 2020 October 28, 2015 3,796 $ 6.59 Series G Liability October 28, 2020 November 4, 2015 22,776 $ 6.59 Series G Liability November 4, 2020 January 26, 2015 45,553 $ 6.59 Series G Liability January 26, 2025 673,241 The grant date fair value of the redeemable convertible warrants was determined using a Black-Scholes model and was recorded as a redeemable convertible preferred stock warrant liability. The Company re-measured the liability associated with the redeemable convertible preferred stock warrants as of December 31, 2019 and determined that the fair value of the redeemable convertible preferred stock warrant liability was $7,220. Upon the closing of the IPO, the warrants to purchase shares of redeemable convertible preferred stock became exercisable and were automatically converted to warrants to purchase shares of common stock, at which time the Company adjusted the redeemable convertible preferred stock warrant liability to fair value at $13,740 (See Note 4, “Fair Value Measurements”). The Company recognized losses in connection with changes in the fair value of the redeemable convertible preferred stock warrant liability of $6,560, $3,519, and $1,877, within other (income) expense, net in the consolidated statements of operations for the years ended December 31, 2020, 2019 and 2018, respectively.

Preferred Stock and Redeemable

Preferred Stock and Redeemable Convertible Preferred Stock	12 Months Ended
Preferred Stock and Redeemable Convertible Preferred Stock	Dec. 31, 2020
Temporary Equity Disclosure [Abstract]
Preferred Stock and Redeemable Convertible Preferred Stock	14. Preferred Stock As of December 31, 2020, the Company’s Certificate of Incorporation, as amended and restated, authorized the Company to issue 10,000,000 shares of preferred stock, par value of $0.001 per share. As of December 31, 2020, there are no holders of the Company’s preferred stock. Redeemable Convertible Preferred Stock As of December 31, 2019, the Company’s Certificate of Incorporation, as amended and restated, authorized the Company to issue 89,338,425 shares of redeemable convertible preferred stock, par value of $0.001 per share. Upon the closing of the Company’s IPO, all shares of redeemable convertible preferred stock then outstanding were automatically converted into 86,257,242 shares of common stock. As of December 31, 2020, there are no holders of the Company’s redeemable convertible preferred stock. As of December 31, 2019, redeemable convertible preferred stock consisted of the following: Preferred Preferred Stock Common Stock Stock Issued and Carrying Liquidation Issuable Upon Authorized Outstanding Value Preference Conversion Series A preferred stock 1,130,000 1,130,000 $ 540 $ 585 1,130,000 Series B preferred stock 6,324,592 6,324,592 4,424 3,500 6,324,592 Series C preferred stock 8,763,634 8,663,634 7,938 8,000 8,663,634 Series D preferred stock 14,528,912 14,278,912 14,899 15,000 14,278,912 Series E preferred stock 12,509,305 12,410,025 19,905 20,000 12,410,025 Series F preferred stock 11,695,449 11,695,449 29,885 30,000 11,695,449 Series G preferred stock 6,829,076 6,605,115 43,358 43,500 6,605,115 Series H preferred stock 7,444,827 7,444,827 64,875 65,000 7,444,827 Series I preferred stock 20,112,630 17,699,115 216,664 220,000 17,699,115 89,338,425 86,251,669 $ 402,488 $ 405,585 86,251,669 Prior to the closing of the Company’s IPO, the holders of redeemable convertible preferred stock had the following rights and preferences: Conversion Each share of redeemable convertible preferred stock was convertible into shares of common stock on a one-for-one basis, subject to appropriate adjustment in the event of any stock split, stock dividend, combination or other similar recapitalization at the option of the stockholder and subject to adjustments in accordance with anti-dilution provisions. In addition, such shares would be converted automatically into common stock at the applicable conversion ratio then in effect for each series of redeemable convertible preferred stock upon the earlier of (i) the immediate closing of a firm commitment underwritten public offering of the Company’s common stock with gross proceeds to the Company of at least $50,000 or (ii) obtaining the affirmative vote of the holders of at least 65% of the outstanding shares of the redeemable convertible preferred stock (voting together as a single class on an as-if-converted basis), two-thirds of the then outstanding shares of Series G (voting as a separate series), a majority of the then outstanding shares of Series H (voting as a separate series), and a majority of the outstanding shares of Series I (voting as a separate series) of the shares of redeemable convertible preferred stock outstanding at the time of such vote. Voting Rights Each share of redeemable convertible preferred stock had voting rights equivalent to the number of shares of common stock into which it was convertible. In addition, for so long as at least 1,000,000 shares of each class of redeemable convertible preferred stock remained outstanding, the holders of Series B, C, D, E, F and G redeemable convertible preferred stock, voting as a separate class, were each entitled to elect one director of the Company. As long as at least 1,000,000 shares of Series I remained outstanding, the holders of Series I were entitled to elect two directors of the Company. The holders of redeemable convertible preferred stock, together with the holders of common stock and voting as a single class, were entitled to elect the remaining directors of the Company by vote of a majority of such shares. In addition, in certain circumstances, certain actions related to major transactions were subject to a separate vote by Series I preferred stockholders in a more limited manner. Dividends Redeemable convertible preferred stockholders were entitled to receive noncumulative dividends if and as declared by the Board of Directors out of any assets legally available, prior to, and in preference to, any declaration or payment of any dividend on the common stock. The dividend rate for redeemable convertible preferred stock per share per annum was 6% for Series A, Series C, Series D and Series E and 8% for Series B, Series F, Series G, Series H and Series I of the original issue price. Liquidation In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the affairs of the Company, a change in control, or a sale of substantially all of the Company’s assets, (“liquidation event”), each holder of a share of redeemable convertible preferred stock was entitled to receive, prior to, and in preference to, any distribution of any of the assets or property of the Company to the holders of the common stock, for each outstanding share of redeemable convertible preferred stock, an amount per share equal to $0.500 for Series A, $0.574 for Series B, $0.923 for Series C, $1.051 for Series D, $1.612 for Series E, $2.565 for Series F, $6.586 for Series G, $8.731 for Series H, and $12.43 for Series I, plus all declared and unpaid dividends. If, upon any such liquidation event, the assets of 1Life were insufficient to make payment in full to all holders of redeemable convertible preferred stock, then such assets would be first distributed to Series I holders, then distributed among the holders of redeemable convertible preferred stock at the time outstanding, ratably in proportion to the full amounts to which they would otherwise be, respectively, entitled. Redemption The holders of the Company’s redeemable convertible preferred stock had no voluntary rights to redeem shares. A liquidation or winding up of the Company, a change in control, or a sale of substantially all of the Company’s assets would constitute a redemption event which may be outside of the Company’s control. Accordingly, these shares were considered contingently redeemable and were classified as temporary equity on the consolidated balance sheet.

Common Stock

Common Stock	12 Months Ended
Common Stock	Dec. 31, 2020
Equity [Abstract]
Common Stock	15. As of December 31, 2020 and 2019, the Company’s Certificate of Incorporation, as amended and restated, authorized the Company to issue 1,000,000,000 and 150,000,000 shares of common stock, respectively, par value of $0.001 per share. Each share of common stock is entitled to one vote. In June 2020, the Company completed a secondary offering in which certain stockholders sold 8,300,000 shares of common stock at an offering price of $31.00 per share. The selling stockholders received all of the net proceeds from the sale of shares in this offering. The Company did not sell any shares or receive any proceeds in this secondary offering. The Company had reserved shares of common stock for issuance in connection with the following: December 31, 2020 2019 Conversion of outstanding shares of redeemable convertible preferred stock - 86,251,669 Warrants to purchase redeemable convertible preferred stock (as converted to common stock) - 673,241 Options outstanding under the Equity Incentive Plans 28,273,033 27,806,309 Unvested restricted stock 1,290,953 - Options available for future issuance 9,855,031 1,350,202 39,419,017 116,081,421

Stock-Based Compensation and Em

Stock-Based Compensation and Employee Benefit Plans	12 Months Ended
Stock-Based Compensation and Employee Benefit Plans	Dec. 31, 2020
Employee Benefits And Share Based Compensation [Abstract]
Stock-Based Compensation and Employee Benefit Plans	16. Stock-Based Compensation and Employee Benefit Plans Stock Incentive Plan The Company has the following stock-based compensation plans: 2007 Equity Incentive Plan (the “2007 Plan”), the 2017 Equity Incentive Plan (the “2017 Plan”), and the 2020 Equity Incentive Plan (the “2020 Plan", and, together with the 2007 Plan and the 2017 Plan, the “Plans”). In January 2020, the Company’s stockholders approved the Company’s 2020 Equity Incentive Plan, which took effect upon the execution of the underwriting agreement for the Company’s IPO in January 2020. The 2020 Plan is intended as the successor to and continuation of the 2007 Plan and the 2017 Plan. No additional stock awards will be granted under these prior plans. The number of shares of common stock reserved for issuance under the Company’s 2020 Plan will automatically increase on January 1 of each year, beginning on January 1, 2021, and continuing through and including January 1, 2030, by 4% of the total number of shares of common stock outstanding on December 31 of the immediately preceding calendar year, or a lesser number of shares determined by the Company’s board prior to the applicable January 1st. The number of shares issuable under the Plans is adjusted for capitalization changes, forfeitures, expirations and certain share reacquisitions. The Plan provides for the grants of incentive stock options (“ISOs”), nonstatutory stock options (“NSOs”), restricted stock awards, and restricted stock unit awards (“RSUs”). ISOs may be granted only to employees, including officers. All other awards may be granted to employees, including officers, non-employee directors and consultants. The 2020 Plan provides that grants of ISOs will be made at no less than the estimated fair value of common stock, as determined by the Board of Directors, at the date of grant. Stock options granted to employees and nonemployees under the Plans generally vest over four years. Options granted under the Plans generally expire ten years after the date of grant. At December 31, 2020, 7,404,593 shares were available for future grants. 2020 Employee Stock Purchase Plan In January 2020, the Company’s stockholders approved the 2020 Employee Stock Purchase Plan (“ESPP”) Plan. The 2020 ESPP became effective upon the execution of the underwriting agreement for the Company’s IPO in January 2020. The Company has initially reserved 2,800,000 shares of common stock for issuance under the 2020 ESPP. The reserve will automatically increase on January 1st of each calendar year for a period of up to ten years, commencing on January 1, 2021 and ending on (and including) January 1, 2030, in an amount equal to the lesser of (1) 1.5% of the total number of shares of Common Stock outstanding on December 31st of the preceding fiscal year, (2) 2,800,000 shares, and (3) a number of shares determined by the Company’s board. At December 31, 2020, 2,450,438 shares were available for future issuance. The ESPP allows eligible employees to contribute, through payroll deductions, up to 15% of their earnings for the purchase of the Company’s common stock at a discounted price per share, subject to limitations imposed by federal income tax regulations. The price at which common stock is purchased under the ESPP is equal to 85% of the fair market value of the Company’s common stock on the first or last day of the offering period, whichever is lower. The initial offering period ran from January 31, 2020 to August 15, 2020 and the second offering period ran from August 16, 2020 to November 15, 2020. On a going forward basis, the ESPP will provide for separate six-month offering periods beginning on May 16 and November 16 of each year. During the year ended December 31, 2020, the Company’s employees purchased approximately 350,000 shares under the ESPP at a weighted-average price of $13.83 per share. The stock-based compensation expense recognized for the ESPP was $2,058 during the year ended December 31, 2020. The fair value of the stock purchase right granted under the ESPP was estimated on the first day of each offering period using the Black-Scholes option pricing model. The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP: Year Ended December 31, 2020 Expected term in years 0.3 - 0.5 Expected stock price volatility 53.7% - 63.5% Risk-free interest rate 0.1% - 1.5% Expected dividend yield 0.0 % At December 31, 2020, there was $902 in unrecognized stock-based compensation expense related to the ESPP that is expected to be recognized over a period of 0.4 years. Stock Options The following table summarizes stock option activity under the Plans: Weighted- Weighted- Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Price Term (Years) Value Outstanding as of December 31, 2017 23,826,773 $ 4.07 8.51 $ 14,071 Granted 4,591,384 5.45 Exercised (3,767,795 ) 3.98 Canceled (3,146,367 ) 4.58 Outstanding as of December 31, 2018 21,503,995 $ 4.30 8.00 $ 74,546 Granted 7,702,397 10.39 Exercised (815,959 ) 3.73 Canceled (584,124 ) 5.99 Outstanding as of December, 2019 27,806,309 $ 5.97 7.76 $ 207,956 Granted 380,572 22.32 Exercised (8,122,909 ) 4.39 Canceled (436,762 ) 8.06 Market-based stock options granted 8,645,823 43.31 Outstanding as of December, 2020 28,273,033 $ 18.03 8.20 $ 724,339 Options exercisable as of December 31, 2020 9,607,761 $ 5.20 6.81 $ 369,432 Options vested and expected to vest as of December 31, 2020 17,137,578 $ 6.53 7.30 $ 636,227 The aggregate intrinsic value of service-based options exercised for the years ended December 31, 2020, 2019 and 2018 was $206,143, $4,998 and $17,715, respectively. At December 31, 2020 and 2019, there was $12,983 and $22,156, respectively, in unrecognized compensation expense related to service-based options, net of forfeitures, that is expected to be recognized over a weighted-average period of 1.9 years and 2.2 years, respectively. Fair Value of Stock Options Granted The fair value of stock option grants with service-based vesting conditions is estimated using the Black-Scholes option-pricing model. The Company lacks company-specific historical and implied volatility information. Therefore, it estimated its expected stock volatility based on the historical volatility of a publicly traded set of peer companies. For options with service-based vesting conditions, the expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. We estimated the fair value of stock option grants with service-based vesting conditions using a Black-Scholes option pricing model with the following assumptions presented on a weighted-average basis: Year Ended December 31, 2020 2019 2018 Expected term in years 6.0 6.3 6.0 Expected stock price volatility 57.4 % 44.8 % 47.7 % Risk-free interest rate 0.9 % 1.9 % 2.9 % Expected dividend yield 0.0 % 0.0 % 0.0 % Estimated fair value per option granted $ 11.88 $ 4.78 $ 2.64 The fair value of stock option grants with service-based vesting conditions for the years ended December 31, 2020, 2019 and 2018 was $4,519, $36,785 and $12,137, respectively. Market-based Stock Options During the year ended December 31, 2020, the Board of Directors (“Board”) approved the grant of a long-term market-based stock option (the “Performance Stock Option”) to the Company’s Chief Executive Officer and President. The Performance Stock Option was granted to acquire up to 8,645,823 shares of the Company’s common stock upon exercise. The Performance Stock Option consists of four separate tranches and each tranche will vest over a seven-year time period and only if the Company’s stock price sustains achievement of pre-determined increases for a period of 90 consecutive calendar days and the Chief Executive Officer remains employed with the Company. The exercise price per share of the Stock Option is the closing price of a share of the Company’s common stock on the date of grant. The vesting of the Performance Stock Option can also be triggered upon a change in control. The following table presents additional information relating to each tranche of the Performance Stock Option: Tranche Stock Price Milestone Number of Options Tranche 1 $55 per share 1,330,127 Tranche 2 $70 per share 1,995,190 Tranche 3 $90 per share 2,660,253 Tranche 4 $110 per share 2,660,253 The grant date fair value of the Performance Stock Option is determined using a Monte Carlo simulation that incorporates estimates of the potential outcomes of the market condition on the grant Year Ended December 31, 2020 Derived service period in years 1.16 - 3.09 Expected stock price volatility 55.0 % Risk-free interest rate 0.7 % Expected dividend yield 0.0 % Weighted-average fair value per option granted $ 22.84 The Company will recognize aggregate stock-based compensation expense of $197,469 over the derived service period of each tranche using the accelerated attribution method as long as the service-based vesting conditions are satisfied. If the market conditions are achieved sooner than the derived service period, the Company will adjust its stock-based compensation to reflect the cumulative expense associated with the vested awards. The Company recorded stock-based compensation expense of $490 related to the award for the year ended December 31, 2020, which is included in general and administrative on the consolidated statements of operations. Unamortized stock-based compensation expense related to the award was $196,978 as of December 31, 2020. Restricted Stock Units In March 2016, the Company issued 150,000 shares of restricted stock pursuant to a purchase agreement that was subject to a twenty-four-month pro-rata vesting period with any unvested shares forfeited upon termination of the employees. The fair value of these shares was recorded as stock-based compensation expense in the Company’s consolidated financial statements. The following table summarizes restricted stock unit activity under the Plans: Number of Grant Date Shares Fair Value Unvested and outstanding as of December 31, 2017 2,083 $ 6.19 Granted - Vested (2,083 ) 6.19 Canceled and forfeited - Unvested and outstanding as of December 31, 2018 - $ - Granted - Vested - Canceled and forfeited - Unvested and outstanding as of December 31, 2019 - $ - Granted 1,490,274 21.52 Vested (65,023 ) 15.00 Canceled and forfeited (134,298 ) 18.74 Unvested and outstanding as of December 31, 2020 1,290,953 $ 22.14 The fair value of restricted stock units granted for the year ended December 31, 2020 was $32,071. As of December 31, 2020, there was $11,779 in unrecognized compensation expense related to restricted stock units, net of forfeitures, that is expected to be recognized over a weighted-average period of 1.9 years. As of December 31, 2019, there was no unrecognized compensation expense related to restricted stock granted by the Company. Stock-Based Compensation Expense Total stock-based compensation expense for employees and nonemployees recognized by the Company for the years ended December 31, 2020, 2019 and 2018, was $35,095, $14,877 and $21,181, respectively. A tax benefit of $53,749, $707 and $3,946 for the years ended December 31, 2020, 2019 and 2018, respectively, was included in the Company’s net operating loss carry-forward that could potentially reduce future tax liabilities. Stock-based compensation expense was classified in the consolidated statements of operations as follows: Year Ended December 31, 2020 2019 2018 Sales and marketing $ 2,385 $ 1,256 $ 552 General and administrative 32,710 13,621 20,629 Total $ 35,095 $ 14,877 $ 21,181 For the year ended December 31, 2020, 1,589,798 options held by a named executive officer that were subject to immediate vesting upon the execution of the IPO underwriting agreement vested and accordingly, $3,506 of stock-based compensation expense was recognized. In connection with the common stock repurchase and retirement in October 2018 (See Note 15, “Common Stock”), the Company recorded stock-based compensation expense for the year ended December 31, 2018 of $7,239 of which $208 is included in sales and marketing and $7,031 is included in general and administrative on the consolidated statements of operations and in the table above. Employee Benefit Plan Effective January 1, 2007, the Company adopted a 401(k) plan that is available to all full-time employees over the age of 18, who have been employed at least three months with the Company. Eligible employees may contribute up to 60% of their annual compensation to the 401(k) plan, subject to limitations imposed by federal income tax regulations. The Company matches 50% of the first 3% of amounts contributed by employees, subject to limitations by federal income tax regulations. The Company’s contribution was $5,051, $3,618, and $1,764 for the years ended December 31, 2020, 2019 and 2018, respectively.

Income Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	17. The provision for (benefit from) income taxes consists of the following: Year Ended December 31, 2020 2019 2018 Current: Federal $ 869 $ 1 $ 2 State 1,664 86 23 Total current 2,533 87 25 Deferred: Federal (1,895 ) — — State (761 ) — — Total deferred (2,656 ) — — Total provision for (benefit from) income taxes $ (123 ) $ 87 $ 25 The following table reconciles the Federal statutory income tax provision to the Company’s effective income tax provision. Amounts may not sum due to rounding. Year Ended December 31, 2020 2019 2018 Federal statutory income tax rate 21.0 % 21.0 % 21.0 % Valuation allowance (49.8 )% (12.6 )% (16.9 )% Section 382 limitations 0.0 % (10.0 )% 0.0 % State income tax expense (6.3 )% (1.4 )% (1.4 )% Stock-based compensation 38.6 % 4.5 % (1.1 )% Warrant fair value adjustment (1.5 )% (1.4 )% (0.9 )% Other, net (1.8 )% (0.3 )% (0.9 )% Effective income tax rate 0.1 % (0.2 )% (0.1 )% Deferred income taxes reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company’s deferred income tax assets and liabilities at December 31, 2020 and 2019 were comprised of the following: December 31, 2020 2019 Deferred tax assets: Net operating loss and credit carryforwards $ 114,662 $ 53,070 Reserves and allowances 1,713 - Basis difference in fixed and intangible assets 72 73 Stock-based compensation 11,970 8,874 Lease liability 52,045 40,122 Section 163(j) interest 2,750 1,352 Total gross deferred tax assets 183,212 103,491 Valuation allowance (113,770 ) (66,535 ) Total deferred tax assets 69,442 36,956 Deferred tax liabilities: Basis difference in fixed and intangible assets (3,460 ) (2,426 ) Right-of-use assets (42,249 ) (32,651 ) Capitalized commissions (250 ) (52 ) Reserves and allowances - (1,827 ) Convertible note debt discount (20,827 ) - Total deferred tax liabilities (66,786 ) (36,956 ) Net deferred tax assets $ 2,656 $ - Of the total deferred tax assets, none are related to the noncontrolling interest as of December 31, 2020 and 2019, respectively. A valuation allowance is required to be established when it is more likely than not that all or a portion of a deferred tax asset will not be realized. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain. A full review of all positive and negative evidence needs to be considered, including the Company’s current and past performance, the market environments in which the Company operates, the utilization of past tax credits, length of carry back and carry forward periods, as well as tax planning strategies that might be implemented. Management believes that, based on a number of factors, it is more likely than not, that most of the deferred tax assets may not be realized; and accordingly, as of December 31, 2020, the Company has provided a partial valuation allowance against its deferred tax assets in entities with recent cumulative losses. A full valuation allowance was established against all the deferred tax assets as of December 31, 2019. The change in total valuation allowance was an increase of $47,235 and $5,483 for the years ended December 31, 2020 and 2019, respectively. At December 31, 2020, the Company had net operating loss carryforwards for federal and state and local income tax purposes of $398,150 and $465,206, respectively, which are available to reduce future income subject to income taxes. Federal net operating losses generated after 2017, of $261,434, do not expire. The remaining federal and state net operating loss carry forwards will begin to expire, if not used, at various dates beginning in tax year 2025 and 2024, respectively. As of December 31, 2020, the Company had no federal credits and state credit carryforwards of $480 which are available to reduce future income tax. Some of the state credit carryforwards will begin to expire, if not used, in tax year 2023. Utilization of some of the federal, state and local net operating loss and credit carryforwards may be subject to annual limitations due to the “change in ownership” provisions of the Internal Revenue Code of 1986 and similar state and local provisions. The annual limitations may result in the expiration of net operating losses and credits before utilization. The Company performed a Section 382 analysis through December 31, 2018, on 1Life ownership history. The net federal operating losses carryforwards of $344,258 and state and local net operating loss carryforwards of $381,753 generated by 1Life are not expected to expire unutilized as a result of ownership changes identified through December 31, 2018. The Company has identified $25,215 and $31,704 of federal and state net operating losses, respectively, in the PCs that will expire unused due to ownership changes in the non-controlling interests. State credits of $71 will not be able to be utilized due to ownership change limitations in the PCs. Intended to provide economic relief to those impacted by the COVID-19 pandemic, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted on March 27, 2020 and includes provisions, among others, addressing the carryback of net operating losses for specific periods, refunds of alternative minimum tax credits, temporary modifications to the limitations placed on the tax deductibility of net interest expenses, and technical amendments for qualified improvement property (“QIP”). Additionally, the CARES Act, in efforts to enhance business’ liquidity, provides for refundable employee retention tax credits and the deferral of the employer paid portion of social security taxes. The CARES Act did not have a material impact on the Company’s income taxes. On June 29, 2020, California Governor Newsom signed into law the state’s budget package which included Assembly Bill 85 (“AB 85”). AB 85 contained two major tax changes: (1) the suspension of net operating loss (“NOLs”) utilization for certain taxpayers; and (2) the limitation of certain business tax credits for tax years 2020, 2021 and 2022. AB 85 resulted in an additional $105 of current expense to the Company’s state income tax provision. The Company has analyzed its filing positions in all significant Federal and State jurisdictions where it is required to file income tax returns, as well as open tax years in these jurisdictions. As of December 31, 2020 and 2019, the Company had no uncertain tax positions. The Company’s tax returns continue to remain subject to examination by U.S. federal and state taxing authorities for effectively all years since inception due to net operating loss carryforwards. The Company is not currently under examination in any jurisdictions.

Net Loss Per Share

Net Loss Per Share	12 Months Ended
Net Loss Per Share	Dec. 31, 2020
Earnings Per Share [Abstract]
Net Loss Per Share	18. Net Loss Per Share Net Loss Per Share Attributable to 1Life Healthcare, Inc. Stockholders Basic and diluted net loss per share attributable to 1Life Healthcare, Inc. stockholders were calculated as follows: Year Ended December 31, 2020 2019 2018 Numerator: Net loss $ (89,421 ) $ (53,695 ) $ (45,501 ) Less: Net loss attributable to noncontrolling interest (704 ) (1,141 ) (1,086 ) Net loss attributable to 1Life Healthcare, Inc. stockholders $ (88,717 ) $ (52,554 ) $ (44,415 ) Denominator: Weighted average common shares outstanding— basic and diluted 118,379,300 18,476,127 16,735,541 Net loss per share attributable to 1Life Healthcare, Inc. stockholders— basic and diluted $ (0.75 ) $ (2.84 ) $ (2.65 ) The Company’s potentially dilutive securities, which include stock options, unvested RSUs, 2025 Notes, redeemable convertible preferred stock and warrants to purchase shares of redeemable convertible preferred stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to 1Life Healthcare, Inc. stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to 1Life Healthcare, Inc. stockholders for the periods indicated because including them would have had an anti-dilutive effect: Year Ended December 31, 2020 2019 2018 Options to purchase common stock 28,273,033 27,806,309 21,503,995 Unvested restricted stock 1,290,953 - - Redeemable convertible preferred stock (as converted to common stock) - 86,251,669 86,251,669 Warrants to purchase redeemable convertible preferred stock (as converted to common stock) - 673,241 673,241 29,563,986 114,731,219 108,428,905 As the Company expects to settle the principal amount of the 2025 Notes in cash and any excess in cash or shares of the Company’s common stock, the Company uses the treasury stock method for calculating any potential dilutive effect on diluted net income per share, if applicable. The conversion spread of 7,117,270 shares will have a dilutive impact on diluted net income per share of common stock when the average market price of the Company’s common stock for a given period exceeds the conversion price of $44.43 per share.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	19 . Commitments and Contingencies Indemnification Agreements In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board of Directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. As of December 31, 2020 and 2019, the Company has not incurred any material costs as a result of such indemnifications. Legal Matters In May 2018, a class action complaint was filed by two former members against the Company in the Superior Court of California for the County of San Francisco, or the Court, alleging that the Company made certain misrepresentations resulting in them paying the Annual Membership Fee, or AMF in violation of California’s Consumers Legal Remedies Act, California’s False Advertising Law and California’s Unfair Competition Law, and seeking damages and injunctive relief. In September 2018, the Company filed a motion to compel the plaintiffs to individually arbitrate their claims, which motion was granted as to one plaintiff and denied as to the other. The Company is appealing the denial of its motion to compel arbitration and filed its appellate brief in November 2019. Appellate proceedings are delayed due to COVID-related court shutdowns. An arbitrator conducted arbitration between the Company and the plaintiff, and in June 2020, issued a decision that the arbitration agreement is unenforceable against the plaintiff. The Company filed its challenge to the arbitrator’s decision in August 2020. The trial court upheld the arbitrator’s decision, and the appellate court denied the Company’s writ petition for review. The Company answered the complaint in November 2020, denying the allegations and asserting various defenses. In addition, from time to time, the Company has been and may be involved in various legal proceedings arising in the ordinary course of business. The Company currently believes that the outcome of these legal proceedings, either individually or in the aggregate, will not have a material effect on its consolidated financial position, results of operations or cash flows. Government Inquiries and Investigations In March 2021, the Company received (i) requests for information and documents from the United States House Select Subcommittee on the Coronavirus Crisis and (ii) a request for information from the California Attorney General and the Alameda County District Attorney’s Office relating to the Company’s provision of COVID-19 vaccinations. The Company has also received inquiries from state and local public health departments regarding its vaccine administration practices. The Company is cooperating with these requests and is unable to predict the outcome or timeline of these matters at this time or if any additional requests, inquiries, investigations or other government actions may arise relating to such circumstances Sales and Use Tax During 2017 and 2018, a state jurisdiction engaged in an audit of 1Life’s sales and use tax records applicable to that jurisdiction from March 2011 through February 2017. As of December 31, 2020, the Company estimated a probable loss from the audit and recorded the estimate in accrued expenses related to one aspect of the finding, including interest and penalties. The Company disputes the other finding representing the majority of the state’s proposed audit change and has filed a notice of appeal. An administrative law judge with the state’s tax division conducted a hearing on the appeal in October 2020. A decision from the judge is expected to be issued in the second half of 2021. At this time, the Company believes it has a compelling basis to dispute the audit finding and it is not able to estimate the amount of loss or range of loss, if any, related to this matter.

Related Party Transactions

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	2 0 . Related Party Transactions Certain of the Company’s investors are also customers of the Company. The Company recognized revenue under contractual obligations from such customers of $2,093, $27,748 and $22,273 for the years ended December 31, 2020, 2019 and 2018, respectively. The outstanding receivable balance from such customers was immaterial as of December 31, 2020 and was $2,344 as of December 31, 2019.

Selected Quarterly Financial Da

Selected Quarterly Financial Data (unaudited)	12 Months Ended
Selected Quarterly Financial Data (unaudited)	Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Financial Data (unaudited)	21 . Selected Quarterly Financial Data (unaudited) The following tables set forth selected unaudited quarterly consolidated statements of operations data for each of the eight quarters in fiscal 2020 and fiscal 2019. The information for each of these eight quarters has been prepared on the same basis as the audited annual consolidated financial statements included in this Annual Report on Form 10-K and, in the opinion of management, includes all adjustments, which consist only of normal recurring adjustments, necessary for the fair statement of the results of operations for these periods in accordance with generally accepted accounting principles, or GAAP. This data should be read in conjunction with the audited consolidated financial statements and related notes included in this Annual Report on Form 10-K. These quarterly operating results are not necessarily indicative of the Company’s operating results for a full year or any future period. For the Quarter Ended March 31, 2020 June 30, 2020 September 30, 2020 December 31, 2020 (unaudited) Net revenue $ 78,756 $ 78,000 $ 101,667 $ 121,800 Loss from operations $ (29,028 ) $ (28,713 ) $ (10,822 ) $ (2,796 ) Net loss $ (34,558 ) $ (30,301 ) $ (16,415 ) $ (8,147 ) Less: Net loss attributable to noncontrolling interests (704 ) - - - Net loss attributable to 1Life Healthcare, Inc. stockholders $ (33,854 ) $ (30,301 ) $ (16,415 ) $ (8,147 ) Net loss per share attributable to 1Life Healthcare, Inc. stockholders — $ (0.40 ) $ (0.24 ) $ (0.13 ) $ (0.06 ) For the Quarter Ended March 31, 2019 June 30, 2019 September 30, 2019 December 31, 2019 (unaudited) Net revenue $ 63,010 $ 66,233 $ 69,629 $ 77,386 Loss from operations $ (8,163 ) $ (11,310 ) $ (15,678 ) $ (18,962 ) Net loss $ (7,044 ) $ (11,488 ) $ (15,645 ) $ (19,518 ) Less: Net loss attributable to noncontrolling interests (374 ) (287 ) (388 ) (92 ) Net loss attributable to 1Life Healthcare, Inc. stockholders $ (6,670 ) $ (11,201 ) $ (15,257 ) $ (19,426 ) Net loss per share attributable to 1Life Healthcare, Inc. stockholders — $ (0.37 ) $ (0.61 ) $ (0.82 ) $ (1.03 )

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2020
Accounting Policies [Abstract]
Initial Public Offering	Initial Public Offering On February 4, 2020, the Company closed its initial public offering (“IPO”) and sold 20,125,000 shares of common stock, including the underwriters’ option to purchase additional shares at the IPO price. The public offering price of the shares sold in the IPO was $14.00 per share. In aggregate, the shares issued in the offering generated $258,119 in net proceeds, which amount is net of $18,314 in underwriters’ discount and commissions, and $5,317 in offering costs. Upon the closing of the IPO, all shares of redeemable convertible preferred stock then outstanding were automatically converted into 86,257,242 shares of common stock and all redeemable preferred stock warrants were converted into warrants to purchase 667,668 shares of common stock. In addition, 1,589,798 options held by a named executive officer that were subject to immediate vesting upon the execution of the IPO underwriting agreement vested and accordingly, $3,506 of stock-based compensation expense was recognized.
Certain Risks and Uncertainties	Certain Risks and Uncertainties The Company has incurred losses from operations since inception. Management expects that operating losses and negative cash flows from operations will continue in the foreseeable future; however, it currently believes that the Company’s current cash, cash equivalents and short-term marketable securities are sufficient to fund its operating expenses and capital expenditure requirements for the next twelve months. In March 2020, the World Health Organization declared a pandemic due to the global COVID-19 outbreak. Due to the ongoing COVID-19 pandemic, the global economy and financial markets have been and continue to be affected, and there is a significant amount of uncertainty about the length and severity of the consequences caused by the pandemic. The Company has considered information available to it as of the date of issuance of these financial statements and is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or an adjustment to the carrying value of its assets or liabilities. The accounting estimates and other matters assessed include, but were not limited to, allowance for doubtful accounts, inventory reserves, adverse inventory purchase commitments, goodwill and other long-lived assets, and revenue recognition. These estimates may change as new events occur and additional information becomes available. Actual results could differ materially from these estimates.
Basis of Presentation	Basis of Presentation The Company has prepared the consolidated financial statements in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and include the accounts of 1Life and variable interest entities (“VIE”) in which 1Life has an interest and is the primary beneficiary (see Note 3, “Variable Interest Entities”). All significant intercompany balances and transactions have been eliminated in consolidation. The noncontrolling interest attributable to the Company’s variable interest entities are presented as a separate component of equity in the consolidated balance sheets. Certain reclassifications have been made to prior periods to conform with the current presentation. During the three months ended March 31, 2020, the company identified a balance sheet misclassification which was not material to the previously issued financial statements. However, the Company has corrected the December 31, 2019 comparative amounts to increase accounts receivable, net and deferred revenue by $3,146 as presented in t he condensed consolidated balance sheet.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements and related disclosures in conformity with U.S. GAAP and regulations of the SEC requires management to make estimates and assumptions that affect the amount reported in the consolidated financial statements and accompanying notes. Estimates include, but are not limited to, revenue recognition, determination of useful lives for property and equipment, intangible assets including goodwill, capitalized internal-use software, allowance for doubtful accounts, valuation of redeemable convertible preferred stock warrant liabilities, self-insurance reserves, valuation of common stock, stock options valuations, convertible senior notes fair value, contingent liabilities and income taxes. Actual results could differ materially from those estimates.
Deferred Offering Costs	Deferred Offering Costs The Company capitalizes certain legal, accounting and other third-party fees that are directly related to the Company’s in-process equity financings until such financings are consummated, including the Company’s initial public offering in January 2020. After the consummation of the equity financing, these costs are recorded as a reduction of the gross proceeds. Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are immediately written off to operating expenses. There were no deferred offering costs capitalized as of December 31, 2020. As of December 31, 2019, there were $3,627 of deferred offering costs included in other assets on the consolidated balance sheet.
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash The Company considers all short-term, highly liquid investments purchased with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash deposits are all in financial institutions in the United States. Cash and cash equivalents consisted of cash on deposit, investments in money market funds and commercial paper. Restricted cash represents cash held under letters of credit for various leases. The expected duration of restrictions on the Company’s restricted cash generally ranges from 1 to 9 years. The reconciliation of cash, cash equivalents and restricted cash reported within the applicable balance sheet line items that sum to the total of the same such amount shown in the consolidated statements of cash flows is as follows: December 31, 2020 2019 2018 Cash and cash equivalents $ 112,975 $ 27,390 $ 36,692 Restricted cash, current (included in prepaid expenses and other current assets) 119 17 25 Restricted cash, non-current 1,911 1,922 1,939 $ 115,005 $ 29,329 $ 38,656
Marketable Securities	Marketable Securities The Company’s investments in marketable securities are classified as available-for-sale and are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in total equity (deficit). The Company determines the appropriate classification of these investments at the time of purchase and reevaluates such designation at each balance sheet date. The Company classifies the available-for-sale investments as current assets under the caption short-term marketable securities on the consolidated balance sheets as these investments generally consist of highly marketable securities that are identified to be available to meet near-term cash requirements. Realized gains and losses and declines in value determined to be other than temporary are based on the specific identification method and are included as a component of other income (expense), net in the consolidated statements of operations. The Company periodically evaluates its investments in marketable securities for other-than-temporary impairment. When assessing short-term marketable security investments for other-than-temporary declines in value, the Company considers such factors as, among other things, how significant the decline in value is as a percentage of the original cost, how long the market value of the investment has been less than its original cost, the Company’s ability and intent to retain the short-term marketable security investment for a period of time sufficient to allow for any anticipated recovery in fair value and market conditions in general. If any adjustment to fair value reflects a decline in the value of the marketable security that the Company considers to be “other than temporary,” the Company reduces the marketable securities through a charge to the consolidated statement of operations. No such adjustments were necessary during the periods presented.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The three levels of inputs that may be used to measure fair value are defined below: • Level 1 — Quoted prices in active markets for identical assets or liabilities. • Level 2 — Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 — Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The Company determines the fair value of its marketable securities based on quoted prices in active markets (Level 1 inputs) for identical assets and on quoted prices for similar assets (Level 2 inputs), which are classified as available-for-sale. The carrying amounts of the Company’s term notes approximate the fair value based on consideration of current borrowing rates available to the Company (Level 2 inputs.) The Company’s redeemable convertible preferred stock warrant liability is carried at fair value, determined using Level 3 inputs in the fair value hierarchy (See Note 4 “Fair Value Measurements”). Upon the closing of the Company’s IPO in the first quarter of 2020, the warrants to purchase shares of redeemable convertible preferred stock became exercisable and were automatically converted to warrants to purchase shares of common stock. As a result, following the closing of the Company’s IPO, t
Variable Interest Entities	Variable Interest Entities The Company evaluates its ownership, contractual and other interests in entities to determine if it has any variable interest in a variable interest entity (“VIE”). These evaluations are complex, involve judgment, and the use of estimates and assumptions based on available historical information, among other factors. If the Company determines that an entity in which it holds a contractual or ownership interest is a VIE and that the Company is the primary beneficiary, the Company consolidates such entity in its consolidated financial statements. The primary beneficiary of a VIE is the party that meets both of the following criteria: (i) has the power to make decisions that most significantly affect the economic performance of the VIE; and (ii) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively.
Segment Information	Segment Information The Company operates and manages its business as one reportable and operating segment. The Company’s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of evaluating financial performance and allocating resources. All of the Company’s long-lived assets and customers are located in the United States.
Concentration of Credit Risk and Significant Customers	Concentration of Credit Risk and Significant Customers Financial instruments that potentially subject the company to concentration of credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. The Company’s cash balances with individual banking institutions might be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds and commercial paper. The Company’s marketable securities are invested in U.S. Treasury obligations and commercial paper. The Company is not exposed to any significant concentrations of credit risk from these financial instruments. The Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities. The Company grants unsecured credit to patients, most of whom reside in the service area of the One Medical facilities and are largely insured under third-party payer agreements. The Company’s concentration of credit risk is limited by the diversity, geography and number of patients and payers. The table below December 31, 2020 2019 Customer A * 10 % Customer E 12 % * Customer F 24 % 11 % Customer G * 12 % Customer H 16 % * * Represents percentages below 10% of the Company’s accounts receivable in the period. The table below Year Ended December 31, 2020 2019 2018 Customer A 13 % 14 % 15 % Customer B * * 12 % Customer C * * 10 % Customer E 10 % 10 % 10 % Customer F 12 % 12 % * * Represents percentages below 10% of the Company’s net revenue in the period.
Accounts Receivable, net	Accounts Receivable, net Accounts receivable is comprised of amounts due from third-party payers, patients, and health system and other partners for healthcare services and amounts due from enterprise clients, schools and universities who purchase access to memberships for their employees, students and faculty. The Company reports accounts receivable net of estimated contractual adjustments and any allowance for doubtful accounts. Collection of accounts receivable is the Company’s primary source of cash and is critical to its operating performance. The Company’s primary collection risks relate to co-payments and other amounts owed by patients. The Company reviews its overall reserve adequacy by monitoring historical cash collections as a percentage of net revenue as well as other collection indicators such as the age of the balance and the payment history of the customer. The Company writes off accounts against the allowance for doubtful accounts when they are deemed to be uncollectible. Increases and decreases in the allowance for doubtful accounts from patient service revenue are included in net revenue in the consolidated statements of operations. Changes in the allowance for doubtful accounts were as follows: Balance at Beginning of Period Additions Write-offs and Deductions Balance at End of Period Allowance for doubtful accounts Year ended December 31, 2018 $ 405 $ 3,237 $ (3,179 ) $ 463 Year ended December 31, 2019 $ 463 $ 2,931 $ (2,226 ) $ 1,168 Year ended December 31, 2020 $ 1,168 $ 5,773 $ (3,694 ) $ 3,247
Inventories	Inventories Inventories consist of medical supplies such as vaccines and are stated at the lower of cost or net realizable value with cost being determined on a weighted average basis. Net realizable value is determined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of disposal and transportation. The cost of inventory includes product cost, shipping costs and taxes. Write-offs of potentially slow moving or damaged inventory are recorded based on management’s analysis of inventory levels, forecasted future sales volume and pricing and through specific identification of obsolete or damaged products. The Company assesses inventory quarterly for slow moving products and potential impairment. The Company records a reserve for obsolete inventory or inventory that may expire prior to use. The reserve for obsolete inventory was $1,386 as of December 31, 2020 and there was no reserve for obsolete inventory for the year ended December 31, 2019 .
Property and Equipment, net	Property and Equipment, net Property and equipment are stated at cost, net of accumulated depreciation. Depreciation and amortization are computed using the straight-line method over the estimated useful lives. The general range of useful lives of other property and equipment is as follows: Estimated Useful Life Furniture and fixtures 5 to 7 years Computer equipment 3 to 5 years Computer software 1.5 to 5 years Laboratory equipment 5 to 7 years Leasehold improvements Lesser of lease term or 10 years When assets are sold or retired, the cost and related accumulated depreciation are removed from the accounts, with any resulting gain or loss recorded in general and administrative expenses in the consolidated statements of operations. Costs of repairs and maintenance are expensed as incurred.
Software Developed for Internal Use	Software Developed for Internal Use The Company capitalizes costs related to internal-use software during the application development stage including consulting costs and compensation expenses related to employees who devote time to the development projects. The Company records software development costs in property and equipment, net. Costs incurred in the preliminary stages of development activities and post implementation activities are expensed in the period incurred and included in general and administrative expense in the consolidated statements of operations. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Capitalized costs associated with internal-use software are amortized on a straight-line basis over their estimated useful life, which is 1.5 to 5 years, and are included in depreciation and amortization in the consolidated statements of operations.
Goodwill and Long-Lived Assets	Goodwill and Long-Lived Assets The Company recognizes the excess of the purchase price, plus the fair value of any noncontrolling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. The Company performs a qualitative assessment on goodwill at least annually or more frequently if events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable. If it is determined in the qualitative assessment that the fair value of a reporting unit is more likely than not below its carrying amount, then the Company will perform a quantitative impairment test. The quantitative goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. Any excess in the carrying value of a reporting unit’s goodwill over its fair value is recognized as an impairment loss, limited to the total amount of goodwill allocated to that reporting unit. For purposes of goodwill impairment testing, the Company has one reporting unit. The Company’s long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset or asset group may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset or asset group to the future undiscounted cash flows expected to be generated by the asset or asset group. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. During the years ended December 31, 2020 and 2019, the Company has not recorded any impairment charges related to goodwill or long-lived assets.
Leases	Leases The Company adopted Accounting Standards Codification, Topic 842, Leases (“ASC 842”), using the modified retrospective approach through a cumulative-effect adjustment and utilizing the effective date of January 1, 2019 as its date of initial application. As of January 1, 2019, the impact of the adoption to the Company’s consolidated balance sheet includes the recognition of operating lease liabilities, current, of $9,643, operating lease liabilities, non-current, of $63,047 based on the present value of the remaining lease payments for existing operating leases with corresponding right-of-use assets of approximately $60,770. The difference between the amount of right-of-use assets and lease liabilities recognized upon the adoption of ASC 842 is related to adjustments to existing prepaid rent, deferred rent, and lease incentives. The Company determines if a contract meets with definition of a lease at inception of a contract. Lease liabilities represent the obligation to make lease payments and right-of-use (“ROU”) assets represent the right to use the underlying asset during the lease term. Leases with a term greater than one year are recognized on the consolidated balance sheet as The Company has elected not to recognize on the balance sheet leases with terms of one year or less. Operating lease ROU assets are adjusted for (i) payments made at or before the commencement date, (ii) initial direct costs incurred, and (iii) tenant incentives under the lease. When a lease contains an escalation clause or a concession, such as a rent holiday or tenant improvement allowance, the Company includes these items in the determination of the ROU asset and the lease liabilities. The effects of these escalation clauses or concessions have been reflected in lease expenses on a straight-line basis over the expected lease term and any variable lease payments subsequent to establishing the lease liability are expensed as incurred. Certain lease agreements include rental payments that are adjusted periodically for inflation or other variables. In addition to rent, the leases may require the Company to pay additional amounts for taxes, insurance, maintenance and other expenses, which are generally referred to as non-lease components. Such adjustments to rental payments and variable non-lease components are treated as variable lease payments and recognized in the period as incurred. Variable lease components and variable non-lease components are not measured as part of the right-of-use assets and lease liability. Only when lease components and their associated non-lease components are fixed are they recognized as part of the right-of-use assets and lease liability. The Company has made an accounting policy election to not separate lease and non-lease components to all asset classes. Rather, each lease component and the related non-lease components will be accounted for together as a single component. A portfolio approach is applied where appropriate to certain lease contracts with similar characteristics. The Company’s lease agreements do not contain any significant residual value guarantees or material restrictive covenants imposed by the leases. Operating leases are included in right of use assets, operating lease liabilities, current and operating lease liabilities, non-current on the Company’s consolidated balance sheets. Finance leases are included in property and equipment, net, other current liabilities, and other long-term liabilities on the Company’s consolidated balance sheets. Finance leases are not material.
Redeemable Convertible Preferred Stock Warrant Liability	Redeemable Convertible Preferred Stock Warrant Liability The Company classifies the redeemable convertible preferred stock warrants as a liability on the consolidated balance sheets because the warrants are freestanding financial instruments that may require the Company to transfer assets upon exercise. The liability associated with each of these warrants was initially recorded at fair value upon the issuance date of each warrant and is subsequently re-measured to fair value at each reporting date. Changes in the fair value of the warrant liability are recognized as a component of other income (expense), net in the consolidated statements of operations. Upon the closing of the Company’s IPO in the first quarter of 2020, the warrants to purchase shares of redeemable convertible preferred stock became exercisable and were automatically converted to warrants to purchase
Noncontrolling Interest	Noncontrolling Interest The Company recognizes noncontrolling interest related to variable interest entities in which the Company is the primary beneficiary, as equity (deficit) in the consolidated balance sheets separate from 1Life’s equity (deficit). The earnings attributable to noncontrolling interest are recorded in the consolidated statements of operations as net loss attributable to noncontrolling interest. Any change in ownership of a subsidiary while the controlling financial interest is retained is accounted for as an equity transaction between the controlling and noncontrolling interests. In addition, when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary will be initially measured at fair value and the difference between the carrying value and fair value of the retained interest will be recorded as a gain or loss. Please see Note 3, “Variable Interest Entities” to our consolidated financial statements.
Income Taxes	Income Taxes Income taxes are computed using the asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s consolidated financial statements. In estimating future tax consequences, the Company considers all expected future events other than enactment of changes in tax laws or rates. A valuation allowance is recorded, if necessary, to reduce net deferred tax assets to their realizable values if management does not believe it is more likely than not that the net deferred tax assets will be realized. As of December 31, 2020, the Company had recorded a partial valuation allowance against its net deferred tax assets in loss generating entities; as of December 31, 2019, the Company had recorded a full valuation allowance against all its deferred tax assets. The Company follows the provisions of the authoritative guidance from the Financial Accounting Standards Board (“FASB”), on accounting for uncertainty in income taxes. These provisions provide a comprehensive model for the recognition, measurement and disclosure in financial statements of uncertain income tax positions that a company has taken or expects to take on a tax return. Under these provisions, a company can recognize the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit can be recognized. Assessing an uncertain tax position begins with the initial determination of the sustainability of the position and is measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed. Additionally, the Company must accrue interest and related penalties, if applicable, on all tax exposures for which reserves have been established consistent with jurisdictional tax laws. The Company’s policy is to recognize interest and penalties related to uncertain tax positions in the provision for income taxes. As of December 31, 2020 and 2019, the Company had no accrued interest or penalties related to uncertain tax positions.
Net Loss per Share Attributable to 1Life Healthcare, Inc. Stockholders	Net Loss per Share Attributable to 1Life Healthcare, Inc. Stockholders The Company applies the two-class method to compute basic and diluted net loss per share attributable to 1Life Healthcare, Inc. stockholders when shares meet the definition of participating securities. The two-class method determines net loss per share for each class of common and redeemable convertible preferred stock according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and redeemable convertible preferred stock based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed. During periods of loss, there is no allocation required under the two-class method since the redeemable convertible preferred stock does not have a contractual obligation to share in the Company’s losses. Basic net loss per share attributable to 1Life Healthcare, Inc. stockholders is computed by dividing net loss attributable to 1Life Healthcare, Inc. stockholders by the weighted-average number of common shares outstanding during the period without consideration of potentially dilutive common stock. Diluted net loss per share attributable to 1Life Healthcare, Inc. stockholders reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company unless inclusion of such shares would be anti-dilutive. For periods in which the Company reports net losses, diluted net loss per common share attributable to 1Life Healthcare, Inc. stockholders is the same as basic net loss per common share attributable to 1Life Healthcare, Inc. stockholders, because potentially dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.
Revenue Recognition	Revenue Recognition The Company adopted Accounting Standards Codification Topic 606, Revenue from Contracts with Customers, effective January 1, 2019, using the modified retrospective transition method. Net revenue for the years ended December 31, 2020 and 2019 is presented under Topic 606. Net revenue for the year ended December 31, 2018 is presented under Topic 605. The Company generates net revenue through net patient service revenue, partnership revenue and membership revenue. Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. The Company determines revenue recognition through the following steps: (i) Identify the contract(s) with a customer; (ii) Identify the performance obligations in the contract; (iii) Determine the transaction price; (iv) Allocate the transaction price to the performance obligations in the contract; and (v) Recognize revenue as the entity satisfies a performance obligation. Net Patient Service Revenue Net patient service revenue is generated from providing primary care services pursuant to contracts with patients. The Company recognizes revenue as services are rendered, which are delivered over a period of time but typically within one day, when the Company provides services to the patient. The Company receives payments for services from third-party payers as well as from patients who have health insurance where they may bear some cost of the service in the form of co-pays, coinsurance or deductibles. In addition, patients who do not have health insurance are required to pay for their services in full. Providing medical services to patients represents the Company’s performance obligation under the contracts, and accordingly, the transaction price is allocated entirely to the one performance obligation. Net patient service revenue is reported net of provisions for contractual allowances from third-party payers and patients. The Company has certain agreements with third-party payers that provide for reimbursement at amounts different from the Company’s standard billing rates. The differences between the estimated reimbursement rates and the standard billing rates are accounted for as contractual adjustments, which are deducted from gross revenue to arrive at net patient service revenue. The Company estimates implicit price concessions related to payer and patient receivable balances as part of estimating the original transaction price which is based on historical experience, current market conditions, the amount of any receivables in dispute, current receivables aging and other collection indicators. Partnership Revenue Partnership revenue is generated from (i) contracts with employers to provide professional clinical services to employee members at the Company’s on-site clinics, (ii) capitation payments from IPAs to provide professional clinical services to covered participants, (iii) contracts with employers, schools, and universities to provide COVID-19 on-site testing services, and (iv) contracts with health systems as health network partners beginning in 2019. The Company’s main performance obligation under the various partnership arrangements is to stand ready to provide professional clinical services and the associated management and administrative services. As the services are provided concurrently over the contract term and have the same pattern of transfer, the Company has concluded that this represents one performance obligation comprising of a series of distinct services over the contract term. The Company also receives an incentive from certain health network partners to open new clinics, which is considered a distinct performance obligation from the stand-ready obligation to provide clinical and administrative services. Revenue is recognized when the performance obligation is satisfied upon the opening of the new location. While the Company can receive either fixed or variable fees from its enterprise clients (i.e., stated fee per employee per month) for on-site medical services, it generally receives variable fees from IPAs and health networks on a stated fee per member per month basis, based on the number of members (or participants) serviced. The Company also receives variable fees from enterprise clients, schools and, universities on a stated fee per each COVID-19 on-site testing per month basis, based on the number of tests delivered. The Company recognizes revenue as it satisfies its performance obligation. For fixed-fee agreements with its enterprise clients, the Company uses a time-based measure to recognize revenue ratably over the contract term. For variable-fee agreements with health networks, the Company allocates the per member per month variable consideration to the month that the fee is earned, correlated with the amount of services it is providing, which is consistent with the allocation objective of the series guidance. For variable-fee arrangements with employers, schools, and universities to provide COVID-19 on-site testing services, revenue is recognized as services are rendered. The Company generally invoices for the on-site testing services as the work is incurred and monthly in arrears. From time to time, the Company may provide discounts and rebates to the customer. The Company estimates the variable consideration subject to the constraint and recognizes such variable consideration over the contract term. Membership Revenue Membership revenue is generated from annual membership fees paid by consumer members and from enterprise clients who purchase access to memberships for their employees and dependents. The terms of service on the Company’s website serve as the contract between the Company and consumer members. The Company enters into written contracts with enterprise clients. The transaction price for contracts with enterprise clients is determined on a per employee per month basis, based on the number of employees eligible for membership established at the beginning of the contract term, which is generally one year. The transaction price for the contract is stated in the contract or determinable and is generally collected in advance of the contract term. The Company may provide numerous services under the agreements; however, these services are generally not considered individually distinct as they are not separately identifiable in the context of the agreement. As a result, the Company’s single performance obligation in the transaction constitutes a series for the provision of membership and services as and when requested over the membership term. The transaction price relates specifically to the Company’s efforts to transfer the services for a distinct increment of the series. Accordingly, the transaction price is allocated entirely to the one performance obligation. Membership revenue is recognized ratably over the contract period with the individual member or enterprise client. Unrecognized but collected amounts are recorded to deferred revenue and amortized over the remainder of the applicable membership period. Contracts with Multiple Performance Obligations Certain contracts with customers contain multiple performance obligations that are distinct and accounted for separately. The transaction price is allocated to the separate performance obligations on a relative standalone selling price (“SSP”) basis. The Company determines SSP for all performance obligations using observable inputs, such as standalone sales and historical contract pricing. SSP is consistent with the Company’s overall pricing objectives, taking into consideration the type of services. SSP also reflects the amount the Company would charge for that performance obligation if it were sold separately in a standalone sale, and the price the Company would sell to similar customers in similar circumstances. Deferred Revenue The Company records deferred revenue, which is a contract liability, when it has an obligation to provide services to a customer and payment is received in advance of performance.
Deferred Commissions	Deferred Commissions The Company capitalizes expenses that are considered to be incremental to the acquisition of customer contracts, which are then amortized over an estimated period of benefit. The period of benefit of the deferred commissions is determined based on the type of costs incurred, the nature of the related benefits, the historical contractual terms and renewal rates of the customer arrangements. Amortization expense is included in sales and marketing expenses on the consolidated statements of operations. Deferred commissions are primarily related to enterprise sales.
Cost of Care, Exclusive of Depreciation and Amortization	Cost of Care, Exclusive of Depreciation and Amortization Cost of care, exclusive of depreciation and amortization, also excludes stock-based compensation. Cost of care primarily includes all costs relating to the provision of virtual care, including video visits and other synchronous and asynchronous communication via the Company’s app and website, and the operation and maintenance of medical offices, which includes all provider and support employee-related costs, occupancy costs, medical supplies, insurance and other operating costs. Providers include medical doctors, doctors of osteopathy, nurse practitioners, and physician assistants.
Advertising	Advertising The Company expenses advertising costs the first time the advertising takes place. Advertising costs are included in sales and marketing in the consolidated statements of operations. For the years ended December 31, 2020, 2019 and 2018, advertising costs were $15,871, $23,368, and $11,641, respectively.
Stock-Based Compensation	Stock-Based Compensation The Company measures all stock-based awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation expense for those awards, net of estimated forfeitures, over the requisite service period, which is generally the vesting period of the respective award. For stock option grants with only service-based vesting conditions, the fair value is estimated on the date of grant using a Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option, and the Company’s expected dividend yield. The expense for the stock option grants with only service-based vesting conditions is recorded using the straight-line method. The Company also uses the Black‑Scholes option‑pricing model to estimate the fair value of its stock purchase rights under the 2020 Employee Stock Purchase Plan on the grant date. For stock option awards issued with market-based vesting conditions, the grant date fair value is determined based on multiple stock price paths developed through the use of a Monte Carlo simulation that incorporates into the valuation the possibility that the market condition may not be satisfied. A Monte Carlo simulation requires the use of various assumptions, including the underlying stock price, volatility and the risk-free interest rate as of the valuation date, corresponding to the length of the time remaining in the performance period, and expected dividend yield. Stock-based compensation expense associated with market-based awards is recognized over the derived requisite service using the accelerated attribution method, regardless of whether the market conditions are achieved. If the related market conditions are achieved earlier than the derived service period, the stock-based compensation expense will be recognized as a cumulative catch-up expense from the grant date to that point in time in achieving the share price goal
Self-Insurance Program	Self-Insurance Program The Company self-insures for certain levels of employee medical benefits. The Company maintains a stop-loss insurance policy to protect it from individual losses over $250 per claim in 2020, $225 per claim in 2019 and $175 per claim in 2018. A liability for expected claims incurred but not reported is established on a monthly basis. As claims are paid, the liability is relieved. The Company reviews its self-insurance accruals on a quarterly basis based on actuarial methods to determine the liability for actual claims and claims incurred but not yet reported. As of December 31, 2020 and 2019, the Company’s liability for outstanding claims (included in accrued expenses) was $1,936 and $1,753, respectively.
Other Comprehensive Loss	Other Comprehensive Loss Other comprehensive loss includes unrealized gains and losses on short-term marketable securities classified as available-for-sale.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Emerging Growth Company Status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. Recently Adopted Pronouncements as of December 31, 2020 In November 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and also improves consistent application of and simplifies GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The standard is effective for private companies for fiscal years beginning after December 15, 2021 and interim periods within annual periods beginning after December 15, 2022 In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement, which modifies the disclosure requirements for fair value measurements. The standard is effective for all entities for fiscal years and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted. The Company adopted this standard on January 1, 2020. The adoption of this standard did not have a material effect on the Company’s consolidated financial statements. In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815) I. Accounting for Certain Financial Instruments with Down Round Features II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (“ASU 2017-11”). Part I applies to entities that issue financial instruments such as warrants, convertible debt or convertible preferred stock that contain down-round features. Part II replaces the indefinite deferral for certain mandatorily redeemable noncontrolling interests and mandatorily redeemable financial instruments of nonpublic entities contained within Accounting Standards Codification (“ASC”) Topic 480 with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. For private entities, ASU 2017-11 is effective for annual periods beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted. The Company adopted this standard on January 1, 2020. The adoption of this standard did not have a material effect on the Company’s consolidated financial statements. Recently Issued Accounting Pronouncements Not Yet Adopted as of December 31, 2020 In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for convertible instruments by removing certain separation models in Subtopic 470-20, Debt—Debt with Conversion and Other Options, for convertible instruments and also increases information transparency by making disclosure amendments. The convertible debt instruments will be accounted for as a single liability measured at amortized cost. This will also result in the interest expense recognized for convertible debt instruments to be typically closer to the coupon interest rate when applying the guidance in Topic 835, Interest. Further, the ASU made amendments to the EPS guidance in Topic 260 for convertible instruments, the most significant impact of which is requiring the use of the if-converted method for diluted EPS calculation, and no longer allowing the net share settlement method. The standard is effective for private companies for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company plans to early adopt this standard on January 1, 2021 on a modified retrospective basis. The adoption is expected to reduce additional paid in capital by approximately $75,635 for the equity component of the convertible senior notes (“the 2025 Notes”) remaining outstanding, which was initially separated and recorded in equity, and remove the remaining debt issuance cost recorded for this previous separation for approximately $2,242, as a result. The net effect of these adjustments will result in a reduction in the balance of the opening accumulated deficit of approximately $6,656 as of January 1, 2021, which represents the cumulative non-cash interest expense recorded from the amortization of the debt issuance discount. The Company currently expects the adoption of the ASU to result in the reduction of non-cash interest expense of approximately $13,000 for the year ending December 31, 2021 and until the 2025 Notes have been settled. The reduction in interest expense will decrease the net loss attributable to common stockholders and decrease the basic net loss per share. The required use of the if converted method will not impact the diluted net loss per share as long as the Company is in a net loss position. The adoption will have no impact on the consolidated statement of cash flows. In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use-software. The standard is effective for private companies for fiscal years beginning after December 15, 2020 and interim periods within annual periods beginning after December 15, 2021. Early adoption is permitted. The Company will adopt this standard on a prospective basis on January 1, 2021 and does not expect the adoption to have a material impact on the Company’s consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments and also issued subsequent amendments to the initial guidance (collectively, Topic 326). Topic 326 replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. The standard is effective for private companies for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of this accounting standard update on its consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Dec. 31, 2020
Accounting Policies [Abstract]
Reconciliation of Cash, Cash Equivalents and Restricted Cash	The reconciliation of cash, cash equivalents and restricted cash reported within the applicable balance sheet line items that sum to the total of the same such amount shown in the consolidated statements of cash flows is as follows: December 31, 2020 2019 2018 Cash and cash equivalents $ 112,975 $ 27,390 $ 36,692 Restricted cash, current (included in prepaid expenses and other current assets) 119 17 25 Restricted cash, non-current 1,911 1,922 1,939 $ 115,005 $ 29,329 $ 38,656
Summary of Customers Representing 10% or More of Accounts Receivables	The table below December 31, 2020 2019 Customer A * 10 % Customer E 12 % * Customer F 24 % 11 % Customer G * 12 % Customer H 16 % * * Represents percentages below 10% of the Company’s accounts receivable in the period.
Summary of Customers Representing 10% or More of Net Revenue	The table below Year Ended December 31, 2020 2019 2018 Customer A 13 % 14 % 15 % Customer B * * 12 % Customer C * * 10 % Customer E 10 % 10 % 10 % Customer F 12 % 12 % * * Represents percentages below 10% of the Company’s net revenue in the period.
Changes in Allowance for Doubtful Accounts	Changes in the allowance for doubtful accounts were as follows: Balance at Beginning of Period Additions Write-offs and Deductions Balance at End of Period Allowance for doubtful accounts Year ended December 31, 2018 $ 405 $ 3,237 $ (3,179 ) $ 463 Year ended December 31, 2019 $ 463 $ 2,931 $ (2,226 ) $ 1,168 Year ended December 31, 2020 $ 1,168 $ 5,773 $ (3,694 ) $ 3,247
General Range of Useful Lives of Property and Equipment	Property and equipment are stated at cost, net of accumulated depreciation. Depreciation and amortization are computed using the straight-line method over the estimated useful lives. The general range of useful lives of other property and equipment is as follows: Estimated Useful Life Furniture and fixtures 5 to 7 years Computer equipment 3 to 5 years Computer software 1.5 to 5 years Laboratory equipment 5 to 7 years Leasehold improvements Lesser of lease term or 10 years Property and equipment consisted of the following: December 31, 2020 2019 Leasehold improvements 118,434 $ 83,018 Computer software, including internal-use software 25,708 16,508 Computer equipment 21,502 16,653 Furniture and fixtures 11,805 7,359 Laboratory equipment 6,541 3,428 Construction in progress 8,550 12,288 192,540 139,254 Less: Accumulated depreciation and amortization (66,503 ) (48,538 ) $ 126,037 $ 90,716

Variable Interest Entities (Tab

Variable Interest Entities (Tables)	12 Months Ended
Variable Interest Entities (Tables)	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Summary of Deconsolidation of Joint Venture	At the point of deconsolidation, 100% of the net assets were attributable to the noncontrolling interest. The following table shows the balances immediately preceding the deconsolidation of the joint venture that occurred on April 1, 2020: Partially Owned April 1, 2020 Assets Current assets: Cash and cash equivalents $ 810 Accounts receivable, net 768 Prepaid expenses and other current assets 18 Total current assets 1,596 Other assets 19 Property and equipment, net 1,504 Right-of-use assets 1,509 Total assets $ 4,628 Liabilities Current liabilities: Accounts payable and accrued expenses $ 9 Operating lease liabilities, current 273 Other current liabilities 143 Total current liabilities 425 Operating lease liabilities, non-current 1,872 Total liabilities $ 2,297
Assets and Liabilities Excluding Intercompany Balances are Eliminated in Consolidated for Joint Ventures	The table below present the assets and liabilities (excluding intercompany balances that are eliminated in consolidation) for the joint venture as of December 31, 2019: Partially Owned December 31, 2019 Assets Current assets: Cash and cash equivalents $ 1,411 Accounts receivable, net 817 Prepaid expenses and other current assets 24 Total current assets 2,252 Other assets 19 Property and equipment, net 1,521 Right-of-use assets 1,553 Total assets $ 5,345 Liabilities Current liabilities: Accounts payable and accrued expenses $ 60 Operating lease liabilities, current 265 Other current liabilities 57 Total current liabilities 382 Operating lease liabilities, non-current 1,946 Total liabilities $ 2,328

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
Fair Value Measurements (Tables)	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis: Fair Value Measurements as of December 31, 2020 Using: Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market fund $ 50,761 $ - $ - $ 50,761 Commercial paper - 19,999 - 19,999 Short-term investments: U.S. Treasury obligations 416,158 - - 416,158 U.S. government agency securities 20,000 - - 20,000 Commercial paper - 133,865 - 133,865 $ 486,919 $ 153,864 $ - $ 640,783 Fair Value Measurements as of December 31, 2019 Using: Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market fund $ 13,580 $ - $ - $ 13,580 Commercial paper - 4,997 - $ 4,997 Short-term investments: U.S. Treasury obligations 48,968 - - $ 48,968 Commercial paper - 70,178 - 70,178 $ 62,548 $ 75,175 $ - $ 137,723 Liabilities: Redeemable convertible preferred stock warrant liability $ - $ - $ 7,220 $ 7,220 $ - $ - $ 7,220 $ 7,220
Schedule of Assumptions Used to Determine Fair Value of Redeemable Convertible Preferred Stock Warrants	The assumptions that the Company used to determine the fair value of the redeemable convertible preferred stock warrants were as follows: Year Ended December 31, 2020 2019 2018 Expected stock price volatility 46.5% - 55.0% 39.9% - 55.4% 40.4% - 44.6% Risk-free interest rate 1.5% - 1.6% 1.6% - 1.7% 2.7 % Remaining contractual term 0.1 - 5 years 0.2 - 5 years 1 - 6 years Expected dividend yield 0.0 % 0.0 % 0.0 % Estimated fair value $16.93 - $22.52 $7.10 - $12.53 $2.67 - $6.90
Schedule of Aggregate Fair Values of Redeemable Convertible Preferred Stock Warrant Liability	The following table provides a roll forward of the aggregate fair values of the Company’s redeemable convertible preferred stock warrant liability, for which fair value is determined using Level 3 inputs: Convertible Redeemable Preferred Stock Warrant Liability Balance as of December 31, 2017 $ 2,686 Warrant exercise (862 ) Change in fair value 1,877 Balance as of December 31, 2018 3,701 Change in fair value 3,519 Balance as of December 31, 2019 7,220 Warrant exercise (40 ) Change in fair value 6,560 Conversion of preferred stock warrants into common stock warrants (13,740 ) Balance as of December 31, 2020 $ -

Revenue Recognition (Tables)

Revenue Recognition (Tables)	12 Months Ended
Revenue Recognition (Tables)	Dec. 31, 2020
Revenue From Contract With Customer [Abstract]
Summary of Net Revenue	The following table summarizes the Company’s net revenue by primary source: Year Ended December 31, 2020 2019 2018 Net revenue: Net patient service revenue $ 149,695 $ 145,389 $ 144,080 Partnership revenue 159,482 78,734 25,408 Total net patient service and partnership revenue 309,177 224,123 169,488 Membership revenue 68,466 52,135 43,190 Grant income 2,580 - - Net revenue $ 380,223 $ 276,258 $ 212,678
Summary of Net Patient Service Revenue by Source	The following table summarizes net patient service revenue by source: Year Ended December 31, 2020 2019 2018 Net patient service revenue: Commercial and government third-party payers 136,388 121,502 119,657 Patients, including self-pay, insurance co-pays and deductibles 13,307 23,887 24,423 Net patient service revenue 149,695 145,389 144,080
Schedule of Contract Assets and Deferred Revenue	As summarized in the table below, the Company recorded contract assets and deferred revenue as a result of timing differences between the Company’s performance and the customer’s payment. December 31, 2020 2019 Balances from contracts with customers: Accounts receivable $ 67,895 $ 33,601 Contract asset (included in prepaid expenses and other current assets) 513 600 Deferred revenue 43,590 27,024
Schedule of Remaining Performance Obligation	The Company does not disclose the value of remaining performance obligations for (i) contracts with an original contract term of one year or less, (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice when that amount corresponds directly with the value of services performed, and (iii) variable consideration allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied distinct service that forms part of a single performance obligation. For those contracts that do not meet the above criteria, the Company’s remaining performance obligation as of December 31, 2020, is expected to be recognized as follows: Less than Greater or equal to than 12 months 12 months Total As of December 31, 2020 $ 5,107 $ 10,562 $ 15,669

Cash Equivalents and Short-Te_2

Cash Equivalents and Short-Term Marketable Securities (Tables)	12 Months Ended
	Dec. 31, 2020
Cash Cash Equivalents And Short Term Investments [Abstract]
Summary of Cash Equivalents and Short-Term Marketable Securities	At December 31, 2020 and 2019, the Company’s cash equivalents and short-term marketable securities were as follows: December 31, 2020 Gross Amortized unrealized cost gains (losses) Fair value Cash equivalents: Money market fund $ 50,761 $ - $ 50,761 Commercial paper 19,999 19,999 Total cash equivalents 70,760 - 70,760 Short-term marketable securities: U.S. Treasury obligations 416,150 8 416,158 U.S. government agency securities 20,000 - 20,000 Commercial paper 133,865 - 133,865 Total short-term marketable securities 570,015 8 570,023 Total cash equivalents and short-term marketable securities $ 640,775 $ 8 $ 640,783 December 31, 2019 Gross Amortized unrealized cost gains (losses) Fair value Cash equivalents: Money market fund $ 13,580 $ - $ 13,580 Commercial paper 4,997 - 4,997 Total cash equivalents 18,577 - 18,577 Short-term marketable securities: U.S. Treasury obligations 48,930 38 48,968 Commercial paper 70,178 - 70,178 Total short-term marketable securities 119,108 38 119,146 Total cash equivalents and short-term marketable securities $ 137,685 $ 38 $ 137,723

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	12 Months Ended
Property and Equipment, net (Tables)	Dec. 31, 2020
Property Plant And Equipment [Abstract]
General Range of Useful Lives of Property and Equipment	Property and equipment are stated at cost, net of accumulated depreciation. Depreciation and amortization are computed using the straight-line method over the estimated useful lives. The general range of useful lives of other property and equipment is as follows: Estimated Useful Life Furniture and fixtures 5 to 7 years Computer equipment 3 to 5 years Computer software 1.5 to 5 years Laboratory equipment 5 to 7 years Leasehold improvements Lesser of lease term or 10 years Property and equipment consisted of the following: December 31, 2020 2019 Leasehold improvements 118,434 $ 83,018 Computer software, including internal-use software 25,708 16,508 Computer equipment 21,502 16,653 Furniture and fixtures 11,805 7,359 Laboratory equipment 6,541 3,428 Construction in progress 8,550 12,288 192,540 139,254 Less: Accumulated depreciation and amortization (66,503 ) (48,538 ) $ 126,037 $ 90,716

Leases (Tables)

Leases (Tables)	12 Months Ended
Leases (Tables)	Dec. 31, 2020
Leases [Abstract]
Components of Operating Lease Costs	The components of operating lease costs were as follows: Year Ended December 31, 2020 2019 Operating lease costs $ 25,250 $ 19,165 Variable lease costs 4,166 2,612 Total lease costs $ 29,416 $ 21,777
Supplemental Cash Flow Information	Supplemental Cash Flow Information Year Ended December 31, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 24,735 $ 17,260 Non-cash leases activity: Right-of-use lease assets obtained in exchange for new operating lease liabilities $ 45,957 $ 57,621
Lease Term and Discount Rate	Lease Term and Discount Rate As of December 31, 2020 2019 Weighted-average remaining lease term (in years) 8.36 7.26 Weighted-average discount rate 7.60 % 7.50 %
Future Minimum Lease Payments Under Non-cancellable Operating Leases	Future minimum lease payments under non-cancellable operating leases as of December 31, 2020 were as follows (excluding the effect of lease incentives to be received that are recorded in prepaid expenses and other current assets of $5,563 which serve to reduce total lease payments): Year Ended December 31, As of December 31, 2020 2021 $ 29,866 2022 28,572 2023 27,763 2024 27,070 2025 25,071 Thereafter 97,247 Total lease payments 235,589 Less: interest (64,557 ) Total lease liabilities $ 171,032

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
Goodwill and Intangible Assets (Tables)	Dec. 31, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Accumulated Amortization	Intangible assets became fully amortized and were removed from the consolidated balance sheet as of December 31, 2020. The following summarizes the Company’s intangible assets and accumulated amortization as of December 31, 2019: December 31, 2019 Original Accumulated Net Book Cost Amortization Value Independent physician association agreements $ 6,460 $ (6,460 ) $ - Non compete agreements 1,175 (1,152 ) 23 Customer relationships 200 (200 ) - Trade names 100 (100 ) - $ 7,935 $ (7,912 ) $ 23

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
Accrued Expenses (Tables)	Dec. 31, 2020
Payables And Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following: December 31, 2020 2019 Accrued employee compensation and benefits $ 28,414 $ 13,929 Inventories received not yet invoiced 3,749 563 Construction in progress 811 3,844 Self-insurance programs 1,936 1,753 Legal and professional fees 1,486 1,032 Medical office and lab supplies 3,581 289 Other accrued expenses 6,550 3,453 Total $ 46,527 $ 24,863

Self-Insurance Reserves (Tables

Self-Insurance Reserves (Tables)	12 Months Ended
Self-Insurance Reserves (Tables)	Dec. 31, 2020
Insurance Loss Reserves [Abstract]
Summary of Insurance Reserves	The following table provides a rollforward of the insurance reserves related to the Company’s self-insurance program: December 31, 2020 2019 Beginning balance $ 1,753 $ 819 Losses paid (16,394 ) (10,867 ) Reserves for current period 16,577 11,801 Ending balance $ 1,936 $ 1,753

Debt (Tables)

Debt (Tables)	12 Months Ended
Debt (Tables)	Dec. 31, 2020
Summary of Interest Expense Recognized Related to Convertible Senior Notes	The following table sets forth the interest expense recognized related to the 2025 Notes: Year Ended December 31, 2020 Contractual interest expense $ 5,587 Amortization of debt discount 7,194 Amortization of issuance costs 556 Total interest expense related to the 2025 Notes $ 13,337
Debt Liability Component
Net Carrying Amount of Convertible Senior Notes	The net carrying amount of the liability component of the 2025 Notes was as follows: December 31, 2020 Principal $ 316,250 Unamortized debt discount (68,441 ) Unamortized issuance costs (6,576 ) Net carrying amount $ 241,233
Debt Equity Component
Net Carrying Amount of Convertible Senior Notes	The net carrying amount of the equity component of the 2025 Notes was as follows: December 31, 2020 Debt discount related to value of conversion option $ 75,635 Issuance costs (2,242 ) Net carrying amount $ 73,393

Redeemable Convertible Prefer_2

Redeemable Convertible Preferred Stock Warrants (Tables)	12 Months Ended
Redeemable Convertible Preferred Stock Warrants (Tables)	Dec. 31, 2020
Warrants And Rights Note Disclosure [Abstract]
Summary of Outstanding Redeemable Convertible Preferred Stock Warrants	As of December 31, 2019, outstanding redeemable convertible preferred stock warrants to purchase shares of redeemable convertible preferred stock consisted of the following: Number of Exercise Date Exercisable Shares Issuable Price Exercisable for Classification Expiration February 26, 2010 100,000 $ 0.92 Series C Liability February 26, 2020 June 28, 2011 250,000 $ 1.05 Series D Liability June 28, 2021 January 30, 2013 99,280 $ 1.61 Series E Liability January 30, 2023 October 3, 2015 11,010 $ 6.59 Series G Liability October 3, 2020 October 5, 2015 10,837 $ 6.59 Series G Liability October 5, 2020 October 7, 2015 4,918 $ 6.59 Series G Liability October 7, 2020 October 8, 2015 5,573 $ 6.59 Series G Liability October 8, 2020 October 12, 2015 5,619 $ 6.59 Series G Liability October 12, 2020 October 14, 2015 113,879 $ 6.59 Series G Liability October 14, 2020 October 28, 2015 3,796 $ 6.59 Series G Liability October 28, 2020 November 4, 2015 22,776 $ 6.59 Series G Liability November 4, 2020 January 26, 2015 45,553 $ 6.59 Series G Liability January 26, 2025 673,241

Preferred Stock and Redeemabl_2

Preferred Stock and Redeemable Convertible Preferred Stock (Tables)	12 Months Ended
	Dec. 31, 2020
Temporary Equity Disclosure [Abstract]
Schedule of Redeemable Preferred Stock	As of December 31, 2019, redeemable convertible preferred stock consisted of the following: Preferred Preferred Stock Common Stock Stock Issued and Carrying Liquidation Issuable Upon Authorized Outstanding Value Preference Conversion Series A preferred stock 1,130,000 1,130,000 $ 540 $ 585 1,130,000 Series B preferred stock 6,324,592 6,324,592 4,424 3,500 6,324,592 Series C preferred stock 8,763,634 8,663,634 7,938 8,000 8,663,634 Series D preferred stock 14,528,912 14,278,912 14,899 15,000 14,278,912 Series E preferred stock 12,509,305 12,410,025 19,905 20,000 12,410,025 Series F preferred stock 11,695,449 11,695,449 29,885 30,000 11,695,449 Series G preferred stock 6,829,076 6,605,115 43,358 43,500 6,605,115 Series H preferred stock 7,444,827 7,444,827 64,875 65,000 7,444,827 Series I preferred stock 20,112,630 17,699,115 216,664 220,000 17,699,115 89,338,425 86,251,669 $ 402,488 $ 405,585 86,251,669

Common Stock (Tables)

Common Stock (Tables)	12 Months Ended
Common Stock (Tables)	Dec. 31, 2020
Equity [Abstract]
Schedule of Reserved Shares of Common Stock for Issuance	The Company had reserved shares of common stock for issuance in connection with the following: December 31, 2020 2019 Conversion of outstanding shares of redeemable convertible preferred stock - 86,251,669 Warrants to purchase redeemable convertible preferred stock (as converted to common stock) - 673,241 Options outstanding under the Equity Incentive Plans 28,273,033 27,806,309 Unvested restricted stock 1,290,953 - Options available for future issuance 9,855,031 1,350,202 39,419,017 116,081,421

Stock-Based Compensation and _2

Stock-Based Compensation and Employee Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2020
Summary of Stock Option Activity	The following table summarizes stock option activity under the Plans: Weighted- Weighted- Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Price Term (Years) Value Outstanding as of December 31, 2017 23,826,773 $ 4.07 8.51 $ 14,071 Granted 4,591,384 5.45 Exercised (3,767,795 ) 3.98 Canceled (3,146,367 ) 4.58 Outstanding as of December 31, 2018 21,503,995 $ 4.30 8.00 $ 74,546 Granted 7,702,397 10.39 Exercised (815,959 ) 3.73 Canceled (584,124 ) 5.99 Outstanding as of December, 2019 27,806,309 $ 5.97 7.76 $ 207,956 Granted 380,572 22.32 Exercised (8,122,909 ) 4.39 Canceled (436,762 ) 8.06 Market-based stock options granted 8,645,823 43.31 Outstanding as of December, 2020 28,273,033 $ 18.03 8.20 $ 724,339 Options exercisable as of December 31, 2020 9,607,761 $ 5.20 6.81 $ 369,432 Options vested and expected to vest as of December 31, 2020 17,137,578 $ 6.53 7.30 $ 636,227
Schedule of Additional Information Relating to Tranche	The following table presents additional information relating to each tranche of the Performance Stock Option: Tranche Stock Price Milestone Number of Options Tranche 1 $55 per share 1,330,127 Tranche 2 $70 per share 1,995,190 Tranche 3 $90 per share 2,660,253 Tranche 4 $110 per share 2,660,253
Summary of Restricted Stock Unit Activity	The following table summarizes restricted stock unit activity under the Plans: Number of Grant Date Shares Fair Value Unvested and outstanding as of December 31, 2017 2,083 $ 6.19 Granted - Vested (2,083 ) 6.19 Canceled and forfeited - Unvested and outstanding as of December 31, 2018 - $ - Granted - Vested - Canceled and forfeited - Unvested and outstanding as of December 31, 2019 - $ - Granted 1,490,274 21.52 Vested (65,023 ) 15.00 Canceled and forfeited (134,298 ) 18.74 Unvested and outstanding as of December 31, 2020 1,290,953 $ 22.14
Summary of Stock-Based Compensation Expense	Stock-based compensation expense was classified in the consolidated statements of operations as follows: Year Ended December 31, 2020 2019 2018 Sales and marketing $ 2,385 $ 1,256 $ 552 General and administrative 32,710 13,621 20,629 Total $ 35,095 $ 14,877 $ 21,181
Service Based Vesting Conditions
Schedule of Fair Value of Stock Options Granted Using Option Pricing Model	We estimated the fair value of stock option grants with service-based vesting conditions using a Black-Scholes option pricing model with the following assumptions presented on a weighted-average basis: Year Ended December 31, 2020 2019 2018 Expected term in years 6.0 6.3 6.0 Expected stock price volatility 57.4 % 44.8 % 47.7 % Risk-free interest rate 0.9 % 1.9 % 2.9 % Expected dividend yield 0.0 % 0.0 % 0.0 % Estimated fair value per option granted $ 11.88 $ 4.78 $ 2.64
Performance Stock Option
Schedule of Fair Value of Stock Options Granted Using Option Pricing Model	The grant date fair value of the Performance Stock Option is determined using a Monte Carlo simulation that incorporates estimates of the potential outcomes of the market condition on the grant Year Ended December 31, 2020 Derived service period in years 1.16 - 3.09 Expected stock price volatility 55.0 % Risk-free interest rate 0.7 % Expected dividend yield 0.0 % Weighted-average fair value per option granted $ 22.84
2020 ESPP
Schedule of Fair Value of Stock Options Granted Using Option Pricing Model	The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP: Year Ended December 31, 2020 Expected term in years 0.3 - 0.5 Expected stock price volatility 53.7% - 63.5% Risk-free interest rate 0.1% - 1.5% Expected dividend yield 0.0 %

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of Provision for (Benefit from) Income Taxes	The provision for (benefit from) income taxes consists of the following: Year Ended December 31, 2020 2019 2018 Current: Federal $ 869 $ 1 $ 2 State 1,664 86 23 Total current 2,533 87 25 Deferred: Federal (1,895 ) — — State (761 ) — — Total deferred (2,656 ) — — Total provision for (benefit from) income taxes $ (123 ) $ 87 $ 25
Schedule of Reconciliation of Federal Statutory Income Tax Provision to Effective Income Tax Provision	The following table reconciles the Federal statutory income tax provision to the Company’s effective income tax provision. Amounts may not sum due to rounding. Year Ended December 31, 2020 2019 2018 Federal statutory income tax rate 21.0 % 21.0 % 21.0 % Valuation allowance (49.8 )% (12.6 )% (16.9 )% Section 382 limitations 0.0 % (10.0 )% 0.0 % State income tax expense (6.3 )% (1.4 )% (1.4 )% Stock-based compensation 38.6 % 4.5 % (1.1 )% Warrant fair value adjustment (1.5 )% (1.4 )% (0.9 )% Other, net (1.8 )% (0.3 )% (0.9 )% Effective income tax rate 0.1 % (0.2 )% (0.1 )%
Schedule of Deferred Income Tax Assets and Liabilities	The Company’s deferred income tax assets and liabilities at December 31, 2020 and 2019 were comprised of the following: December 31, 2020 2019 Deferred tax assets: Net operating loss and credit carryforwards $ 114,662 $ 53,070 Reserves and allowances 1,713 - Basis difference in fixed and intangible assets 72 73 Stock-based compensation 11,970 8,874 Lease liability 52,045 40,122 Section 163(j) interest 2,750 1,352 Total gross deferred tax assets 183,212 103,491 Valuation allowance (113,770 ) (66,535 ) Total deferred tax assets 69,442 36,956 Deferred tax liabilities: Basis difference in fixed and intangible assets (3,460 ) (2,426 ) Right-of-use assets (42,249 ) (32,651 ) Capitalized commissions (250 ) (52 ) Reserves and allowances - (1,827 ) Convertible note debt discount (20,827 ) - Total deferred tax liabilities (66,786 ) (36,956 ) Net deferred tax assets $ 2,656 $ -

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
Net Loss Per Share (Tables)	Dec. 31, 2020
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Share	Basic and diluted net loss per share attributable to 1Life Healthcare, Inc. stockholders were calculated as follows: Year Ended December 31, 2020 2019 2018 Numerator: Net loss $ (89,421 ) $ (53,695 ) $ (45,501 ) Less: Net loss attributable to noncontrolling interest (704 ) (1,141 ) (1,086 ) Net loss attributable to 1Life Healthcare, Inc. stockholders $ (88,717 ) $ (52,554 ) $ (44,415 ) Denominator: Weighted average common shares outstanding— basic and diluted 118,379,300 18,476,127 16,735,541 Net loss per share attributable to 1Life Healthcare, Inc. stockholders— basic and diluted $ (0.75 ) $ (2.84 ) $ (2.65 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to 1Life Healthcare, Inc. stockholders for the periods indicated because including them would have had an anti-dilutive effect: Year Ended December 31, 2020 2019 2018 Options to purchase common stock 28,273,033 27,806,309 21,503,995 Unvested restricted stock 1,290,953 - - Redeemable convertible preferred stock (as converted to common stock) - 86,251,669 86,251,669 Warrants to purchase redeemable convertible preferred stock (as converted to common stock) - 673,241 673,241 29,563,986 114,731,219 108,428,905

Selected Quarterly Financial _2

Selected Quarterly Financial Data (unaudited) (Tables)	12 Months Ended
Selected Quarterly Financial Data (unaudited) (Tables)	Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Summary of Unaudited Consolidated Financial Statements	The following tables set forth selected unaudited quarterly consolidated statements of operations data for each of the eight quarters in fiscal 2020 and fiscal 2019. The information for each of these eight quarters has been prepared on the same basis as the audited annual consolidated financial statements included in this Annual Report on Form 10-K and, in the opinion of management, includes all adjustments, which consist only of normal recurring adjustments, necessary for the fair statement of the results of operations for these periods in accordance with generally accepted accounting principles, or GAAP. This data should be read in conjunction with the audited consolidated financial statements and related notes included in this Annual Report on Form 10-K. These quarterly operating results are not necessarily indicative of the Company’s operating results for a full year or any future period. For the Quarter Ended March 31, 2020 June 30, 2020 September 30, 2020 December 31, 2020 (unaudited) Net revenue $ 78,756 $ 78,000 $ 101,667 $ 121,800 Loss from operations $ (29,028 ) $ (28,713 ) $ (10,822 ) $ (2,796 ) Net loss $ (34,558 ) $ (30,301 ) $ (16,415 ) $ (8,147 ) Less: Net loss attributable to noncontrolling interests (704 ) - - - Net loss attributable to 1Life Healthcare, Inc. stockholders $ (33,854 ) $ (30,301 ) $ (16,415 ) $ (8,147 ) Net loss per share attributable to 1Life Healthcare, Inc. stockholders — $ (0.40 ) $ (0.24 ) $ (0.13 ) $ (0.06 ) For the Quarter Ended March 31, 2019 June 30, 2019 September 30, 2019 December 31, 2019 (unaudited) Net revenue $ 63,010 $ 66,233 $ 69,629 $ 77,386 Loss from operations $ (8,163 ) $ (11,310 ) $ (15,678 ) $ (18,962 ) Net loss $ (7,044 ) $ (11,488 ) $ (15,645 ) $ (19,518 ) Less: Net loss attributable to noncontrolling interests (374 ) (287 ) (388 ) (92 ) Net loss attributable to 1Life Healthcare, Inc. stockholders $ (6,670 ) $ (11,201 ) $ (15,257 ) $ (19,426 ) Net loss per share attributable to 1Life Healthcare, Inc. stockholders — $ (0.37 ) $ (0.61 ) $ (0.82 ) $ (1.03 )

Nature of the Business and Ba_2

Nature of the Business and Basis of Presentation - Additional Information (Details) - USD ($)	Feb. 04, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Deferred offering costs capitalized		$ 0
Redeemable convertible preferred stock converted into shares of common stock			86,251,669
Stock based compensation expense		35,095,000	$ 14,877,000	$ 21,181,000
Accounts receivable, net		67,895,000	33,601,000
Deferred revenue, current		$ 35,966,000	27,024,000
Restatement Adjustment
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Accounts receivable, net			3,146,000
Deferred revenue, current			$ 3,146,000
IPO
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Stock issued during period, shares, new issues	20,125,000
Public offering price of the shares sold in the IPO	$ 14
Net proceeds from shares issued in the offering, net of underwriting discount and offering costs	$ 258,119,000
Underwriters’ discount	18,314,000
Deferred offering costs capitalized	$ 5,317,000
Redeemable convertible preferred stock converted into shares of common stock	86,257,242	86,257,242
IPO \| Warrants to Purchase Common Stock
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Warrants to purchase shares of common stock	667,668
IPO \| Stock Options
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Stock options vested	1,589,798
Stock based compensation expense	$ 3,506,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details)	Jan. 01, 2021USD ($)	Dec. 31, 2020USD ($)SegmentReporting_unit	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Jan. 01, 2019USD ($)
Summary Of Significant Accounting Policies [Line Items]
Deferred offering costs capitalized		$ 0
Marketable securities, adjustment to fair value		$ 0	$ 0	$ 0
Number of reportable segment \| Segment		1
Number of operating segment \| Segment		1
Reserve for obsolete inventory		$ 1,386,000	0
Number of reporting unit \| Reporting_unit		1
Impairment charges related to goodwill		$ 0	0
Impairment charges related to long-lived assets		0	0
Operating lease liabilities, current		17,418,000	12,575,000
Operating lease liabilities, non-current		153,614,000	120,497,000
Operating leases right-of-use assets		138,840,000	108,046,000
Accrued interest or penalties related to uncertain tax positions		0	0
Advertising costs		15,871,000	23,368,000	11,641,000
Estimate of possible loss per claim		250,000	225,000	175,000
Self-insurance programs		1,936,000	1,753,000	$ 819,000
Reduction in additional paid in capital for the equity component of convertible senior notes		73,393,000
Accumulated deficit		369,785,000	281,068,000
3.0% Convertible Senior Notes due 2025
Summary Of Significant Accounting Policies [Line Items]
Expected reduction in non-cash expense in next twelve months		$ 7,194,000
ASC 842
Summary Of Significant Accounting Policies [Line Items]
Operating lease liabilities, current					$ 9,643,000
Operating lease liabilities, non-current					63,047,000
Operating leases right-of-use assets					$ 60,770,000
ASU 2020-06 \| Subsequent Event \| 3.0% Convertible Senior Notes due 2025 \| Debt Equity Component
Summary Of Significant Accounting Policies [Line Items]
Reduction in additional paid in capital for the equity component of convertible senior notes	$ 75,635,000
Debt issuance cost	2,242,000
Expected reduction in non-cash expense in next twelve months	13,000,000
ASU 2020-06 \| Cumulative Effect Period of Adoption Adjustment [Member] \| Subsequent Event \| Debt Equity Component
Summary Of Significant Accounting Policies [Line Items]
Accumulated deficit	$ 6,656,000
Maximum
Summary Of Significant Accounting Policies [Line Items]
Operating leases, options to extend leases term		7 years
Maximum \| Software Developed for Internal Use
Summary Of Significant Accounting Policies [Line Items]
Internal-use software, estimated useful life		5 years
Minimum
Summary Of Significant Accounting Policies [Line Items]
Operating leases, options to extend leases term		1 year
Minimum \| Software Developed for Internal Use
Summary Of Significant Accounting Policies [Line Items]
Internal-use software, estimated useful life		1 year 6 months
Other Assets
Summary Of Significant Accounting Policies [Line Items]
Deferred offering costs capitalized			$ 3,627,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Cash and cash equivalents	$ 112,975	$ 27,390	$ 36,692
Restricted cash, current (included in prepaid expenses and other current assets)	119	17	25
Restricted cash, non-current	1,911	1,922	1,939
Cash, cash equivalents and restricted cash	$ 115,005	$ 29,329	$ 38,656

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Summary of Customers Representing 10% or More of Accounts Receivables (Details) - Customer Concentration Risk - Accounts Receivable, Net	12 Months Ended
	Dec. 31, 2020		Dec. 31, 2019
Customer A
Product Information [Line Items]
Concentration risk, percentage		[1]	10.00%
Customer E
Product Information [Line Items]
Concentration risk, percentage	12.00%			[1]
Customer F
Product Information [Line Items]
Concentration risk, percentage	24.00%		11.00%
Customer G
Product Information [Line Items]
Concentration risk, percentage		[1]	12.00%
Customer H
Product Information [Line Items]
Concentration risk, percentage	16.00%			[1]

[1]	Represents percentages below 10% of the Company’s accounts receivable in the period.

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Summary of Customers Representing 10% or More of Net Revenue (Details) - Customer Concentration Risk - Net Revenue	12 Months Ended
	Dec. 31, 2020		Dec. 31, 2019		Dec. 31, 2018
Customer A
Product Information [Line Items]
Concentration risk, percentage	13.00%		14.00%		15.00%
Customer B
Product Information [Line Items]
Concentration risk, percentage		[1]		[1]	12.00%
Customer C
Product Information [Line Items]
Concentration risk, percentage		[1]		[1]	10.00%
Customer E
Product Information [Line Items]
Concentration risk, percentage	10.00%		10.00%		10.00%
Customer F
Product Information [Line Items]
Concentration risk, percentage	12.00%		12.00%			[1]

[1]	Represents percentages below 10% of the Company’s net revenue in the period.

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Changes in Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Allowance for doubtful accounts
Balance at Beginning of Period	$ 1,168	$ 463	$ 405
Additions	5,773	2,931	3,237
Write-offs and Deductions	(3,694)	(2,226)	(3,179)
Balance at End of Period	$ 3,247	$ 1,168	$ 463

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - General Range of Useful Lives of Other Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2020
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, useful lives	Lesser of lease term or 10 years
Minimum \| Computer Software
Property Plant And Equipment [Line Items]
Property and equipment, useful lives	1 year 6 months
Minimum \| Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, useful lives	5 years
Minimum \| Computer Equipment
Property Plant And Equipment [Line Items]
Property and equipment, useful lives	3 years
Minimum \| Laboratory Equipment
Property Plant And Equipment [Line Items]
Property and equipment, useful lives	5 years
Maximum \| Computer Software
Property Plant And Equipment [Line Items]
Property and equipment, useful lives	5 years
Maximum \| Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, useful lives	7 years
Maximum \| Computer Equipment
Property Plant And Equipment [Line Items]
Property and equipment, useful lives	5 years
Maximum \| Laboratory Equipment
Property Plant And Equipment [Line Items]
Property and equipment, useful lives	7 years

Variable Interest Entities - Ad

Variable Interest Entities - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended
	Sep. 30, 2014	Dec. 31, 2020	Apr. 01, 2020	Dec. 31, 2019
Variable Interest Entity [Line Items]
Current assets		$ 774,699		$ 200,037
Current liabilities		117,426		83,481
Deconsolidation Joint Venture
Variable Interest Entity [Line Items]
Current assets			$ 1,596
Current liabilities			$ 425
1Life Healthcare Incorporation \| Deconsolidation Joint Venture
Variable Interest Entity [Line Items]
Minority interest entity interest percentage			100.00%
Variable Interest Entity, Primary Beneficiary \| Healthcare System \| 1Life Healthcare Incorporation
Variable Interest Entity [Line Items]
Other party majority interest percentage	56.90%
Cash received in noncontrolling interests	$ 10,000
Variable Interest Entity, Primary Beneficiary \| 1Life Management Expertise \| 1Life Healthcare Incorporation
Variable Interest Entity [Line Items]
Minority interest entity interest percentage	43.10%
Variable Interest Entity, Primary Beneficiary \| PCs
Variable Interest Entity [Line Items]
Current assets		48,182		28,227
Current liabilities		$ 31,462		$ 13,927

Variable Interest Entities - Su

Variable Interest Entities - Summary of Deconsolidation of Joint Venture (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Apr. 01, 2020	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 112,975		$ 27,390	$ 36,692
Accounts receivable, net	67,895		33,601
Prepaid expenses and other current assets	16,693		16,708
Total current assets	774,699		200,037
Other assets	5,546		8,249
Property and equipment, net	126,037		90,716
Right-of-use assets	138,840		108,046
Total assets	1,070,990		430,294
Current liabilities:
Operating lease liabilities, current	17,418		12,575
Other current liabilities	4,861		1,884
Total current liabilities	117,426		83,481
Operating lease liabilities, non-current	153,614		120,497
Total liabilities	$ 522,515		$ 211,837
Deconsolidation Joint Venture
Current assets:
Cash and cash equivalents		$ 810
Accounts receivable, net		768
Prepaid expenses and other current assets		18
Total current assets		1,596
Other assets		19
Property and equipment, net		1,504
Right-of-use assets		1,509
Total assets		4,628
Current liabilities:
Accounts payable and accrued expenses		9
Operating lease liabilities, current		273
Other current liabilities		143
Total current liabilities		425
Operating lease liabilities, non-current		1,872
Total liabilities		$ 2,297

Variable Interest Entities - As

Variable Interest Entities - Assets and Liabilities Excluding Intercompany Balances are Eliminated in Consolidated for Joint Ventures (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 112,975	$ 27,390	$ 36,692
Accounts receivable, net	67,895	33,601
Prepaid expenses and other current assets	16,693	16,708
Total current assets	774,699	200,037
Other assets	5,546	8,249
Property and equipment, net	126,037	90,716
Right-of-use assets	138,840	108,046
Total assets	1,070,990	430,294
Current liabilities:
Operating lease liabilities, current	17,418	12,575
Other current liabilities	4,861	1,884
Total current liabilities	117,426	83,481
Operating lease liabilities, non-current	153,614	120,497
Total liabilities	$ 522,515	211,837
Joint Venture \| Variable Interest Entity, Primary Beneficiary
Current assets:
Cash and cash equivalents		1,411
Accounts receivable, net		817
Prepaid expenses and other current assets		24
Total current assets		2,252
Other assets		19
Property and equipment, net		1,521
Right-of-use assets		1,553
Total assets		5,345
Current liabilities:
Accounts payable and accrued expenses		60
Operating lease liabilities, current		265
Other current liabilities		57
Total current liabilities		382
Operating lease liabilities, non-current		1,946
Total liabilities		$ 2,328

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Assets:
Short-term Investments, Fair Value	$ 640,783	$ 137,723
Recurring
Assets:
Assets, Fair Value	640,783	137,723
Liabilities:
Liabilities, Fair Value		7,220
Recurring \| Redeemable Convertible Preferred Stock Warrant Liability
Liabilities:
Liabilities, Fair Value		7,220
Recurring \| Money Market Funds
Assets:
Cash Equivalents, Fair Value	50,761	13,580
Recurring \| Commercial Paper
Assets:
Cash Equivalents, Fair Value	19,999	4,997
Short-term Investments, Fair Value	133,865	70,178
Recurring \| US Treasury Obligations
Assets:
Short-term Investments, Fair Value	416,158	48,968
Recurring \| U.S. Government Agency Securities
Assets:
Short-term Investments, Fair Value	20,000
Recurring \| Level 1
Assets:
Assets, Fair Value	486,919	62,548
Recurring \| Level 1 \| Money Market Funds
Assets:
Cash Equivalents, Fair Value	50,761	13,580
Recurring \| Level 1 \| US Treasury Obligations
Assets:
Short-term Investments, Fair Value	416,158	48,968
Recurring \| Level 1 \| U.S. Government Agency Securities
Assets:
Short-term Investments, Fair Value	20,000
Recurring \| Level 2
Assets:
Assets, Fair Value	153,864	75,175
Recurring \| Level 2 \| Commercial Paper
Assets:
Cash Equivalents, Fair Value	19,999	4,997
Short-term Investments, Fair Value	$ 133,865	70,178
Recurring \| Level 3
Liabilities:
Liabilities, Fair Value		7,220
Recurring \| Level 3 \| Redeemable Convertible Preferred Stock Warrant Liability
Liabilities:
Liabilities, Fair Value		$ 7,220

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details)	Dec. 31, 2020USD ($)	Jun. 30, 2020	May 31, 2020	Dec. 31, 2019USD ($)	Dec. 31, 2018
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value, assets, level 1 to level 2 transfers, amount	$ 0			$ 0
Fair value, assets, level 2 to level 1 transfers, amount	0			0
Fair value, liabilities, level 1 to level 2 transfers, amount	0			0
Fair value, liabilities, level 2 to level 1 transfers, amount	0			0
Fair value, assets, level 1 to level 3 transfers, amount	0			0
Fair value, assets, level 3 to level 1 transfers, amount	0			0
Fair value, liabilities, level 1 to level 3 transfers, amount	0			0
Fair value, liabilities, level 3 to level 1 transfers, amount	0			0
Fair value, assets, level 2 to level 3 transfers, amount	0			0
Fair value, assets, level 3 to level 2 transfers, amount	0			0
Fair value, liabilities, level 2 to level 3 transfers, amount	0			0
Fair value, liabilities, level 3 to level 2 transfers, amount	0			$ 0
3.0% Convertible Senior Notes due 2025
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Aggregate principal amount outstanding	316,250,000
Interest rate		3.00%	3.00%
Convertible notes fair value	$ 397,472,000
Measurement Input, Expected Dividend Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected dividend yield	0			0	0

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Assumptions Used to Determine Fair Value of Redeemable Convertible Preferred Stock Warrants (Details)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Expected Stock Price Volatility \| Minimum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Measurement Input	0.465	0.399	0.404
Expected Stock Price Volatility \| Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Measurement Input	0.550	0.554	0.446
Risk-free Interest Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Measurement Input			0.027
Risk-free Interest Rate \| Minimum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Measurement Input	0.015	0.016
Risk-free Interest Rate \| Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Measurement Input	0.016	0.017
Remaining Contractual Term \| Minimum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Measurement Input	1 month 6 days	2 months 12 days	1 year
Remaining Contractual Term \| Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Measurement Input	5 years	5 years	6 years
Expected Dividend Yield
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Measurement Input	0	0	0
Estimated Fair Value \| Minimum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Measurement Input	16.93	7.10	2.67
Estimated Fair Value \| Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Measurement Input	22.52	12.53	6.90

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Aggregate Fair Values of Redeemable Convertible Preferred Stock Warrant Liability (Details) - Level 3 - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value, beginning balance	$ 7,220	$ 3,701	$ 2,686
Warrant exercise	(40)		(862)
Change in fair value	6,560	3,519	1,877
Conversion of preferred stock warrants into common stock warrants	(13,740)
Fair value, ending balance	$ 0	$ 7,220	$ 3,701

Revenue Recognition - Summary o

Revenue Recognition - Summary of Net Revenue (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disaggregation Of Revenue [Line Items]
Net revenue	$ 121,800	$ 101,667	$ 78,000	$ 78,756	$ 77,386	$ 69,629	$ 66,233	$ 63,010	$ 380,223	$ 276,258	$ 212,678
Net Patient Service Revenue
Disaggregation Of Revenue [Line Items]
Net revenue									149,695	145,389	144,080
Partnership Revenue
Disaggregation Of Revenue [Line Items]
Net revenue									159,482	78,734	25,408
Net Patient Service and Partnership Revenue
Disaggregation Of Revenue [Line Items]
Net revenue									309,177	224,123	169,488
Membership Revenue
Disaggregation Of Revenue [Line Items]
Net revenue									68,466	$ 52,135	$ 43,190
Grant Income
Disaggregation Of Revenue [Line Items]
Net revenue									$ 2,580

Revenue Recognition - Summary_2

Revenue Recognition - Summary of Net Patient Service Revenue by Source (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disaggregation Of Revenue [Line Items]
Net revenue	$ 121,800	$ 101,667	$ 78,000	$ 78,756	$ 77,386	$ 69,629	$ 66,233	$ 63,010	$ 380,223	$ 276,258	$ 212,678
Net Patient Service Revenue
Disaggregation Of Revenue [Line Items]
Net revenue									149,695	145,389	144,080
Commercial and Government Third-Party Payers \| Health Care, Other
Disaggregation Of Revenue [Line Items]
Net revenue									136,388	121,502	119,657
Patients, Including Self-Pay, Insurance Co-Pays and Deductibles \| Health Care, Patient Service
Disaggregation Of Revenue [Line Items]
Net revenue									$ 13,307	$ 23,887	$ 24,423

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disaggregation Of Revenue [Line Items]
Contract with customer, liability, revenue recognized									$ 26,026	$ 21,004
Net revenue	$ 121,800	$ 101,667	$ 78,000	$ 78,756	$ 77,386	$ 69,629	$ 66,233	$ 63,010	380,223	$ 276,258	$ 212,678
Reduction in revenue									(7,390)
Deferred revenue recognized related to variable consideration	6,774								6,774
Contract with customer liability related to variable consideration non-current	$ 5,865								5,865
Grant Income
Disaggregation Of Revenue [Line Items]
Net revenue									2,580
CARES Act \| Provider Relief Fund by HHS \| COVID-19 \| Grant Income
Disaggregation Of Revenue [Line Items]
Net revenue									$ 2,580

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Contract Assets and Deferred Revenue (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Balances from contracts with customers:
Accounts receivable	$ 67,895	$ 33,601
Contract asset (included in prepaid expenses and other current assets)	513	600
Deferred revenue	$ 43,590	$ 27,024

Revenue Recognition - Schedul_2

Revenue Recognition - Schedule of Remaining Performance Obligation (Details1) $ in Thousands	Dec. 31, 2020USD ($)
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue remaining performance obligation expected to be recognized	$ 15,669
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2021-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue remaining performance obligation expected to be recognized	$ 5,107
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue remaining performance obligation expected to be recognized	$ 10,562

Revenue Recognition - Schedul_3

Revenue Recognition - Schedule of Remaining Performance Obligation (Details) $ in Thousands	Dec. 31, 2020USD ($)
Revenue From Contract With Customer [Abstract]
Revenue remaining performance obligation expected to be recognized	$ 15,669

Cash Equivalents and Short-Te_3

Cash Equivalents and Short-Term Marketable Securities - Summary of Cash Equivalents and Short-Term Marketable Securities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Cash Cash Equivalents And Short Term Marketable Securities [Line Items]
Amortized cost	$ 640,775	$ 137,685
Gross unrealized gains (losses)	8	38
Fair value	640,783	137,723
Cash Equivalents
Cash Cash Equivalents And Short Term Marketable Securities [Line Items]
Amortized cost	70,760	18,577
Fair value	70,760	18,577
Short-Term Marketable Securities
Cash Cash Equivalents And Short Term Marketable Securities [Line Items]
Amortized cost	570,015	119,108
Gross unrealized gains (losses)	8	38
Fair value	570,023	119,146
US Treasury Obligations \| Short-Term Marketable Securities
Cash Cash Equivalents And Short Term Marketable Securities [Line Items]
Amortized cost	416,150	48,930
Gross unrealized gains (losses)	8	38
Fair value	416,158	48,968
Money Market Funds \| Cash Equivalents
Cash Cash Equivalents And Short Term Marketable Securities [Line Items]
Amortized cost	50,761	13,580
Fair value	50,761	13,580
U.S. Government Agency Securities \| Short-Term Marketable Securities
Cash Cash Equivalents And Short Term Marketable Securities [Line Items]
Amortized cost	20,000
Fair value	20,000
Commercial Paper \| Cash Equivalents
Cash Cash Equivalents And Short Term Marketable Securities [Line Items]
Amortized cost	19,999	4,997
Fair value	19,999	4,997
Commercial Paper \| Short-Term Marketable Securities
Cash Cash Equivalents And Short Term Marketable Securities [Line Items]
Amortized cost	133,865	70,178
Fair value	$ 133,865	$ 70,178

Property and Equipment, net - S

Property and Equipment, net - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 192,540	$ 139,254
Less: Accumulated depreciation and amortization	(66,503)	(48,538)
Property and equipment, net	126,037	90,716
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	118,434	83,018
Computer Software, Including Internal-Use Software
Property Plant And Equipment [Line Items]
Property and equipment, gross	25,708	16,508
Computer Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	21,502	16,653
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	11,805	7,359
Laboratory Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	6,541	3,428
Construction in Progress
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 8,550	$ 12,288

Property and Equipment, net - A

Property and Equipment, net - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Property Plant And Equipment [Line Items]
Disposal of property and equipment	$ 2,777	$ 6,466	$ 2,735
Property and equipment, net	126,037	90,716
Depreciation and amortization expense	22,301	13,970	9,586
Software Developed for Internal Use
Property Plant And Equipment [Line Items]
Capitalized internal use software development costs	10,069	6,914	3,466
Depreciation expense	4,907	3,152	$ 2,137
Property and equipment, net	$ 14,106	$ 8,944

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2018
Lessee Lease Description [Line Items]
Rent expense		$ 13,810
Operating leases, options to terminate	Certain lease agreements contain options to terminate the lease before maturity.
Operating lease, existence of option to terminate [true false]	true
Operating lease liability payments, not yet commenced	$ 40,809
Prepaid Expenses and Other Current Assets
Lessee Lease Description [Line Items]
Lease incentives to be received	$ 5,563
Maximum
Lessee Lease Description [Line Items]
Operating leases, options to extend leases term	7 years
Minimum
Lessee Lease Description [Line Items]
Operating leases, options to extend leases term	1 year
Practice Expenses
Lessee Lease Description [Line Items]
Rent expense		10,698
General and Administrative Expenses
Lessee Lease Description [Line Items]
Rent expense		$ 3,112

Leases - Components of Operatin

Leases - Components of Operating Lease Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Operating lease costs	$ 25,250	$ 19,165
Variable lease costs	4,166	2,612
Total lease costs	$ 29,416	$ 21,777

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 24,735	$ 17,260
Non-cash leases activity:
Right-of-use lease assets obtained in exchange for new operating lease liabilities	$ 45,957	$ 57,621

Leases - Lease Term and Discoun

Leases - Lease Term and Discount Rate (Details)	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Weighted-average remaining lease term (in years)	8 years 4 months 9 days	7 years 3 months 3 days
Weighted-average discount rate	7.60%	7.50%

Leases - Future Minimum Lease P

Leases - Future Minimum Lease Payments Under Non-cancellable Operating Leases (Details) $ in Thousands	Dec. 31, 2020USD ($)
Leases [Abstract]
2021	$ 29,866
2022	28,572
2023	27,763
2024	27,070
2025	25,071
Thereafter	97,247
Total lease payments	235,589
Less: interest	(64,557)
Total lease liabilities	$ 171,032

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets - Schedule of Intangible Assets and Accumulated Amortization (Details) $ in Thousands	Dec. 31, 2019USD ($)
Finite Lived Intangible Assets [Line Items]
Original Cost	$ 7,935
Accumulated Amortization	(7,912)
Net Book Value	23
Independent Physician Association Agreements
Finite Lived Intangible Assets [Line Items]
Original Cost	6,460
Accumulated Amortization	(6,460)
Net Book Value	0
Non Compete Agreements
Finite Lived Intangible Assets [Line Items]
Original Cost	1,175
Accumulated Amortization	(1,152)
Net Book Value	23
Customer Relationships
Finite Lived Intangible Assets [Line Items]
Original Cost	200
Accumulated Amortization	(200)
Net Book Value	0
Trade Names
Finite Lived Intangible Assets [Line Items]
Original Cost	100
Accumulated Amortization	(100)
Net Book Value	$ 0

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets - Amortization Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Finite Lived Intangible Assets [Line Items]
Amortization expense	$ 23	$ 281	$ 361
Minimum \| 2016 Acquisition
Finite Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	2 years
Maximum \| 2016 Acquisition
Finite Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	4 years
PCs
Finite Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	5 years
Medical Practices
Finite Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	4 years

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Payables And Accruals [Abstract]
Accrued employee compensation and benefits	$ 28,414	$ 13,929
Inventories received not yet invoiced	3,749	563
Construction in progress	811	3,844
Self-insurance programs	1,936	1,753	$ 819
Legal and professional fees	1,486	1,032
Medical office and lab supplies	3,581	289
Other accrued expenses	6,550	3,453
Total	$ 46,527	$ 24,863

Self-Insurance Reserves - Summa

Self-Insurance Reserves - Summary of Insurance Reserves (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Insurance Loss Reserves [Abstract]
Beginning balance	$ 1,753	$ 819
Losses paid	(16,394)	(10,867)
Reserves for current period	16,577	11,801
Ending balance	$ 1,936	$ 1,753

Debt - Additional Information (

Debt - Additional Information (Details)	1 Months Ended		12 Months Ended
Debt - Additional Information (Details)	May 31, 2020USD ($)Tradingday$ / sharesshares	Jan. 31, 2013USD ($)shares	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)	Jun. 30, 2020USD ($)
Debt Instrument [Line Items]
Number of warrants issued \| shares				673,241
3.0% Convertible Senior Notes due 2025
Debt Instrument [Line Items]
Interest rate	3.00%					3.00%
Debt instrument maturity date	Jun. 15, 2025
Debt instrument face amount	$ 275,000					$ 41,250,000
Proceeds from debt offering	306,868,000
Debt instrument convertible conversion amount	$ 1,000
Debt converted to common stock \| shares	22.5052
Debt instrument conversion price \| $ / shares	$ 44.43
Debt instrument terms of conversion feature	Holders may convert the 2025 Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2025 only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on September 30, 2020 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined below) per $1 principal amount of the 2025 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day; (3) if the Company calls such 2025 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. It is the Company’s current intent to settle conversions through combination settlement comprising of cash and equity
Debt instrument convertible, latest date	Mar. 15, 2025
Debt instrument, repurchase price percentage	100.00%
Debt instrument terms of redemption feature	The Company may redeem for cash all or any portion of the 2025 Notes, at the Company’s option, on or after June 20, 2023 and prior to March 15, 2025, if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the 2025 Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the notes.
Debt instrument, redemption threshold trading days \| Tradingday	20
Debt instrument, redemption consecutive trading days \| Tradingday	30
Debt instrument, redemption conversion percentage	130.00%
Debt instrument, redemption period, start date	Jun. 20, 2023
Debt instrument, redemption period, end date	Mar. 15, 2025
Debt issuance cost	$ 9,374,000
3.0% Convertible Senior Notes due 2025 \| Debt Liability Component
Debt Instrument [Line Items]
Liability component at the time of issuance date	240,637,000
Issuance costs attributable to liability	$ 7,132,000
3.0% Convertible Senior Notes due 2025 \| Debt Equity Component
Debt Instrument [Line Items]
Debt instrument effective interest rate	9.68%
Debt discount related to value of conversion option	$ 75,635,000
Issuance costs attributable to equity	$ 2,242,000
3.0% Convertible Senior Notes due 2025 \| Conversion Scenario One
Debt Instrument [Line Items]
Debt instrument consecutive trading days \| Tradingday	30
Debt instrument, threshold trading days \| Tradingday	20
Debt instrument conversion percentage	130.00%
3.0% Convertible Senior Notes due 2025 \| Conversion Scenario Two
Debt Instrument [Line Items]
Debt instrument convertible conversion amount	$ 1,000
Percentage applied to product of common stock price and conversion rate	98.00%
LSA
Debt Instrument [Line Items]
Maximum borrowings		$ 11,000,000
Number of warrants issued \| shares		494,833
Debt instrument maturity date		Sep. 1, 2020
Debt instrument, description		On September 1, 2020, the term notes under the LSA matured and the remaining outstanding principal was repaid, plus accrued and unpaid interest.
Interest expense			$ 86,000	$ 469,000	$ 801,000
Debt instrument effective interest rate			6.00%	7.20%	6.70%
Aggregate principal payments			$ 3,300,000	$ 4,400,000	$ 3,300,000
LSA \| Maximum
Debt Instrument [Line Items]
Interest rate greater of prime plus		1.81%
LSA \| Minimum
Debt Instrument [Line Items]
Interest rate		5.56%

Debt - Summary of Net Carrying

Debt - Summary of Net Carrying Amount of Liability Component of Convertible Senior Notes (Details) - Convertible Senior Notes Due 2025 - Debt Liability Component $ in Thousands	Dec. 31, 2020USD ($)
Debt Instrument [Line Items]
Principal	$ 316,250
Unamortized debt discount	(68,441)
Unamortized issuance costs	(6,576)
Net carrying amount	$ 241,233

Debt - Summary of Net Carryin_2

Debt - Summary of Net Carrying Amount of Equity Component of Convertible Senior Notes (Details) - Convertible Senior Notes Due 2025 - Debt Equity Component $ in Thousands	Dec. 31, 2020USD ($)
Debt Instrument [Line Items]
Debt discount related to value of conversion option	$ 75,635
Issuance costs	(2,242)
Net carrying amount	$ 73,393

Debt - Summary of Interest Expe

Debt - Summary of Interest Expense Recognized Related to Convertible Senior Notes (Details) - Convertible Senior Notes Due 2025 $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Debt Instrument [Line Items]
Contractual interest expense	$ 5,587
Expected reduction in non-cash expense in next twelve months	7,194
Amortization of issuance costs	556
Total interest expense related to the 2025 Notes	$ 13,337

Redeemable Convertible Prefer_3

Redeemable Convertible Preferred Stock Warrants - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Feb. 04, 2020	Feb. 03, 2020
Class Of Warrant Or Right [Line Items]
Number of warrants issued		673,241
Fair value of redeemable convertible preferred stock warrant liability		$ 7,220
Convertible redeemable preferred stock warrant liability				$ 13,740
Changes in fair value of redeemable convertible preferred stock warrant liability	$ (6,560)	(3,519)	$ (1,877)
Other (Income) Expense, Net
Class Of Warrant Or Right [Line Items]
Changes in fair value of redeemable convertible preferred stock warrant liability	$ 6,560	$ 3,519	$ 1,877
Series G \| Redeemable Convertible Preferred Stock Warrants Exercisable
Class Of Warrant Or Right [Line Items]
Number of warrants issued					5,573
IPO \| Warrants to Purchase Common Stock
Class Of Warrant Or Right [Line Items]
Warrants to purchase shares of common stock				667,668

Redeemable Convertible Prefer_4

Redeemable Convertible Preferred Stock Warrants - Summary of Outstanding Redeemable Convertible Preferred Stock Warrants (Details)	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Class Of Warrant Or Right [Line Items]
Number of Shares Issuable	673,241
Redeemable Convertible Preferred Stock Warrants Exercisable Date One \| Series C
Class Of Warrant Or Right [Line Items]
Date Exercisable	Feb. 26, 2010
Number of Shares Issuable	100,000
Exercise Price \| $ / shares	$ 0.92
Expiration	Feb. 26, 2020
Redeemable Convertible Preferred Stock Warrants Exercisable Date Two \| Series D
Class Of Warrant Or Right [Line Items]
Date Exercisable	Jun. 28, 2011
Number of Shares Issuable	250,000
Exercise Price \| $ / shares	$ 1.05
Expiration	Jun. 28, 2021
Redeemable Convertible Preferred Stock Warrants Exercisable Date Three \| Series E
Class Of Warrant Or Right [Line Items]
Date Exercisable	Jan. 30, 2013
Number of Shares Issuable	99,280
Exercise Price \| $ / shares	$ 1.61
Expiration	Jan. 30, 2023
Redeemable Convertible Preferred Stock Warrants Exercisable Date Four \| Series G
Class Of Warrant Or Right [Line Items]
Date Exercisable	Oct. 3, 2015
Number of Shares Issuable	11,010
Exercise Price \| $ / shares	$ 6.59
Expiration	Oct. 3, 2020
Redeemable Convertible Preferred Stock Warrants Exercisable Date Five \| Series G
Class Of Warrant Or Right [Line Items]
Date Exercisable	Oct. 5, 2015
Number of Shares Issuable	10,837
Exercise Price \| $ / shares	$ 6.59
Expiration	Oct. 5, 2020
Redeemable Convertible Preferred Stock Warrants Exercisable Date Six \| Series G
Class Of Warrant Or Right [Line Items]
Date Exercisable	Oct. 7, 2015
Number of Shares Issuable	4,918
Exercise Price \| $ / shares	$ 6.59
Expiration	Oct. 7, 2020
Redeemable Convertible Preferred Stock Warrants Exercisable Date Seven \| Series G
Class Of Warrant Or Right [Line Items]
Date Exercisable	Oct. 8, 2015
Number of Shares Issuable	5,573
Exercise Price \| $ / shares	$ 6.59
Expiration	Oct. 8, 2020
Redeemable Convertible Preferred Stock Warrants Exercisable Date Eight \| Series G
Class Of Warrant Or Right [Line Items]
Date Exercisable	Oct. 12, 2015
Number of Shares Issuable	5,619
Exercise Price \| $ / shares	$ 6.59
Expiration	Oct. 12, 2020
Redeemable Convertible Preferred Stock Warrants Exercisable Date Nine \| Series G
Class Of Warrant Or Right [Line Items]
Date Exercisable	Oct. 14, 2015
Number of Shares Issuable	113,879
Exercise Price \| $ / shares	$ 6.59
Expiration	Oct. 14, 2020
Redeemable Convertible Preferred Stock Warrants Exercisable Date Ten \| Series G
Class Of Warrant Or Right [Line Items]
Date Exercisable	Oct. 28, 2015
Number of Shares Issuable	3,796
Exercise Price \| $ / shares	$ 6.59
Expiration	Oct. 28, 2020
Redeemable Convertible Preferred Stock Warrants Exercisable Date Eleven \| Series G
Class Of Warrant Or Right [Line Items]
Date Exercisable	Nov. 4, 2015
Number of Shares Issuable	22,776
Exercise Price \| $ / shares	$ 6.59
Expiration	Nov. 4, 2020
Redeemable Convertible Preferred Stock Warrants Exercisable Date Twelve \| Series G
Class Of Warrant Or Right [Line Items]
Date Exercisable	Jan. 26, 2015
Number of Shares Issuable	45,553
Exercise Price \| $ / shares	$ 6.59
Expiration	Jan. 26, 2025

Preferred Stock and Redeemabl_3

Preferred Stock and Redeemable Convertible Preferred Stock - Additional Information (Details)	12 Months Ended
	Dec. 31, 2020USD ($)Director$ / sharesshares	Feb. 04, 2020shares	Dec. 31, 2019$ / sharesshares
Temporary Equity [Line Items]
Preferred stock, authorized	10,000,000
Preferred stock, par value \| $ / shares	$ 0.001
Preferred stock, shares outstanding	0
Redeemable convertible preferred stock, shares authorized	0		89,338,425
Redeemable convertible preferred stock, par value \| $ / shares	$ 0.001		$ 0.001
Redeemable convertible preferred stock converted into shares of common stock			86,251,669
Redeemable convertible preferred stock, shares outstanding	0		86,251,669
Preferred stock, conversion basis	one-for-one basis
Series A
Temporary Equity [Line Items]
Redeemable convertible preferred stock dividend rate, percentage	6.00%
Redeemable convertible preferred stock, liquidation \| $ / shares	$ 0.500
Series B
Temporary Equity [Line Items]
Number of directors entitled to be elected \| Director	1
Redeemable convertible preferred stock dividend rate, percentage	8.00%
Redeemable convertible preferred stock, liquidation \| $ / shares	$ 0.574
Series C
Temporary Equity [Line Items]
Number of directors entitled to be elected \| Director	1
Redeemable convertible preferred stock dividend rate, percentage	6.00%
Redeemable convertible preferred stock, liquidation \| $ / shares	$ 0.923
Series D
Temporary Equity [Line Items]
Number of directors entitled to be elected \| Director	1
Redeemable convertible preferred stock dividend rate, percentage	6.00%
Redeemable convertible preferred stock, liquidation \| $ / shares	$ 1.051
Series E
Temporary Equity [Line Items]
Number of directors entitled to be elected \| Director	1
Redeemable convertible preferred stock dividend rate, percentage	6.00%
Redeemable convertible preferred stock, liquidation \| $ / shares	$ 1.612
Series F
Temporary Equity [Line Items]
Number of directors entitled to be elected \| Director	1
Redeemable convertible preferred stock dividend rate, percentage	8.00%
Redeemable convertible preferred stock, liquidation \| $ / shares	$ 2.565
Series G
Temporary Equity [Line Items]
Number of directors entitled to be elected \| Director	1
Redeemable convertible preferred stock dividend rate, percentage	8.00%
Redeemable convertible preferred stock, liquidation \| $ / shares	$ 6.586
Series H
Temporary Equity [Line Items]
Redeemable convertible preferred stock dividend rate, percentage	8.00%
Redeemable convertible preferred stock, liquidation \| $ / shares	$ 8.731
Series I
Temporary Equity [Line Items]
Number of directors entitled to be elected \| Director	2
Redeemable convertible preferred stock dividend rate, percentage	8.00%
Redeemable convertible preferred stock, liquidation \| $ / shares	$ 12.43
Minimum
Temporary Equity [Line Items]
Cash proceeds \| $	$ 50,000,000
Minimum \| Series B
Temporary Equity [Line Items]
Redeemable convertible preferred stock, shares outstanding	1,000,000
Minimum \| Series C
Temporary Equity [Line Items]
Redeemable convertible preferred stock, shares outstanding	1,000,000
Minimum \| Series D
Temporary Equity [Line Items]
Redeemable convertible preferred stock, shares outstanding	1,000,000
Minimum \| Series E
Temporary Equity [Line Items]
Redeemable convertible preferred stock, shares outstanding	1,000,000
Minimum \| Series F
Temporary Equity [Line Items]
Redeemable convertible preferred stock, shares outstanding	1,000,000
Minimum \| Series G
Temporary Equity [Line Items]
Redeemable convertible preferred stock, shares outstanding	1,000,000
Minimum \| Series I
Temporary Equity [Line Items]
Redeemable convertible preferred stock, shares outstanding	1,000,000
IPO
Temporary Equity [Line Items]
Redeemable convertible preferred stock converted into shares of common stock	86,257,242	86,257,242
Redeemable convertible preferred stock, shares outstanding	0

Preferred Stock and Redeemabl_4

Preferred Stock and Redeemable Convertible Preferred Stock - Schedule of Redeemable Preferred Stock (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Temporary Equity [Line Items]
Preferred Stock Authorized	0	89,338,425
Preferred Stock Issued	0	86,251,669
Preferred Stock Outstanding	0	86,251,669
Carrying Value		$ 402,488
Liquidation Preference	$ 0	$ 405,585
Common Stock Issuable Upon Conversion		86,251,669
Series A Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Preferred Stock Authorized		1,130,000
Preferred Stock Issued		1,130,000
Preferred Stock Outstanding		1,130,000
Carrying Value		$ 540
Liquidation Preference		$ 585
Common Stock Issuable Upon Conversion		1,130,000
Series B Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Preferred Stock Authorized		6,324,592
Preferred Stock Issued		6,324,592
Preferred Stock Outstanding		6,324,592
Carrying Value		$ 4,424
Liquidation Preference		$ 3,500
Common Stock Issuable Upon Conversion		6,324,592
Series C Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Preferred Stock Authorized		8,763,634
Preferred Stock Issued		8,663,634
Preferred Stock Outstanding		8,663,634
Carrying Value		$ 7,938
Liquidation Preference		$ 8,000
Common Stock Issuable Upon Conversion		8,663,634
Series D Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Preferred Stock Authorized		14,528,912
Preferred Stock Issued		14,278,912
Preferred Stock Outstanding		14,278,912
Carrying Value		$ 14,899
Liquidation Preference		$ 15,000
Common Stock Issuable Upon Conversion		14,278,912
Series E Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Preferred Stock Authorized		12,509,305
Preferred Stock Issued		12,410,025
Preferred Stock Outstanding		12,410,025
Carrying Value		$ 19,905
Liquidation Preference		$ 20,000
Common Stock Issuable Upon Conversion		12,410,025
Series F Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Preferred Stock Authorized		11,695,449
Preferred Stock Issued		11,695,449
Preferred Stock Outstanding		11,695,449
Carrying Value		$ 29,885
Liquidation Preference		$ 30,000
Common Stock Issuable Upon Conversion		11,695,449
Series G Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Preferred Stock Authorized		6,829,076
Preferred Stock Issued		6,605,115
Preferred Stock Outstanding		6,605,115
Carrying Value		$ 43,358
Liquidation Preference		$ 43,500
Common Stock Issuable Upon Conversion		6,605,115
Series H Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Preferred Stock Authorized		7,444,827
Preferred Stock Issued		7,444,827
Preferred Stock Outstanding		7,444,827
Carrying Value		$ 64,875
Liquidation Preference		$ 65,000
Common Stock Issuable Upon Conversion		7,444,827
Series I Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Preferred Stock Authorized		20,112,630
Preferred Stock Issued		17,699,115
Preferred Stock Outstanding		17,699,115
Carrying Value		$ 216,664
Liquidation Preference		$ 220,000
Common Stock Issuable Upon Conversion		17,699,115

Common Stock - Additional Infor

Common Stock - Additional Information (Details) - $ / shares	1 Months Ended
	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Class Of Stock [Line Items]
Common stock, shares authorized		1,000,000,000	150,000,000
Common stock, par value		$ 0.001	$ 0.001
Common Stock \| Secondary Offering
Class Of Stock [Line Items]
Number of shares sold	8,300,000
Stock price	$ 31

Common Stock - Schedule of Rese

Common Stock - Schedule of Reserved Shares of Common Stock for Issuance (Details) - shares	Dec. 31, 2020	Dec. 31, 2019
Class Of Stock [Line Items]
Common stock reserved for future issuance	39,419,017	116,081,421
Conversion of Outstanding Shares of Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Common stock reserved for future issuance		86,251,669
Warrants to Purchase Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Common stock reserved for future issuance		673,241
Options Outstanding Under the Equity Incentive Plans
Class Of Stock [Line Items]
Common stock reserved for future issuance	28,273,033	27,806,309
Unvested Restricted Stock
Class Of Stock [Line Items]
Common stock reserved for future issuance	1,290,953
Option Available for Future Issuance
Class Of Stock [Line Items]
Common stock reserved for future issuance	9,855,031	1,350,202

Stock-Based Compensation and _3

Stock-Based Compensation and Employee Benefit Plans - Additional Information (Detail) - USD ($)	Feb. 04, 2020	Jan. 01, 2007	Jan. 31, 2020	Mar. 31, 2016	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance					39,419,017	116,081,421
Stock based compensation expense					$ 35,095,000	$ 14,877,000	$ 21,181,000
Weighted-average period over which unrecognized compensation cost is expected to be recognized					1 year 10 months 24 days	2 years 2 months 12 days
Aggregate intrinsic value of options exercised					$ 206,143,000	$ 4,998,000	$ 17,715,000
Unrecognized compensation expense related to service-based options					$ 12,983,000	$ 22,156,000
Number of options, granted					380,572	7,702,397	4,591,384
Restricted stock issued				150,000
Tax benefits related to stock based awards					$ 53,749,000	$ 707,000	$ 3,946,000
Percentage of maximum eligible employees contribution plan		60.00%
Percentage of maximum eligible employees contribution plan		onem:FourZeroOneKMember
Percentage of eligible employees matches contribution plan		50.00%
Percentage of first eligible employees matches contribution plan		3.00%
Defined contribution plan, cost					5,051,000	3,618,000	1,764,000
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Defined contribution plan employed term		3 months
Sales and Marketing
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense					2,385,000	1,256,000	552,000
General and Administrative Expenses
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense					$ 32,710,000	13,621,000	20,629,000
Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares purchased by employees					349,562
Stock based compensation expense							7,239,000
Restricted stock issued					40,166
Common Stock \| Sales and Marketing
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense							208,000
Common Stock \| General and Administrative Expenses
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense							7,031,000
Stock Options \| IPO
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	$ 3,506,000
Stock options vested	1,589,798
Service Based Vesting Conditions
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of stock option granted					$ 4,519,000	36,785,000	$ 12,137,000
Performance Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period					7 years
Stock based compensation expense					$ 490,000
Number of options, granted					8,645,823
Vesting rights					if the Company’s stock price sustains achievement of pre-determined increases for a period of 90 consecutive calendar days and the Chief Executive Officer remains employed with the Company.
Aggregate stock-based compensation expense if service-based vesting conditions are met					$ 197,469,000
Unamortized stock-based compensation expense					$ 196,978,000
Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period				24 months
Weighted-average period over which unrecognized compensation cost is expected to be recognized					1 year 10 months 24 days
Fair value of restricted stock units granted					$ 32,071,000
Unrecognized compensation expenses					$ 11,779,000	$ 0
2007 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of additional stock awards granted					0
2017 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of additional stock awards granted					0
2020 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of additional stock awards granted					0
Share based payment award description					The number of shares of common stock reserved for issuance under the Company’s 2020 Plan will automatically increase on January 1 of each year, beginning on January 1, 2021, and continuing through and including January 1, 2030, by 4% of the total number of shares of common stock outstanding on December 31 of the immediately preceding calendar year, or a lesser number of shares determined by the Company’s board prior to the applicable January 1st.
Shares available for future grants					7,404,593
2020 Equity Incentive Plan \| Common Stock Reserve Auto Increase
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of number of shares of common stock outstanding					4.00%
2020 Equity Incentive Plan \| Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period					4 years
Term of options granted					10 years
2020 ESPP
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares available for future grants					2,450,438
Common stock reserved for future issuance			2,800,000
Common stock available for issuance automatic increase period			10 years
Share-based Compensation Arrangement by Share-based Payment Award, Maximum employee contribution, percentage					15.00%
Share-based compensation arrangement by share-based payment award, purchase price of common stock, percentage					85.00%
Share-based compensation arrangement by share-based payment award, offering period					The initial offering period ran from January 31, 2020 to August 15, 2020 and the second offering period ran from August 16, 2020 to November 15, 2020. On a going forward basis, the ESPP will provide for separate six-month offering periods beginning on May 16 and November 16 of each year.
Number of shares purchased by employees					350,000
Weighted average price per share					$ 13.83
Stock based compensation expense					$ 2,058,000
Unrecognized compensation expenses					$ 902,000
Weighted-average period over which unrecognized compensation cost is expected to be recognized					4 months 24 days
2020 ESPP \| Common Stock Reserve Auto Increase, Scenario One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of number of shares of common stock outstanding			1.50%
2020 ESPP \| Common Stock Reserve Auto Increase, Scenario Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance			2,800,000

Stock-Based Compensation and _4

Stock-Based Compensation and Employee Benefit Plans - Schedule of Estimated Fair Value of Stock Purchase Right Granted Using a Black-Scholes Option Pricing Mode (Detail) - 2020 ESPP	12 Months Ended
	Dec. 31, 2020
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Expected stock price volatility, minimum	53.70%
Expected stock price volatility, maximum	63.50%
Risk-free interest rate, minimum	0.10%
Risk-free interest rate, maximum	1.50%
Expected dividend yield	0.00%
Minimum
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Expected term in years	3 months 18 days
Maximum
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Expected term in years	6 months

Stock-Based Compensation and _5

Stock-Based Compensation and Employee Benefit Plans - Summary of Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options, Outstanding	27,806,309	21,503,995	23,826,773
Number of Options, Granted	380,572	7,702,397	4,591,384
Number of Options, Exercised	(8,122,909)	(815,959)	(3,767,795)
Number of Options, Canceled	(436,762)	(584,124)	(3,146,367)
Number of Options, Outstanding	28,273,033	27,806,309	21,503,995	23,826,773
Number of Options, Exercisable	9,607,761
Number of Options, Vested and expected to vest	17,137,578
Weighted-Average Exercise Price, Outstanding	$ 5.97	$ 4.30	$ 4.07
Weighted-Average Exercise Price, Granted	22.32	10.39	5.45
Weighted-Average Exercise Price, Exercised	4.39	3.73	3.98
Weighted-Average Exercise Price, Canceled	8.06	5.99	4.58
Weighted-Average Exercise Price, Outstanding	18.03	$ 5.97	$ 4.30	$ 4.07
Weighted-Average Exercise Price, Options exercisable	5.20
Weighted-Average Exercise Price, Options vested and expected to vest	$ 6.53
Weighted-Average Remaining Contractual Term (Years), Outstanding	8 years 2 months 12 days	7 years 9 months 3 days	8 years	8 years 6 months 3 days
Weighted-Average Remaining Contractual Term (Years), Options exercisable	6 years 9 months 21 days
Weighted-Average Remaining Contractual Term (Years), Options vested and expected to vest	7 years 3 months 18 days
Aggregate Intrinsic Value, Outstanding	$ 724,339	$ 207,956	$ 74,546	$ 14,071
Aggregate Intrinsic Value, Options exercisable	369,432
Aggregate Intrinsic Value, Options vested and expected to vest	$ 636,227
Market-based Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options, Granted	8,645,823
Weighted-Average Exercise Price, Granted	$ 43.31

Stock-Based Compensation and _6

Stock-Based Compensation and Employee Benefit Plans - Schedule of Estimated Fair Value of Stock Option Grants Using a Black-Scholes Option Pricing Model (Detail) - Service Based Vesting Conditions - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	6 years	6 years 3 months 18 days	6 years
Expected stock price volatility	57.40%	44.80%	47.70%
Risk-free interest rate	0.90%	1.90%	2.90%
Expected dividend yield	0.00%	0.00%	0.00%
Estimated fair value per option granted	$ 11.88	$ 4.78	$ 2.64

Stock-Based Compensation and _7

Stock-Based Compensation and Employee Benefit Plans - Schedule of Additional Information Relating to Tranche (Detail) - Performance Stock Option	12 Months Ended
	Dec. 31, 2020shares
Tranche 1 - $55 per share
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options	1,330,127
Tranche 2 - $70 per share
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options	1,995,190
Tranche 3 - $90 per share
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options	2,660,253
Tranche 4 - $110 per share
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options	2,660,253

Stock-Based Compensation and _8

Stock-Based Compensation and Employee Benefit Plans - Schedule of Estimated Fair Value of Performance Stock Option Using a Monte Carlo Simulation (Detail) - Performance Stock Option	12 Months Ended
	Dec. 31, 2020$ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected stock price volatility	55.00%
Risk-free interest rate	0.70%
Expected dividend yield	0.00%
Weighted-average fair value per option granted	$ 22.84
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Derived service period in years	1 year 1 month 28 days
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Derived service period in years	3 years 1 month 2 days

Stock-Based Compensation and _9

Stock-Based Compensation and Employee Benefit Plans - Summary of Restricted Stock Unit Activity (Detail) - Restricted Stock - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Unvested and outstanding		2,083
Number of Shares, Granted	1,490,274
Number of Shares, Vested	(65,023)	(2,083)
Number of Shares, Canceled and forfeited	(134,298)
Number of Shares, Unvested and outstanding	1,290,953
Grant-Date Fair Value, Unvested and outstanding		$ 6.19
Grant-Date Fair Value, Granted	$ 21.52
Grant-Date Fair Value, Vested	15	$ 6.19
Grant-Date Fair Value, Canceled and forfeited	18.74
Grant-Date Fair Value, Unvested and outstanding	$ 22.14

Stock-Based Compensation and_10

Stock-Based Compensation and Employee Benefit Plans - Summary of Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total	$ 35,095	$ 14,877	$ 21,181
Sales and Marketing
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total	2,385	1,256	552
General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total	$ 32,710	$ 13,621	$ 20,629

Income Taxes - Schedule of Prov

Income Taxes - Schedule of Provision for (Benefit from) Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Current:
Federal	$ 869	$ 1	$ 2
State	1,664	86	23
Total current	2,533	87	25
Deferred:
Federal	(1,895)
State	(761)
Total deferred	(2,656)
Provision for (benefit from) income taxes	$ (123)	$ 87	$ 25

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Federal Statutory Income Tax Provision to Effective Income Tax Provision (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Federal statutory income tax rate	21.00%	21.00%	21.00%
Valuation allowance	(49.80%)	(12.60%)	(16.90%)
Section 382 limitations	0.00%	(10.00%)	0.00%
State income tax expense	(6.30%)	(1.40%)	(1.40%)
Stock-based compensation	38.60%	4.50%	(1.10%)
Warrant fair value adjustment	(1.50%)	(1.40%)	(0.90%)
Other, net	(1.80%)	(0.30%)	(0.90%)
Effective income tax rate	0.10%	(0.20%)	(0.10%)

Income Taxes - Components of De

Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets:
Net operating loss and credit carryforwards	$ 114,662	$ 53,070
Reserves and allowances	1,713	0
Basis difference in fixed and intangible assets	72	73
Stock-based compensation	11,970	8,874
Lease liability	52,045	40,122
Section 163(j) interest	2,750	1,352
Total gross deferred tax assets	183,212	103,491
Valuation allowance	(113,770)	(66,535)
Total deferred tax assets	69,442	36,956
Deferred tax liabilities:
Basis difference in fixed and intangible assets	(3,460)	(2,426)
Right-of-use assets	(42,249)	(32,651)
Capitalized commissions	(250)	(52)
Reserves and allowances	0	(1,827)
Convertible note debt discount	(20,827)	0
Total deferred tax liabilities	(66,786)	(36,956)
Net deferred tax assets	$ 2,656	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
Income Taxes - Additional Information (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax [Line Items]
Change in valuation allowance of deferred tax assets	$ 47,235,000	$ 5,483,000
Additional current state income tax provision (benefit)	1,664,000	$ 86,000	$ 23,000
AB 85
Income Tax [Line Items]
Additional current state income tax provision (benefit)	105,000
Federal
Income Tax [Line Items]
Net operating loss carryforwards	398,150,000
Operating loss carry forwards not subject to expiration	261,434,000
Tax credit carryforward	0
Federal \| Section 382
Income Tax [Line Items]
Net operating loss carryforwards	344,258,000
Federal \| Section 382 \| PCs
Income Tax [Line Items]
Net operating loss carryforwards	$ 25,215,000
Federal \| Minimum
Income Tax [Line Items]
Operating loss carryforwards, expiration year	2025
State and Local
Income Tax [Line Items]
Net operating loss carryforwards	$ 465,206,000
Tax credit carryforward	480,000
State and Local \| Section 382
Income Tax [Line Items]
Net operating loss carryforwards	381,753,000
State and Local \| Section 382 \| PCs
Income Tax [Line Items]
Net operating loss carryforwards	31,704,000
Tax credit carryforward	$ 71,000
State and Local \| Minimum
Income Tax [Line Items]
Operating loss carryforwards, expiration year	2024
Tax credit carryforward expiration year	2023

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Numerator:
Net loss	$ (8,147)	$ (16,415)	$ (30,301)	$ (34,558)	$ (19,518)	$ (15,645)	$ (11,488)	$ (7,044)	$ (89,421)	$ (53,695)	$ (45,501)
Less: Net loss attributable to noncontrolling interest				(704)	(92)	(388)	(287)	(374)	(704)	(1,141)	(1,086)
Net loss attributable to 1Life Healthcare, Inc. stockholders	$ (8,147)	$ (16,415)	$ (30,301)	$ (33,854)	$ (19,426)	$ (15,257)	$ (11,201)	$ (6,670)	$ (88,717)	$ (52,554)	$ (44,415)
Denominator:
Weighted average common shares outstanding — basic and diluted									118,379,300	18,476,127	16,735,541
Net loss per share attributable to 1Life Healthcare, Inc. stockholders — basic and diluted	$ (0.06)	$ (0.13)	$ (0.24)	$ (0.40)	$ (1.03)	$ (0.82)	$ (0.61)	$ (0.37)	$ (0.75)	$ (2.84)	$ (2.65)

Net Loss Per Share - Schedule_2

Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities	29,563,986	114,731,219	108,428,905
Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities	28,273,033	27,806,309	21,503,995
Unvested Restricted Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities	1,290,953
Warrants to Purchase Redeemable Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities		673,241	673,241
Redeemable Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities		86,251,669	86,251,669

Net Loss Per Share - Additional

Net Loss Per Share - Additional Information (Details) - Convertible Senior Notes Due 2025	12 Months Ended
	Dec. 31, 2020$ / sharesshares
Earnings Per Share Basic [Line Items]
Debt converted to common stock \| shares	7,117,270
Debt instrument conversion price \| $ / shares	$ 44.43

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details)	Sep. 30, 2018Plaintiff
Commitments And Contingencies Disclosure [Abstract]
Number of plaintiffs	1

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Related Party Transactions [Abstract]
Revenue recognized under contractual obligation	$ 2,093	$ 27,748	$ 22,273
Outstanding receivable balances		$ 2,344

Selected Quarterly Financial _3

Selected Quarterly Financial Data (unaudited) - Summary of Unaudited Consolidated Financial Statements (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Net revenue	$ 121,800	$ 101,667	$ 78,000	$ 78,756	$ 77,386	$ 69,629	$ 66,233	$ 63,010	$ 380,223	$ 276,258	$ 212,678
Loss from operations	(2,796)	(10,822)	(28,713)	(29,028)	(18,962)	(15,678)	(11,310)	(8,163)	(71,359)	(54,113)	(45,046)
Net loss	(8,147)	(16,415)	(30,301)	(34,558)	(19,518)	(15,645)	(11,488)	(7,044)	(89,421)	(53,695)	(45,501)
Less: Net loss attributable to noncontrolling interest				(704)	(92)	(388)	(287)	(374)	(704)	(1,141)	(1,086)
Net loss attributable to 1Life Healthcare, Inc. stockholders	$ (8,147)	$ (16,415)	$ (30,301)	$ (33,854)	$ (19,426)	$ (15,257)	$ (11,201)	$ (6,670)	$ (88,717)	$ (52,554)	$ (44,415)
Net loss per share attributable to 1Life Healthcare, Inc. stockholders — basic and diluted	$ (0.06)	$ (0.13)	$ (0.24)	$ (0.40)	$ (1.03)	$ (0.82)	$ (0.61)	$ (0.37)	$ (0.75)	$ (2.84)	$ (2.65)